

CTAD Alzheimer 2022

Clinical Trials on Alzheimer's Disease

Program



ONSITE



ONLINE

November 29 - December 2, 2022
San Francisco, USA

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11
Monte Carlo '12 / San Diego '13 / Philadelphia '14 / Barcelona '15
San Diego '16 / Boston '17 / Barcelona '18 / San Diego '19 / Virtual '20 / Boston '21

www.ctad-alzheimer.com

Email: ctad@ant-congres.com





SUMMARY

Editorial	3
Organizing & Scientific Committees	4
Lifetime Achievement Award	5
Keynotes	6
Program at a glance	9
Program	
Tuesday, November 29	10
Wednesday, November 30	11
Thursday, December 1	15
Friday, December 2	19
Poster presentations	24
Practical details	55
CTAD Partners	56

Editorial

Dear colleagues,

The field of Alzheimer's disease diagnostics and therapeutics has become one of the most exciting areas in all of medical research. The Clinical Trials on Alzheimer's Disease (CTAD) meeting, being held this **November 29-December 2, 2022**, promises to continue the excitement!

Why is our field so exciting? Rapid progress in our field has resulted from huge investments by governments into basic science research, followed by more recent huge investments by the private sector into diagnostic, biotech, and pharmaceutical companies. It has only been 15 years since molecular imaging with amyloid PET scans first demonstrated the ability to detect Alzheimer's disease pathology in living people. Now, amyloid PET is widely available, tau PET is being employed by many clinical trials, and very recently blood tests for Alzheimer's disease have shown great promise for screening, and even for diagnosis.


But, without question there is growing evidence that monoclonal antibodies, which remove amyloid plaque, appear to slow cognitive decline. Unfortunately, these treatments are also associated with ARIA, including brain swelling and bleeding in the brain. There is considerable controversy concerning the significance and impact of these findings, including whether or not governments and medical insurance will provide financial coverage for such treatments.

These issues will be at the center of the CTAD meeting being held in San Francisco. Experts from academics and industry will be attending, presenting their data and discussing the pros and cons of various controversial topics. In addition to the formal program there will be extensive networking and discussions around the poster sessions, coffee breaks, formal receptions, and in the hallways.

San Francisco is an especially beautiful city, surrounded by the Pacific Ocean and the San Francisco Bay. Golden Gate Park, and the Presidio are huge parks filled with trees, flowers and historical sites. We have three internationally famous universities, the worlds' largest biotech hub just south of the city, and Silicon Valley further south. Don't forget to include some vacation time and consider visiting the Muir Woods, the Napa Valley, and Carmel/Big Sur to the south.

I'm looking forward to seeing old friends, and making new ones at the CTAD meeting in beautiful San Francisco.

Dr. Mike Weiner
President of the CTAD22 Scientific Committee





President of the CTAD22 Scientific Committee

Michael W. WEINER, MD

University of California at San Francisco (UCSF)

Organizing and Scientific Committees

Susan ABUSHAKRA (San Francisco, USA); Paul AISEN* (San Diego, USA); Rebecca E. AMARIGLIO (Boston, USA); Randall J. BATEMAN (St. Louis, USA); Kaj BLENNOW (Molndal, Sweden); Merce BOADA (Barcelona, Spain); Marc CANTILLON (Livingston, USA); Maria CARRILLO (Chicago, USA); Suzanne CRAFT (Winston-Salem, USA); Steven DEKOSKY (Miami, USA); Michael C. DONOHUE (San Diego, USA); Rachelle DOODY (Basel, Switzerland); Bruno DUBOIS (Paris, France); Howard FELDMAN (San Diego, USA); Howard FILLIT (New York, USA); Nick FOX (London, UK); Giovanni B. FRISONI (Brescia, Italy); Serge GAUTHIER (Montreal, Canada); Michael GRUNDMANN (San Diego, USA); Harald HAMPEL (Nutley, USA); Oskar HANSSON (Lund, Sweden); Tobias HARTMANN (Homburg, Germany); Takeshi IWATSUBO (Tokyo, Japan); Frank JESSEN (Cologne, Germany); Ara KHACHATURIAN (Washington DC, USA); Zaven KHACHATURIAN (Washington DC, USA); Yan LI (St. Louis, USA); Jorge J. LLIBRE GUERRA (St. Louis, USA); Constantine G. LYKETSOS (Baltimore, USA); Gad A. MARSHALL (Boston, USA); Lefkos T. MIDDLETON (London, UK); José Luis MOLINUEVO (Valby, Denmark); Ronald PETERSEN (Minnesota, USA); Michael S. RAFII (San Diego, USA); Rema RAMAN (San Diego, USA); Craig W. RITCHIE (Edinburgh, UK); Robert RISSMAN (San Diego, USA); Marwan SABBAGH (Las Vegas, USA); Stephen SALLOWAY (Providence, USA); Rachel SCHINDLER (New York, USA); Philip SCHELTENS (Amsterdam, NL); Lon SCHNEIDER (Los Angeles, USA); Eric SIEMERS (Philadelphia, USA); Yong SHEN (Heife, China); Jiong SHI (Las Vegas, USA); Reisa SPERLING (Boston, USA); Yaakov STERN (New York, USA); Jacques TOUCHON* (Montpellier, France); Christopher H. VAN DYCK (New Haven, USA); Bruno VELLAS* (Toulouse, France); Michael W. WEINER* (San Francisco, USA); Bengt WINBLAD (Stockholm, Sweden); Jin-Tai YU (Shanghai, China)

* Organizing Committee Member

CTAD 2022 Lifetime Achievement Award

This year the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research is awarded to Reisa Sperling MD, and Keith Johnson, MD, in recognition for their outstanding contributions to the advancement of AD clinical trials research.



Reisa SPERLING MD

Professor of Neurology at Harvard Medical School and Director of the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital, Boston, MA (USA)

Dr. Reisa Sperling is a neurologist focused on the detection and treatment of Alzheimer's disease (AD) at the pre-symptomatic or "preclinical" stage of AD. Dr. Sperling is a Professor in Neurology at Harvard Medical School, and Director of the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital and Massachusetts General Hospital. Dr. Sperling is the co-Principal Investigator of the Harvard Aging Brain Study, and the NIH funded Alzheimer's Clinical Trial Consortium (ACTC). She co-leads the Anti-Amyloid Treatment in Asymptomatic Alzheimer's disease (A4) Study, and recently launched two new prevention trials in the AHEAD 3-45 Study with the ACTC.



Keith JOHNSON MD

Professor of Radiology and Neurology at Harvard Medical School and Director of Molecular Neuroimaging in the Division of Nuclear Medicine and Molecular Imaging at the Massachusetts General Hospital, Boston, MA (USA)

Dr. Johnson is a Professor of Radiology and Neurology at the Harvard Medical School. He is also an Associate Radiologist and the Director of Molecular Neuroimaging in the Division of Nuclear Medicine and Molecular Imaging at the Massachusetts General Hospital (MGH). He also serves as an associate physician and staff neurologist in the Memory Disorders Unit at the Brigham and Women's Hospital as well as a Clinical Associate in Neurology at the MGH. He is co-director of the Neuroimaging Program of the Massachusetts Alzheimer's Disease Research Center and its Dominantly Inherited Alzheimer Network (DIAN) research initiatives. He oversees the Clinical Brain Positron Emission Tomography (PET) Service at the MGH and also practices as a neurologist that specializes in neurodegenerative disorders. Dr. Johnson also maintains an Internet teaching atlas of neuroimaging known as the Whole Brain Atlas. His major research interests include the early diagnosis and treatment monitoring of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and dementia with Lewy bodies.

Keynotes



“The Current and Future State of AD plasma biomarkers”

Kaj Blennow, MD, PhD

Academic Chair in Clinical Neurochemistry, University of Gothenburg, Head of the Clinical Neurochemistry Lab, Sahlgrenska University Hospital, Gothenburg, Sweden

Kaj Blennow is Professor and Academic Chair in Clinical Neurochemistry at University of Gothenburg, and Head of the Clinical Neurochemistry Lab at Sahlgrenska University Hospital, Gothenburg, Sweden. His main research interest is CSF and blood biomarkers for Alzheimer’s disease (AD) and other brain disorders, and the application of these to increase the understanding of AD pathophysiology, as well as for screening, diagnostics and in therapy monitoring in clinical trials. Dr. Blennow has published more than 1700 original research papers and review articles in peer-reviewed journals, with more than 110.000 citations, and he has an H-index of 151. He is President of the Society for CSF analysis and Clinical Neurochemistry and head of the Alzheimer’s Association QC program for CSF and blood biomarkers.



“Targeting Immuno-Metabolic Pathways in Alzheimer’s Disease: Novel Mechanisms and Therapeutic Opportunities”

Suzanne Craft, PhD

Professor in Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, NC (USA)

Dr. Suzanne Craft received her Ph.D. from the University of Texas at Austin, and then completed fellowships at Boston University and Harvard Medical School. She has been a faculty member at Washington University in St. Louis and at the University of Washington. In 2012, she joined the faculty at Wake Forest School of Medicine, where she is Professor of Medicine, and Founding Director of the National Institute on Aging-funded Wake Forest Alzheimer’s Disease Research Center. Dr. Craft has served as a member of the Alzheimer’s Association Medical and Scientific Advisory Group, the NIA Board of Scientific Counselors, and the Executive Committee of the Alzheimer’s Clinical Trial Consortium. Dr. Craft’s research program investigates the role of metabolic disorders in the development of Alzheimer’s disease, through translational studies and innovative clinical trials of pharmacologic and dietary intervention to treat or prevent Alzheimer’s disease. She led a ground-breaking multi-site trial of intranasal insulin for the treatment of Alzheimer’s disease that was funded by the National Alzheimer’s Project Act. She has received a prestigious Zenith Award from the Alzheimer’s Association and a National Institute of Health MERIT award for research excellence. Her work has been featured in HBO’s Emmy-award winning series “The Alzheimer’s Project: Momentum in Science”, in the New York Times and Time magazine, as well as on BBC Newshour, and PBS Newshour.

Keynotes



“Precision Prevention of Dementia and Alzheimer’s Disease: Advancing Multidomain Interventions”

Miia Kivipelto, MD, PhD

Professor in Clinical Geriatrics at Karolinska Institutet, Center for Alzheimer Research, and Director of Research and Development at Karolinska University Hospital, Stockholm (Sweden)

Miia Kivipelto is Professor in Clinical Geriatrics at Karolinska Institutet (KI), Center for Alzheimer Research and senior geriatrician and Director of Research & Development at Theme Aging and Inflammation and Medical Unit Aging at Karolinska University Hospital, Stockholm, Sweden. Part of her Nordic Brain Network multidisciplinary research team (around 100 researchers and clinical staff) is located at University of Eastern Finland and Imperial College London, UK, where she has part time position as Professor. Her frontline research findings have been published in leading journals (340+ publications, H-index 78) and she has received numerous prestigious awards. Dr. Kivipelto’s translational research focuses on the prevention, early diagnosis and treatment of cognitive impairment, dementia and Alzheimer’s disease (AD). Through epidemiological studies, Prof. Kivipelto has identified various lifestyle and vascular risk factors for dementia and interactions with genetic factors and clarified underlying mechanisms. She is the PI of the landmark FINGER trial and founder and scientific leader of World-Wide FINGERS network. Professor Kivipelto is often invited to leading global dementia conferences and task forces.



“Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer’s Disease”

Roger Nitsch, MD

CEO and President Neurimmune, Schlieren (Switzerland)

Roger Nitsch serves as CEO and President of Neurimmune, which he founded in 2006 with two business partners. A neuroscientist with a background in medicine, Roger is recognized as an opinion leader in neurodegenerative diseases with over 30 years of experience in Alzheimer’s disease research. He is a Potamkin Prize winner and Member of the German Academy of Sciences and served as a founding director of the Institute for Regenerative Medicine (IREM), University of Zurich. Roger holds an MD degree from the University of Heidelberg and earned his post-doctoral qualification at the Massachusetts Institute of Technology and Harvard Medical School.

A large audience is seated in a conference hall, facing a stage. Two large presentation screens are visible on the stage, displaying a slide titled "High dose regimen: Individual-level dosing". The audience is diverse in age and appearance, and many are looking towards the stage. The room has a high ceiling with exposed lighting rigs and speakers. The overall atmosphere is professional and focused.

**ONSITE
PROGRAM**
in San Francisco
Available via livestream
on the CTAD22
digital platform

Program at a glance

● Tuesday, NOVEMBER 29

- 4.00 p.m. Opening Ceremony and CTAD Lifetime Achievement Award
- 4.30 p.m. **KEYNOTE 1:** Targeting Immuno-Metabolic Pathways in Alzheimer's Disease: Novel Mechanisms and Therapeutic Opportunities
- 4.50 p.m. **Clarity AD: A Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study Evaluating Lecanemab in Early Alzheimer's Disease**
- 6.30 -7.30 p.m. CTAD Welcome Reception with the support of the Alzheimer's Association 

● Wednesday, NOVEMBER 30

- 8.00 a.m. Welcome coffee - Poster Walking Tour
- 9.00 a.m. **KEYNOTE 2:** Precision Prevention of Dementia and Alzheimer's Disease: Advancing Multidomain Interventions
- 9.20 a.m. **SYMPOSIUM 1:** CTAD 2022 fluid biomarker symposium: Recent advances in plasma and CSF Alzheimer biomarkers to improve clinical practice and trials
- 10.00 a.m. Coffee break and poster session
- 10.30 a.m. **LATE BREAKING ORAL COMMUNICATIONS**
- 11.00 a.m. **ORAL COMMUNICATIONS**
- 12.15 p.m. Lunch on your own and poster session
- 1.20 p.m. **SYMPOSIUM 2:** Decentralization Approaches for Clinical Trials on Alzheimer's Disease
- 2.00 p.m. **ORAL COMMUNICATIONS' FOCUS SESSION:** New Insights for Amyloid and Tau PET Imaging
- 3.00 p.m. **LATE BREAKING COMMUNICATIONS**
- 3.45 p.m. Coffee break and poster session
- 4.15 p.m. **Topline Results of Phase III GRADUATE I & II Pivotal Trials with Subcutaneous Gantenerumab**

● Thursday, DECEMBER 1

- 8.00 a.m. Welcome coffee - Poster Walking Tour
- 9.00 a.m. **KEYNOTE 3:** The Current and Future State of AD plasma biomarkers
- 9.20 a.m. CTAD open discussion: Anti Amyloid Phase 3 results
- 9.50 a.m. **ORAL COMMUNICATIONS' FOCUS SESSION:** Beyond Amyloid and Tau: Emerging solutions
- 10.55 a.m. Coffee break and poster session
- 11.20 a.m. **Tackling Agitation in Alzheimer's Dementia: Brexpiprazole phase III trial results**
- 12.00 p.m. **LATE BREAKING ORAL COMMUNICATIONS**
- 12.30 p.m. Lunch on your own and poster session
- 1.30 p.m. **ORAL COMMUNICATIONS**
- 2.30 p.m. **ROUNDTABLE 1:** Investments in Innovation: Advancing the Path Forward to New Alzheimer's Treatments
- 3.00 p.m. **ORAL COMMUNICATIONS**
- 4.00 p.m. Coffee break and poster session
- 4.30 p.m. **LATE BREAKING ORAL COMMUNICATIONS**

● Friday, DECEMBER 2

- 8.00 a.m. Welcome coffee - Poster Walking Tour
- 9.00 a.m. **KEYNOTE 4:** Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer's Disease
- 9.20 a.m. **LATE BREAKING ORAL COMMUNICATIONS**
- 10.20 a.m. Coffee break and poster session
- 10.45 a.m. **ROUNDTABLE 2:** The Alzheimer's disease Patient Pathway from a sex and gender lens
- 11.15 a.m. **ORAL COMMUNICATIONS' FOCUS SESSION:** Interim or preliminary data and study design
- 12.05 p.m. Lunch on your own and poster session
- 1.05 p.m. **ORAL COMMUNICATIONS**
- 1.35 a.m. **ORAL COMMUNICATIONS' FOCUS SESSION:** Clinical Trials Phase 1 Results
- 2.05 p.m. **ORAL COMMUNICATIONS**
- 3.05 p.m. Coffee break and poster session
- 3.35 p.m. **LATE BREAKING ORAL COMMUNICATION**
- 3.50 p.m. **ORAL COMMUNICATIONS**

● Tuesday,
NOVEMBER 29

All scientific sessions are held
in Grand Ballroom AB - Tower 2

4.00 p.m

Opening Ceremony

Mike Weiner, UCSF, San Francisco, CA (USA), Jacques Touchon, Montpellier University, Montpellier (France), Paul Aisen, Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA (USA), Bruno Vellas, Gerontopole, Toulouse University, Toulouse (France)

CTAD Lifetime Achievement Award Alzheimer's Disease Therapeutic Research

Presented to Reisa Sperling and Keith Johnson, in recognition for their outstanding contributions to the advancement of AD clinical trials research

Introduction by Paul Aisen, Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA (USA).

4.30 p.m

KEYNOTE 1

Targeting Immuno-Metabolic Pathways in Alzheimer's Disease: Novel Mechanisms and Therapeutic Opportunities

Introduction by Jacques Touchon, Montpellier University, Montpellier (France)

Suzanne Craft, Wake Forest University School of Medicine, Winston-Salem, NC (USA)

4.50 p.m

Clarity AD: A Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study Evaluating Lecanemab in Early Alzheimer's Disease

Chairman: Takeshi Iwatsubo, University of Tokyo - Tokyo (Japan)

Presentation 1: Clarity AD: Clinical Trial Background and Study Design Overview

Michael Irizarry, Eisai Inc. - Nutley, NJ (United States)

Presentation 2: Lecanemab for the Treatment of Early Alzheimer's Disease: Topline Efficacy Results from Clarity AD

Christopher van Dyck, Yale School of Medicine - New Haven, CT (United States)

Presentation 3: Safety Profile of Lecanemab in Early Alzheimer's Disease

Marwan Sabbagh, Barrow Neurological Institute - Phoenix, AZ (United States)

Presentation 4: Imaging, Plasma, and CSF Biomarkers Assessments from Clarity AD

Randall J. Bateman, Washington University - St. Louis, MO (United States)

Presentation 5: Context of Clarity AD Results

Sharon Cohen, Toronto Memory Program - Toronto, Ontario (Canada)

Panel Discussion and Q&A

6.05 p.m

End of the Conference Day

6.30 - 7.30 p.m

CTAD Welcome Reception with the support of the Alzheimer's Association



Continental Ballroom - Tower 3



● Wednesday, NOVEMBER 30

All scientific sessions are held
in Grand Ballroom AB - Tower 2

- 08.00 a.m. Welcome coffee - **NEW this year at CTAD > Poster Walking Tour**  Yosemite/Imperial Ballroom & Registration area - Tower 2
- 9.00 a.m. **KEYNOTE 2**
Precision Prevention of Dementia and Alzheimer's Disease: Advancing Multidomain Interventions
Introduction Bruno Vellas, *Toulouse University Hospital, Toulouse (France)*
Miia Kivipelto, *Karolinska Institutet, Center for Alzheimer Research, Karolinska University Hospital, Stockholm (Sweden)*
- 9.20 a.m. **SYMPOSIUM 1**
CTAD 2022 fluid biomarker symposium: Recent advances in plasma and CSF Alzheimer biomarkers to improve clinical practice and trials
Chair: Kaj Blennow, *University of Gothenburg, Gothenburg (Sweden)*
Presentation 1: Relationship between blood plasma and CSF measures of A β 42/40, tau, and NFL species for tracking drug effects in clinical trials of Alzheimer's disease
Randall J. Bateman, Washington University School of Medicine, St. Louis, MO (USA)
Presentation 2: Consideration and use of AT(N) blood-based biomarkers for community screening
Michelle M. Mielke, Wake Forest University School of Medicine, Winston-Salem, NC (USA)
Presentation 3: Implementation of plasma biomarkers into clinical practice and trials
Oskar Hansson, Lund University, Lund (Sweden)
- 10.00 a.m. Coffee break and poster session  Yosemite/Imperial Ballroom & Registration area - Tower 2
- 10.30 a.m. **LATE BREAKING ORAL COMMUNICATIONS**
Chairs: Reisa Sperling, *Brigham and Women's Hospital - Boston, MA (United States)*, Robert Rissman, *UC San Diego and University of Southern California - San Diego, CA (United States)*
- 10.30 a.m. **LB1 - Tau PET associated with plasma p-tau217 and cognitive testing in preclinical AD: Screening data from the AHEAD Study A3 and A45 Trials**
*Keith Johnson*¹, Aaron Schultz¹, Robert Rissman², Oliver Langford², Emma Thibault¹, Matthew Meyer³, Kristopher Kirmess³, Michael Irizarry⁴, Jin Zhou⁴, Michael Donohue², Rema Raman², Paul Aisen², Reisa Sperling^{5,1}, Ahead 3-45 Study Team⁶
¹Massachusetts General Hospital - Boston (United States), ²University of Southern California - San Diego (United States), ³C2N Diagnostics - St. Louis (United States), ⁴Eisai - Nutley (United States), ⁵Brigham and Women's Hospital - Boston (United States), ⁶ACTC - Many Sites (United States)
- 10.45 a.m. **LB2 - Plasma levels of Abeta42/40 and p-tau217 ratios increase accuracy of amyloid PET prediction in preclinical AD**
Robert Rissman^{1,2}, Oliver Langford², Michael Donohue², Rema Raman², Sara Abdel-Latif², Matthew Meyer³, Kristopher Kirmess³, Joel Braunstein³, Michael Irizarry⁴, Keith Johnson⁵, Paul Aisen², Reisa Sperling⁶, Team Ahead 3-45 Study⁷
¹UC San Diego - La Jolla, Ca (United States), ²University of Southern California - San Diego, Ca (United States), ³C2N Diagnostics - St. Louis, Mo (United States), ⁴Eisai - Indianapolis, In (United States), ⁵Massachusetts General Hospital, Harvard University - Boston, Ma (United States), ⁶Brigham and Woman's Hospital, Harvard - Boston, Ma (United States), ⁷ACTC - San Diego, Ca (United States)
- 11.00 a.m. **ORAL COMMUNICATIONS**
Chairs: Michael Irizarry, *Eisai Inc. - Nutley, NJ (United States)* and Michael Weiner, *UCSF, San Francisco, CA (United States)*
- 11.00 a.m. **OC1 - ACI-35.030 and JACI-35.064, two novel anti-phospho-Tau vaccines for the treatment of Alzheimer's Disease: Interim Phase 1b/2a data on safety, tolerability and immunogenicity**
Johannes Streffer^{1,2}, Julien Mermoud¹, Olivier Sol¹, Marija Vukicevic¹, Emma Fiorini¹, Eva Gollwitzer¹, Valérie Hliva¹, David Hickman¹, Julian Gray¹, Piergiorgio Donati¹, Maria Pilar Lopez Deber¹, Julien Rongère¹, Andrea Pfeifer¹, Marie Kosco-Vilbois¹, Philip Scheltens³
¹AC Immune SA - Lausanne (Switzerland), ²University of Antwerp - Antwerp (Belgium), ³VUMC - Amsterdam (The Netherlands)

● Wednesday, NOVEMBER 30

All scientific sessions are held
in Grand Ballroom AB - Tower 2

- 11.15 a.m. **OC2 - Results of a Phase 2/3 Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Study to Evaluate the Efficacy and Safety of 12 Week Treatment with the Phosphodiesterase 9 (PDE9) inhibitor Irsenontrine (E2027) in Subjects With Dementia With Lewy Bodies**
Michael Irizarry¹, Robert Lai², Steven Hersch¹, Kate Pinner², Shobha Dhadda¹, Lynn Kramer¹
¹Eisai Inc. - Nutley (United States), ²Eisai Ltd. - Hatfield (United Kingdom)
- 11.30 a.m. **OC3 - HMTM Topline Results of Phase 3 LUCIDITY – The First Tau Aggregation Inhibitor**
Bjoern Schelker^{1,2}
¹TauRx Therapeutics Ltd - Aberdeen (United Kingdom), ²University of Aberdeen - Aberdeen (United Kingdom)
- 11.45 a.m. **OC4 - Janssen Simoa Plasma p217+tau assay as a precision prescreening tool in Autonomy Ph2 anti-tau monoclonal Ab trial in early Alzheimer's Disease**
Gallen Triana-Baltzer¹, Ziad Saad¹, Setareh Moughadam¹, Randy Slemmon¹, Mary Quiceno¹, David Henley¹, Hartmuth Kolb¹
¹Janssen Research & Development - San Diego (United States)
- 12.00 p.m. **OC5 - Long term and economic outcomes for mirtazapine and carbamazepine versus placebo: new data from the SYMBAD RCT**
Sube Banerjee On Behalf Of The Symbad Group¹
¹University Of Plymouth - Plymouth (United Kingdom)
- 12.15 p.m. Lunch on your own and poster session **Yosemite/Imperial Ballroom & Registration area - Tower 2**
- 1.20 p.m. **SYMPOSIUM 2**
Decentralization Approaches for Clinical Trials on Alzheimer's Disease
Chair: Holly Massett, National Institute on Aging – Bethesda, MD (United States)

Presentation 1: Remote assessments in a follow-on study from TRAILBLAZER-ALZ
Jessica Langbaum, Banner Alzheimer's Institute - Phoenix, AZ (United States)

Presentation 2: Effects of supervision on cognitive and functional assessment outcomes
Paul Maruff, CogState - Melbourne (Australia)

Presentation 3: Decentralization approaches in TRAILBLAZER-ALZ 3
Roy Yaari, Eli Lilly and Company – Indianapolis, IN (United States)

Presentation 4: Investigator experience in a decentralized clinical trial on Alzheimer's Disease
Ralph Lee, Irvine Clinical Research – Irvine, CA (United States)
- 2.00 p.m. **ORAL COMMUNICATIONS' FOCUS SESSION: New Insights for Amyloid and Tau PET Imaging**
Chairs: Jessica Langbaum, Banner Alzheimer's Institute - Phoenix, AZ (United States), Oskar Hansson, Lund University, Lund (Sweden)
- 2.00 p.m. **OC6 - Combination of regional flortaucipir quantification and event-based modeling in clinical trial analyses**
Ixavier Higgins¹, Amanda Morris¹, John Sims¹, Mark Mintun¹, Sergey Shcherbinin¹
¹Eli Lilly and Company - Indianapolis (United States)
- 2.10 p.m. **OC7 - Longitudinal Tau PET increase is highest in brain regions with strongest functional connectivity to regions with most NFT at Baseline: An independent validation**
Ziad S. Saad¹, Ritobrato Datta¹, Christopher Rowe², Hartmuth C. Kolb¹
¹Janssen R&D, Johnson & Johnson - San Diego (United States), ²Austin Health and University of Melbourne - Melbourne (Australia)
- 2.20 p.m. **OC8 - Individualised tau-PET measures might be superior to group level measures when determining change in tau deposition over time in Alzheimer's disease**
Antoine Leuzy¹, Alexa Pichet-Binette¹, Jacob W. Vogel², Gregory Klein³, Edilio Borroni³, Matteo Tonietto³, Olof Strandberg¹, Niklas Mattsson-Carlgrén¹, Sebastian Palmqvist¹, Erik Stomrud¹, Rik Ossenkoppé¹, Ruben Smith¹, Oskar Hansson¹
¹Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund (Sweden), ²Penn/CHOP Lifespan Brain Institute, University of Pennsylvania, Philadelphia (United States), ³F. Hoffmann-La Roche Ltd, Basel (Switzerland)

● Wednesday, NOVEMBER 30

All scientific sessions are held
in Grand Ballroom AB - Tower 2

- 2.30 p.m **OC9 - Prevalence and longitudinal clinical outcomes of visually 18F-flortaucipir PET-positive individuals across the Alzheimer's disease spectrum**
Alexis Moscoso¹, Fiona Heeman¹, Valle Camacho², Martijn Van Essen³, Michel J Grothe⁴, Li Lin⁵, Ismini Mainta⁶, Federica Ribaldi⁷, Michael D Devous⁸, Michael J Pontecorvo⁸, Giovanni B Frisoni⁷, Valentina Garibotto⁷, Michael Schöll¹
¹Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg - Gothenburg (Sweden), ²Department of Nuclear Medicine, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. - Barcelona (Spain), ³Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden. - Gothenburg (Sweden), ⁴Movement Disorders Group, Institute of Biomedicine of Seville-IBiS, Seville, Spain. - Sevilla (Spain), ⁵Department of radiology, the third affiliated hospital of sun yat-sen university. - Guangzhou (China), ⁶Division of Nuclear Medicine, Geneva University Hospitals, Geneva, Switzerland. - Genève (Switzerland), ⁷Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland - Genève (Switzerland), ⁸Avid Radiopharmaceuticals, Philadelphia, PA, USA - Philadelphia (United States)
- 2.40 p.m **OC10 - Concordance of Visual and Quantitative Analysis for Amyloid PET Imaging With Three 18F Tracers in the CHARIOT-PRO Substudy**
Gerald Novak¹, Ziad Saad², David Scott³, Chi Udeh-Momoh⁴, Luc Bracoud⁵, Craig Ritchie⁶, Lefkos Middleton⁷
¹Janssen R&D - Titusville, Nj (United States), ²Janssen R&D - La Jolla, Ca (United States), ³Clario (formerly Bioclinica) - San Mateo, Ca (United States), ⁴Imperial College - London (United Kingdom), ⁵Clario (formerly Bioclinica) - Lyon (France), ⁶University of edinburgh - Edinburgh (United Kingdom), ⁷Imperial College - Edinburgh (United Kingdom)
- 2.50 p.m **OC11 - AmyloidIQ quantification strongly agrees with both histopathology and visual reads across multiple amyloid tracers**
Alex Whittington¹, Santiago Bullich², Lily Porat¹, Roger Gunn¹
¹Invicro - London (United Kingdom), ²Life Molecular Imaging - Berlin (Germany)
- 3.00 p.m **LATE BREAKING ORAL COMMUNICATIONS**
Chairs: Kristine Yaffe, UCSF, San Francisco, CA (United States), Stephen Salloway, Alpert Medical School of Brown University, Providence, RI (United States)
- 3.00 p.m **LB3 - TRAILBLAZER-ALZ 4: Topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer's disease**
Stephen Salloway¹, Elly Lee², Michelle Papka³, Andrew Pain⁴, Ena Oru⁴, Margaret B. Ferguson⁴, Hong Wang⁴, Michael Case⁴, Ming Lu⁴, Emily C. Collins⁴, Dawn Brooks⁴, John Sims⁴
¹Department of Neurology and Department of Psychiatry, Alpert Medical School of Brown University, And Providence, RI, USA, Butler Hospital - Providence (United States), ²Irvine Clinical Research - Irvine (United States), ³The Cognitive and Research Center of New Jersey LLC - Springfield (United States), ⁴Eli Lilly and Company - Indianapolis (United States)
- 3.15 p.m **LB4 - CSF MTBR-tau243 is a non-amyloid specific biomarker of neurofibrillary tangles of Alzheimer's disease**
Kanta Horie^{1,2}, Gemma Salvadó³, Nicolas Barthélemy¹, Yan Li¹, Benjamin Saef¹, Charlie Chen¹, Hong Jiang¹, Brian Gordon¹, Tammie Benzinger¹, David Holtzman¹, Suzanne Schindler¹, Oskar Hansson^{3,4}, Randall Bateman¹
¹Washington University School of Medicine - St. Louis (United States), ²Eisai Inc. - Nutley (United States), ³Lund University - Lund (Sweden), ⁴Skåne University Hospital - Malmö (Sweden)
- 3.30 p.m **LB5 - Top-line Results from the 2-Year Systematic Multi-domain Alzheimer's Risk Reduction Trial (SMARRT)**
Kristine Yaffe¹, Eric Vittinghoff¹, Sascha Dublin², Carrie Peltz¹, Lynn Fleckenstein², Dori Rosenberg², Deborah Barnes¹, Benjamin Balderson², Eric Larson³
¹University of California, San Francisco - San Francisco, Ca (United States), ²Kaiser Permanente Washington Health Research Institute - Seattle, Wa (United States), ³University of Washington - Seattle, Wa (United States)
- 3.45 p.m Coffee break and poster session **Yosemite/Imperial Ballroom & Registration area - Tower 2** 

● Wednesday,
NOVEMBER 30

All scientific sessions are held
in Grand Ballroom AB - Tower 2

4.15 p.m

Topline Results of Phase III GRADUATE I & II Pivotal Trials with Subcutaneous Gantenerumab

Chair: Jeffrey F Cummings, Chambers-Grundq Center for Transformative Neuroscience, University of Nevada Las Vegas (UNLV) - Las Vegas, NV (United States)

Presenter: Randall J Bateman, Washington University School of Medicine - Saint Louis, MO, (United States)

Panelists: Rachele S Doody ^{1,2}, Stephen P Salloway ³ Sandra E Black ^{4,5}

¹F. Hoffmann-La Roche Ltd - Basel (Switzerland), ²Genentech, Inc - South San Francisco, CA, (United States), ³Butler Hospital and Warren Alpert Medical School of Brown University - Providence, RI, (United States), ⁴Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre - Toronto, Ontario (Canada), ⁵ LC Campbell Cognitive Neurology Research Unit, Dr Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, University of Toronto -Toronto, Ontario (Canada)

5.15 p.m

End of the Conference Day

● Thursday,
DECEMBER 1

All scientific sessions are held
in Grand Ballroom AB - Tower 2

- 08.00 a.m. Welcome coffee - **NEW this year at CTAD > Poster Walking Tour**  Yosemite/Imperial Ballroom & Registration area - Tower 2
- 9.00 a.m. **KEYNOTE 3**
The Current and Future State of AD plasma biomarkers
Introduction: Michael Weiner, UCSF - San Francisco, CA (United States)
Kaj Blennow, University of Gothenburg, and Sahlgrenska University Hospital - Gothenburg (Sweden)
- 9.20 a.m. **CTAD open discussion: Anti Amyloid Phase 3 results**
Maria Carrillo¹, David Knopman², Lefkos Middleton³, Ron Petersen²
¹ Alzheimer's Association - Chicago, IL (United States), ² Mayo Clinic - Rochester, MN (United States), ³ Imperial College - London (United Kingdom)
- 9.50 a.m. **ORAL COMMUNICATIONS' FOCUS SESSION: Beyond Amyloid and Tau: Emerging solutions**
Chair: Howard Fillit, Alzheimer's Drug Discovery Foundation, New York, NY (USA)
- 9.55 a.m. **OC12 - Topline Results of EXERT: Can Exercise Protect Against Cognitive Decline in MCI?**
Carl Cotman¹, Howard Feldman², Andrea Lacroix², Aladdin Shadyab², Diane Jacobs², David Salmon², Ron Thomas², Shelia Jin², Judy Pa², Jeffrey Katula³, Robert Rissman⁴, James Brewer², Youngkyoo Jung⁵, Jing Zhang², **Laura Baker**⁶
¹UCI (United States), ²UCSD (United States), ³Wake Forest University (United States), ⁴USC (United States), ⁵UC Davis (United States), ⁶Wake Forest University School of Medicine (United States)
- 10.10 a.m. **OC13 - Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (StoMP-AD) – Pilot Study Results on Central Nervous System Penetration and Alzheimer's Disease Biomarkers**
Mitzi Gonzales¹, Valentina Garbarino¹, Tiffany Kautz¹, Ronald Petersen², Tamara Tchkonja², James Kirkland², Suzanne Craft³, Sudha Seshadri¹, Nicolas Musi¹, Miranda Orr³
¹UT Health San Antonio - San Antonio (United States), ²Mayo Clinic - Rochester (United States), ³Wake Forest School Of Medicine - Winston-Salem (United States)
- 10.25 a.m. **OC14 - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of T2001 in Alzheimer Patients**
Ronald Van Der Geest¹, Anastasia Lili¹, Oscar Van Loosbroek¹, Andreia Almeida¹, Marlies Oosthoek², Charlotte Teunissen², Sietske Sikkes³, Everard Vijverberg²
¹Treeway T2001AD BV - Tilburg (Netherlands), ²Neurochemistry Laboratory, Department of Clinical Chemistry, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), ³Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands)
- 10.40 a.m. **OC15 - Protein Biomarkers in Autosomal Dominant Alzheimer's Disease Cerebrospinal Fluid Identify Early Changes in Brain Glucose Metabolism and the Matrisome**
Shijia Bian¹, E. Kathleen Carter¹, Rafi Haque¹, Caroline Watson¹, Brian Gordon², Lingyan Ping¹, Duc Duong¹, Michael Epstein¹, James Lah¹, Blaine Roberts¹, Anne Fagan², Nicholas Seyfried¹, Allan Levey¹, Erik Johnson¹
¹Emory University - Atlanta (United States), ²Washington University - St. Louis (United States)
- 10.55 a.m. Coffee break and poster session **Yosemite/Imperial Ballroom & Registration area - Tower 2** 
- 11.20 a.m. **Tackling Agitation in Alzheimer's Dementia: Brexpiprazole phase III trial results**
George Grossberg¹, Daniel Lee², Mary Slomkowski², **Nanco Hefting**³, Dalei Chen², Klaus Larsen³, Eva Kohegyi², Mary Hobart², Jeffrey Cummings⁴
¹Department of Psychiatry and Behavioral Neuroscience at Saint Louis University School of Medicine - St. Louis, Missouri (United States), ²Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton, New Jersey (United States), ³H. Lundbeck A/S - Valby, Copenhagen (Denmark), ⁴Chambers-Grundy Center for Transformative Neuroscience at School of Integrated Health Sciences University of Nevada Las Vegas (UNLV) - Las Vegas, Nevada (United States)
- Panel discussion: Mary Sano**¹, Bruno Vellas², Clive Ballard³, Alireza Atri⁴
¹Mount Sinai School of Medicine - New York, NY (United States), ²Toulouse University Hospital - Toulouse (France), ³University of Exeter Medical School - Exeter (United Kingdom), ⁴Banner Sun Health Research Institute - Phoenix, AZ (United States)

12.00 p.m

LATE BREAKING ORAL COMMUNICATIONS

Chairs: Maria Carrillo, Alzheimer's Association - Chicago, IL (United States), Pierre-Jean Ousset, Toulouse University Hospital - Toulouse (France)

12.00 p.m

LB6 - Two-year prognostic utility of plasma p217+tau in the Alzheimer continuum

Azadeh Feizpour^{1,2}, Vincent Doré^{2,3}, James D. Doecke⁴, Ziad S. Saad⁵, Gallen Triana-Baltzer⁵, Natasha Krishnadas^{1,2}, Christopher Fowler¹, Larry Ward¹, Ralph N. Martins^{6,7}, Colin L. Masters¹, Victor L. Villemagne^{2,8}, Jurgen Fripp⁴, Hartmuth C. Kolb⁵, Christopher C. Rowe^{2,1,9}

¹The Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia - Melbourne (Australia), ²Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia - Melbourne (Australia), ³The Australian e-Health Research Centre, CSIRO, Melbourne, Victoria, Australia - Melbourne (Australia), ⁴The Australian e-Health Research Centre, CSIRO, Brisbane, Queensland, Australia - Brisbane (Australia), ⁵Neuroscience Biomarkers, Janssen Research and Development, La Jolla, CA, USA - San Diego (United States), ⁶Edith Cowan University - Perth (Australia), ⁷McCusker Alzheimer's Research Foundation, Nedlands, - Perth (Australia), ⁸Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA - Pittsburgh (United States), ⁹Florey Department of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia - Melbourne (Australia)

12.15 p.m

LB7 - ALZ-NET: Using Real World Evidence to Define the Future of Alzheimer's Treatment and Care

Maria Carrillo¹, Gil Rabinovici², Michael Rafii³

¹Alzheimer's Association - Chicago (United States), ²Memory and Aging Center, Departments of Neurology, Radiology & Biomedical Imaging, University of California, San Francisco - San Francisco (United States), ³Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California - San Diego (United States)

12.30 p.m

Lunch on your own and poster session **Yosemite/Imperial Ballroom & Registration area - Tower 2**

1.30 p.m

ORAL COMMUNICATIONS

Chairs: Philip Scheltens, LSP Dementia Fund at EQT Life, Alzheimer Centre Amsterdam, Amsterdam (The Netherlands), Andrew Stern, Brigham And Women's Hospital, Harvard Medical School - Boston, MA (United States)

1.30 p.m

OC16 - Leveraging novel technologies to design and implement more patient focused clinical trials

Dave Miller¹ ¹Unlearn.AI - Berkeley (United States)

1.45 p.m

OC17 - Amyloid and Tau PET positive cognitively unimpaired individuals: Destined to decline?

Rik Ossenkoppele¹, Alexa Pichet Binette¹, Colin Groot¹, Reisa Sperling², Colin Masters³, Wiesje Van Der Flier⁴, William Jagust⁵, Petersen Ronald⁶, Clifford Jack⁶, Oskar Hansson¹

¹Lund University - Lund (Sweden), ²MGH - Boston (United States), ³The Florey Institute Of Neuroscience And Mental Health Melbourne Victoria Australia - Parkville (Australia), ⁴Amsterdam University Medical Center - Amsterdam (Netherlands), ⁵UC Berkeley - Berkeley (United States), ⁶Mayo Clinic - Rochester (United States)

2.00 p.m

OC18 - Plasma NT1-tau correlates with age and cognitive decline in two large Down syndrome cohorts

Andrew M. Stern¹, Kathryn L. Van Pelt², Lei Liu¹, Amirah K. Anderson¹, Beth Ostaszewski¹, Dennis J. Selkoe¹, Frederick Schmitt², Elizabeth Head³

¹Ann Romney Center For Neurologic Diseases, Brigham And Women's Hospital, Harvard Medical School - Boston, MA (United States), ²Sanders-Brown Center For Aging, Department Of Neurology, University Of Kentucky - Lexington, KY (United States), ³Department Of Pathology And Laboratory Medicine, University Of California, Irvine - Irvine, CA (United States)

2.15 p.m

OC19 - Specific associations between plasma biomarkers and post-mortem amyloid plaque and neurofibrillary tau tangle burden

Gemma Salvadó¹, Rik Ossenkoppele^{1,2}, Nicholas J Ashton^{3,4,5}, Thomas G Beach⁶, Geidy E Serrano⁶, Gwendlyn Kollmorgen⁷, Henrik Zetterberg^{3,8,9,10}, Shorena Janelidze¹, Kaj Blennow³, Oskar Hansson^{1,11}

¹Clinical Memory Research Unit, Department Of Clinical Sciences, Malmö, Lund University - Lund (Sweden), ²Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center - Amsterdam (Netherlands), ³Department Of Psychiatry And Neurochemistry, Institute Of Neuroscience And Physiology, The Sahlgrenska Academy, University Of Gothenburg - Gothenburg (Sweden), ⁴Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, King's College London - London (United Kingdom), ⁵NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley, NHS Foundation - London (United Kingdom), ⁶Banner Sun Health Research Institute - Sun City (United States), ⁷Roche Diagnostics GmbH - Penzberg (Germany), ⁸Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), ⁹Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square - London (United Kingdom), ¹⁰UK Dementia Research Institute at UCL - London (United Kingdom), ¹¹Memory Clinic, Skåne University Hospital - Malmö (Sweden)

● Thursday,
DECEMBER 1

All scientific sessions are held
in Grand Ballroom AB - Tower 2

2.30 p.m

ROUNDTABLE 1

Investments in Innovation: Advancing the Path Forward to New Alzheimer's Treatments

Chair: Niranjan Bose, Gates Ventures, Seattle, WA (United States)

Discussants: Howard Fillit, Alzheimer's Drug Discovery Foundation (ADDF), New York City, NY (United States); Laurence Barker, Partner in the Dementia Discovery Fund (DDF), London (United Kingdom); Philip Scheltens, LSP Dementia Fund at EQT Life, Alzheimer Centre Amsterdam (University Medical Centre Amsterdam, Amsterdam (The Netherlands)); Susan Catalano, CODA Biotherapeutics, San Francisco, CA (United States)

3.00 p.m

ORAL COMMUNICATIONS

Chairs: Elaine Peskind, University of Washington School of Medicine - Seattle, WA (United States), Eric Reiman, Banner Alzheimer's Institute Phoenix, AZ (United States)

3.00 p.m

OC20 - Systemic inflammation and reduced cerebral A β clearance triggered by pancreatic amylin

Florin Despa¹, Nirmal Verma¹, Edric Winford¹, Peter Nelson¹, Gregory Jicha¹, Larry Goldstein¹, Claire Troakes², Henrik Zetterberg³, John Hardy³, Tammaryn Lashley³

¹University Of Kentucky - Lexington (United States), ²King's College London - London (United Kingdom), ³Dementia Research Institute at UCL - London (United Kingdom)

3.15 p.m

OC21 - Prazosin for Agitation in Alzheimer's Disease: PEACE-AD

Elaine Peskind¹, Murray Raskind², Ronald Thomas³, Gregory Jicha⁴, Neela Patel⁵, Amy Pierce⁶, Sharon Brangman⁷, Mary Sano⁸, Jeffrey Kaye⁶, Miranda Lim⁶, Michael Au-Yeung⁶, Michelle Herman⁹, Gabriel Leger⁹, Karen Messer⁹, Howard Feldman⁹

¹VA Northwest Mental Illness Research, Education and Clinical Center (MIRECC), Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine - Seattle (United States), ²VA Northwest Mental Illness Research, Education and Clinical Center (MIRECC) and Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine - Seattle (United States), ³Departments of Family Medicine and Neurosciences, University of California San Diego - La Jolla (United States), ⁴Department of Neurology, University of Kentucky - Lexington (United States), ⁵Department of Family and Community Medicine, UT Health San Antonio - San Antonio (United States), ⁶Department of Neurology, OHSU School of Medicine - Portland (United States), ⁷Department of Geriatrics, SUNY Upstate Medical University - Syracuse (United States), ⁸Department of Psychiatry, Mount Sinai School of Medicine - New York (United States), ⁹Department of Neurosciences, University of California San Diego - La Jolla (United States)

3.30 p.m

OC22 - Demographic Analysis of Industry Sponsored Alzheimer's Disease Trial Populations in the United States

Stephen Peroutka¹ - ¹PPD, Part Of Thermo Fisher Scientific - Carmel, CA (United States)

3.45 p.m

OC23 - Plasma Biomarker Findings from the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial

Eric M. Reiman¹, Francisco Lopera², Silvia Rios-Romenets², Courtney Schiffman³, Derrek Hibar³, Gwendlyn Kollmorgen⁴, Margarita Giraldo², Natalia Acosta², Alejandro Espinosa², Gustavo Villegas², Claudia Muñoz², Laura Serna², Karina Herrera², Yi Su¹, Robert Alexander¹

¹Banner Alzheimer's Institute - Phoenix, Arizona (United States), ²Neurosciences Group of Antioquia, University of Antioquia - Medellín (Colombia), ³Genentech, Inc. - South San Francisco, Ca (United States), ⁴Roche Diagnostics GmbH - Mannheim (Germany)

4.00 p.m

Coffee break and poster session Yosemite/Imperial Ballroom & Registration area - Tower 2



4.30 p.m

LATE BREAKING ORAL COMMUNICATIONS

Chairs: Michelle Farrell, Massachusetts General Hospital - Boston, MA (United States), Howard Fillit, Alzheimer's Drug Discovery Foundation (ADDF) - New York City, NY (United States)

4.30 p.m

LB8 - Top Line Data of ANAVEX®2-73 (blarcamesine) Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2b/3 in Patients with Early Alzheimer's Disease (AD)

Stephen Macfarlane¹, Timo Grimmer², Terence O'Brien³, Edward Hammond⁴, Walter Kaufmann⁴, Emmanuel Fadiran⁴, Christopher Missling⁴

¹Hammoncare - Melbourne (Australia), ²THU Munich - Munich (Germany), ³Monash University, Alfred Health - Melbourne (Australia), ⁴Anavex Life Sciences - New York (United States)

4.45 p.m

LB9 - Higher sensitivity amyloid-PET detection of the earliest focal beta-amyloid accumulation using spatial extent

Michelle E. Farrell¹, Emma G. Thibault¹, J. Alex Becker¹, Julie C. Price¹, Kuang Gong¹, Aaron P. Schultz¹, Michael J Properzi¹, Rachel F Buckley^{1,2}, Heidi I.I. Jacobs¹, Bernard J. Hanseeuw^{1,3}, Reisa A. Sperling^{1,2}, Keith A. Johnson^{1,2}
¹Massachusetts General Hospital - Boston, Ma (United States), ²Brigham & Women's Hospital - Boston, Ma (United States), ³Cliniques Universitaires Saint-Luc, Université Catholique de Louvain - Brussels (Belgium)

5.00 p.m

LB10 - Sample size estimates for preclinical AD intervention trials based on Wisconsin Registry for Alzheimer's Prevention Longitudinal PET amyloid, plasma P-tau217, and cognitive assessment data

Rebecca Langhough Kosciak¹, Derek Norton¹, Tobey Betthausen¹, Lianlian Du¹, Erin Jonaitis¹, Karly Cody¹, Bruce Hermann¹, Kimberly Mueller¹, Rick Chappell¹, Bradley Christian¹, Shorena Janelidze¹, Niklas Mattsson-Carlgrén¹, Oskar Hansson¹, Sterling Johnson¹
¹University of Wisconsin SMPH - Madison (United States)

5.15 p.m

LB11 - Cerebrospinal Fluid Biomarker Effects From a Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Alzheimer's Disease: Results From the PEGASUS Trial

Steven E. Arnold^{1,2}, Newman Knowlton³, Victoria J. Williams⁴, Jeffrey M. Burns⁵, Monica Crane⁶, Alison J. McManus¹, Sanjeev N. Vaishnavi⁷, Zoe Arvanitakis⁸, Judith Neugroschl⁹, Karen Bell¹⁰, Bianca A. Trombetta¹, Becky C. Carlyle¹¹, Pia Kivisäkk^{12,2}, Rudolph E. Tanzi^{13,14}, Kent Leslie^{15,16}
¹Department of Neurology, Massachusetts General Hospital, Boston, MA, USA - Boston (United States), ²Harvard Medical School, Boston, MA, USA - Boston (United States), ³Pentara Corporation, Millcreek, UT, USA - Millcreek (United States), ⁴Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA - Madison (United States), ⁵University of Kansas Alzheimer's Disease Center, Kansas City, KS, USA - Kansas City (United States), ⁶Genesis Neuroscience Clinic, Knoxville, TN, USA - Knoxville (United States), ⁷Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA - Philadelphia (United States), ⁸Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA - Chicago (United States), ⁹Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA - New York (United States), ¹⁰Department of Neurology, Columbia University, New York, NY, USA - New York (United States), ¹¹Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, England, United Kingdom - England (United Kingdom), ¹²Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; ²Harvard Medical School, Boston, MA, USA - Boston (United States), ¹³Harvard Medical School, Boston, MA, USA - Boston (United Kingdom), ¹⁴Department of Neurology, Genetics and Aging Research Unit, McCance Center for Brain Health, Massachusetts General Hospital, Harvard University, Boston, MA, USA - Boston (United States), ¹⁵Amylyx Pharmaceuticals, Inc., Cambridge, MA, USA - Cambridge (United States), ¹⁶Present address: Division of Biology and Biological Engineering Graduate Program, California Institute of Technology, Pasadena, CA, USA - Pasadena (United States)

5.30 p.m

End of the Conference Day

● Friday, DECEMBER 2

All scientific sessions are held
in Grand Ballroom AB - Tower 2

- 08.00 a.m. Welcome coffee - **NEW this year at CTAD > Poster Walking Tour**  Yosemite/Imperial Ballroom & Registration area - Tower 2
- 9.00 a.m. **KEYNOTE 4**
Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer's Disease
Introduction: Paul Aisen, *Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego, CA (USA)*
Roger Nitsch, *Neurimmune, Schlieren (Switzerland)*
- 9.20 a.m. **LATE BREAKING ORAL COMMUNICATIONS**
Chairs: Sandrine Andrieu, *INSERM - Toulouse (France)*, Rachel Schindler, *R. Schindler Consulting, New York City, NY (United States)*
- 9.20 a.m. **LB12 - Use of a Blood-Based Biomarker Test Impacts Clinical Decision Making Among Neurologists Evaluating Patients With Symptoms of Cognitive Impairment**
Joel Braunstein¹, Mark Monane¹, Kim Johnson², B. Joy Snider³, Raymond Scott Turner⁴, Jonathan Drake⁵, Daniel Jacobs⁶, Julia Ortega¹, Joni Henderson¹, Tim West¹
¹*C2N Diagnostics - St Louis (United States)*, ²*Duke University - Durham (United States)*, ³*Washington University - St Louis (United States)*,
⁴*Georgetown University - Washington (United States)*, ⁵*Lifespan - Providence (United States)*, ⁶*Neurological Services of Orlando - Orlando (United States)*
- 9.35 a.m. **LB13 - Phase 1 pharmacokinetic and CNS target engagement properties of the orally administered O-GlcNAcase inhibitor ASN51 in humans**
Ryan Schubert¹, Rolf Pokorny¹, Bruno Permanne¹, Pearl Fang¹, Vanessa Teachout¹, Maud Nény¹, Solenne Ousson¹, Jennifer Hantson¹, Astrid Sand¹, Ruhi Ahmed¹, Manfred Schneider¹, Jean-Francois Stallaert¹, Anna Quattropiani¹, Eric Yuen¹, Dirk Beher¹
¹*Asceneuron, Lausanne (Switzerland)*
- 9.50 a.m. **LB14 - Analysis of 15 software pipelines for validation of [18F]florbetaben PET quantitation**
Aleksandar Jovalekic¹, Nuria Roe-Vellve¹, Norman Koglin¹, Mariana Lagos Quintana¹, Aaron Nelson², Markus Diemling³, Johan Lilja³, Juan Pablo Gomez Gonzalez⁴, Vincent Dore⁵, Pierrick Bourgeat⁵, Alex Whittington⁶, Roger Gunn⁶, Andrew Stephens¹, Santiago Bullich¹
¹*Life Molecular Imaging - Berlin (Germany)*, ²*MIM Software - Cleveland (United States)*, ³*Hermes Medical Solutions - Stockholm (Sweden)*,
⁴*QuBiotech - A Coruna (Spain)*, ⁵*CSIRO - Brisbane (Australia)*, ⁶*Invicro - London (United Kingdom)*
- 10.05 a.m. **LB15 - Results from a clinical Study of an Anti-Galectin-3 Monoclonal antibody in Patients with Moderate to Severe Alzheimer's Disease**
Dongxu Sun¹, George Haig¹, Suhail Rasool¹
¹*Truebinding Inc - Foster City (United States)*
- 10.20 a.m. Coffee break and poster session **Yosemite/Imperial Ballroom & Registration area - Tower 2** 
- 10.45 a.m. **ROUNDTABLE 2**
The Alzheimer's disease Patient Pathway from a sex and gender lens
Chair: Frances Catherine Quevenco^{1,2}
Discussants: Maria Carmela Tartaglia³, Heather Snyder⁴, Phyllis Ferrell⁵, Pernille Poulsen⁶, Antonella Santucciono Chadha^{7,2}
¹*Roche (Switzerland)*, ²*Women's Brain Project (Switzerland)*, ³*University Of Toronto (Canada)*, ⁴*Alzheimer's Association (United States)*, ⁵*Eli Lilly (United States)*, ⁶*Novo Nordisk (Denmark)*, ⁷*Altoia (United States)*
- 11.15 a.m. **ORAL COMMUNICATIONS' FOCUS SESSION: Interim or preliminary data and study design**
Chairs: Susan Abushakra, *Alzheon, Inc - Framingham, MA (United States)*, Nicola Spotorno, *Lund University - Lund (Sweden)*
- 11.15 a.m. **OC24 - Neuroimaging Data From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias**
Kaya Jordan¹, Kennedy Mahdavi^{1,2}, Jonathan Haroon¹, Elisabeth Rindner¹, Margaret Zielinski¹, Victoria Venkatraman^{1,2}, Sergio Becerra², Dayan Goodenowe³, Clarence Ahlem⁴, Christopher Reading⁴, Joseph Palumbo⁴, Bijan Pourat⁵, Sheldon Jordan^{1,2}
¹*The Regenesis Project - Santa Monica (United States)*, ²*Synaptic Network - Santa Monica (United States)*, ³*Prodrome Sciences USA LLC - Temecula (United States)*, ⁴*Biovie Inc. - Carson City (United States)*, ⁵*Pourat MD - Beverly Hills (United States)*

● Friday, DECEMBER 2

All scientific sessions are held
in Grand Ballroom AB - Tower 2

- 11.25 a.m. **OC25 - HOPE4MCI Trial Targeting Hippocampal Overactivity for the treatment of Mild Cognitive Impairment due to Alzheimer's disease with AGB101: Baseline Tau and MRI imaging characteristics**
Richard Mohs¹, Sharon Rosenzweig-Lipson¹, Arnold Bakker², Elizabeth Chang², Nisha Rani², Russell Barton¹, Michela Gallagher^{1,2}
¹AgeneBio, Inc - Baltimore (United States), ²Johns Hopkins University - Baltimore (United States)
- 11.35 a.m. **OC26 - Design of the ABCA1 agonist CS6253 Phase 1 SAD and MAD study in male and female, APOE4 and non-APOE4 carriers to assess safety, PK and biomarker efficacy**
Jan Johansson¹, Hussein Yassine², Danny Michaelson³, Henrik Zetterberg⁴, Jeffrey Cummings⁵, Bengt Winblad⁶
¹Artery Therapeutics, Inc. - San Ramon (United States), ²USC - Los Angeles (United States), ³Tel Aviv University - Tel Aviv (Israel), ⁴U of Gothenburg - Gothenburg (Sweden), ⁵U Nevada Las Vegas - Las Vegas (United States), ⁶Karolinska Institute - Stockholm (Sweden)
- 11.45 a.m. **OC27 - Significant Effects of Oral ALZ-801 on Plasma Biomarkers of Alzheimer's Disease: 12-Month Interim Analysis of Phase 2 Biomarker Study in APOE4 Carriers with Early AD**
Susan Abushakra¹, John Hey¹, Kaj Blennow², Philip Scheltens³, Jakub Hort⁴, Katerina Sheardova⁵, Niels Prins⁶, Sterre Rutgers⁶, Paul Dautzenberg⁷, Ladislav Pazdera⁸, Patrick Kessler¹, Aidan Power¹, Martin Tolar¹
¹Alzheon Inc. - Framingham, Ma (United States), ²Gothenburg University, Institute of Neuroscience & Physiology - Molndal (Sweden), ³Amsterdam University Medical Center - Amsterdam (Netherlands), ⁴Charles University Dept. of Neurology - Prague (Czech Republic), ⁵St. Anne University Hospital & International Clinical Research Center - Brno (Czech Republic), ⁶Brain Research Center - Amsterdam (Netherlands), ⁷Brain Research Center - Den Bosch (Netherlands), ⁸Vestra Research Clinic - Rychnov Nad Kněžnou (Czech Republic)
- 11.55 a.m. **OC28 - Measures of cortical microstructure are linked to amyloid pathology in Alzheimer's disease**
Nicola Spotorno¹, Olof Strandberg¹, Geraline Vis^{2,3}, Erik Stomrud¹, Markus Nilsson^{2,4}, Oskar Hansson¹
¹Clinical Memory Research Unit, Department Of Clinical Sciences, Lund University - Lund (Sweden), ²Diagnostic Radiology, Institution For Clinical Sciences, Lund University - Lund (Sweden), ³Memory Clinic, Skåne University Hospital - Malmö (Sweden), ⁴Memory Clinic, Skåne University Hospital - Malmö (Sweden)
- 12.05 p.m. Lunch on your own and poster session **Yosemite/Imperial Ballroom & Registration area - Tower 2**
- 1.05 p.m. **ORAL COMMUNICATIONS**
- 1.05 p.m. **OC29 - A brief, automated speech-based screener for mild cognitive impairment to support online recruitment at scale**
Caroline Skirrow¹, Jack Weston¹, Marton Meszaros¹, Udeepa Meepegama¹, Emil Fristed¹
¹Novoic - London (United Kingdom)
- 1.20 p.m. **OC30 - Aβ-structure as Precise Risk Plasma Biomarker for Future Conversion to Alzheimer's Disease 17 Years in Advance**
Klaus Gerwert^{1,2}
¹Ruhr-University Bochum - Bochum (Germany), ²Center for Protein Diagnostics (ProDi) - Bochum (Germany)
- 1.35 p.m. **ORAL COMMUNICATIONS' FOCUS SESSION: Clinical Trials Phase 1 Results**
Chairs: Suzanne Hendrix, Pentara Corporation - Salt Lake City, UT (United States and Peter Ljubenkov, UCSF Memory and Aging Center San Francisco, CA (United States)
- 1.35 p.m. **OC31 - NVG-291 Phase 1 Results and Phase 1b/2a Study Design in Individuals with mild cognitive impairment or mild dementia due to Alzheimer's disease**
Daniel Mikol¹, Judy Toews¹, Martin Farlow², Bruce Lamb², George Perry³, Reisa Sperling⁴, Michael Weiner⁵, Henrik Zetterberg⁶, Jeffrey Cummings⁷
¹Nervgen - Vancouver (Canada), ²Indiana University School Of Medicine - Indianapolis (United States), ³University Of Texas, San Antonio - San Antonio (United States), ⁴Harvard Medical School - Cambridge (United States), ⁵University Of California, San Francisco - San Francisco (United States), ⁶University Of Gothenburg - Gothenburg (Sweden), ⁷University Of Nevada, Las Vegas - Las Vegas (United States)

● Friday, DECEMBER 2

All scientific sessions are held
in Grand Ballroom AB - Tower 2

- 1.45 p.m. **OC32 – Introduction to the Veri-T trial: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Verdiperstat in Patients with svPPA Due to FTLD-TDP**
Peter Ljubenkov¹, Adam Staffaroni¹, Lawren Vandevrede¹, Julio Rojas-Martinez¹, Mary Koestler¹, Anton Porsteinsson², Maria B. Pascual³, Joseph Masdeu³, Ian Grant⁴, David Irwin⁵, David Knopman⁶, Robert Bowser⁷, Murray Grossman⁵, Irfan Qureshi⁸, Adam Boxer¹
¹UCSF Memory and Aging Center - San Francisco (United States), ²University of Rochester - Rochester (United States), ³Houston Methodist - Houston (United States), ⁴Northwestern University - Chicago (United States), ⁵University of Pennsylvania - Philadelphia (United States), ⁶Mayo Clinic Rochester - Rochester (United States), ⁷Barrow Neurological Institute - Phoenix (United States), ⁸Biohaven Pharmaceuticals - New Haven (United States)
- 1.55 p.m. **OC33 – A Phase 1, Open-Label, 52-Week, Multicenter Study to Evaluate the Safety and Biochemical Efficacy of AAV Gene Therapy (LX1001) in Patients with APOE4 Homozygote Alzheimer’s Disease – Interim Data**
Michael Kaplitt¹, Philip Leopold², Evan Noch³, Jana Ivanidze⁴, Levi Chazen⁴, Ronald Crystal², Stephen Kaminsky², Haley Bowe², Mei Wang², Douglas Ballon⁴, Jonathan Dyke⁴, Dolan Sondhi², Sam Gandy⁵, Gina Giannantoni-Ibelli⁶, Jay Barth⁶
¹Department of Neurological Surgery, Weill Cornell Medical College - New York (United States), ²Department of Genetic Medicine, Weill Cornell Medical College - New York (United States), ³Department of Neurology, Weill Cornell Medical College - New York (United States), ⁴Department of Radiology, Weill Cornell Medical College - New York (United States), ⁵Departments of Neurology and Psychiatry, Icahn School of Medicine at Mt Sinai - New York (United States), ⁶LEXEO Therapeutics, Inc. - New York (United States)
- 2.05 p.m. **ORAL COMMUNICATIONS**
Chairs: Nicola Coley, INSERM - Toulouse (France) and Michael Donohue, Alzheimer’s Therapeutic Research Institute, University of Southern California - San Diego, CA (United States)
- 2.05 p.m. **OC34 – Preliminary evidence for reliability and validity of the Interpersonal Functioning and Daily Activities Questionnaire (IFDAQ) in the A4/LEARN pre-randomization sample**
Chris Edgar¹, Rebecca Amarglio², Jordan Barbone³, Julie Chandler⁴, Stephen Coons⁵, Michael Donohue⁶, William Lenderking⁷, Reisa Sperling⁸
¹Cogstate - London (United Kingdom), ²Departments of Neurology, Brigham and Women’s Hospital and Massachusetts General Hospital, Harvard Medical School - Boston (United States), ³Cogstate - New Haven (United States), ⁴Eli Lilly and Company - Indianapolis (United States), ⁵Clinical Outcome Assessment Program, Critical Path Institute - Tucson (United States), ⁶Alzheimer’s Therapeutic Research Institute, University of Southern California - San Diego (United States), ⁷Patient-centered Research, Evidera - Bethesda (United States), ⁸Department of Neurology, Brigham and Women’s Hospital - Boston (United States)
- 2.20 p.m. **OC35 – APOE-Targeted Epigenome Therapy for Alzheimer’s Disease**
Boris Kantor^{1,2}, Ornit Chiba-Falek^{1,3}
¹Duke University - Durham (United States), ²CLAIRGene LLC - Durham (United States), ³CLAIRGene - Durham (United States)
- 2.35 p.m. **OC36 – Confounding factors of Alzheimer’s disease plasma biomarkers and their impact on clinical performance**
Alexa Pichet Binette¹, Shorena Janelidze¹, Nicholas Cullen¹, Jeffrey L. Dage², Randall J. Bateman³, Henrik Zetterberg^{4,5}, Kaj Blennow⁴, Erik Stomrud¹, Niklas Mattsson-Carlgrén¹, Oskar Hansson¹
¹Clinical Memory Research Unit, Faculty Of Medicine, Lund University - Lund (Sweden), ²Department Of Neurology, Indiana University School Of Medicine - Indianapolis (United States), ³Department Of Neurology, Washington University School Of Medicine - St. Louis (United States), ⁴Department Of Psychiatry And Neurochemistry, The Sahlgrenska Academy, University Of Gothenburg - Gothenburg (Sweden), ⁵UK Dementia Research Institute, University College London - London (United Kingdom)
- 2.50 p.m. **OC37 – Aducanumab and lecanemab label insoluble, fibrillar, diffusible Aβ aggregates in aqueous extracts of human Alzheimer disease brain**
Andrew M. Stern¹, Angela L. Meunier¹, Wen Liu¹, Maria Ericsson², Dennis J. Selkoe²
¹Ann Romney Center For Neurologic Diseases, Brigham And Women’s Hospital, Harvard Medical School - Boston (United States), ²Harvard Medical School Electron Microscopy Core - Boston (United States)
- 3.05 p.m. Coffee break and poster session Yosemite/Imperial Ballroom & Registration area - Tower 2 

● Friday, DECEMBER 2

All scientific sessions are held
in Grand Ballroom AB - Tower 2

3.35 p.m

LATE BREAKING ORAL COMMUNICATION

Chairs: Francesca Cormack, Cambridge Cognition - Cambridge (United Kingdom), Jacques Touchon, University of Montpellier Montpellier (France)

3.35 p.m

LB16 - Phase 1 Preventive Adjuvanted Tau Vaccine, AV-1980R

Lon Schneider¹, Anahit Ghichikyan², Robert Alexander³, Henrik Zetterberg³, Eric Reiman³, Duygu Tosun⁴, Michael Agadjanyan²
¹USC - Los Angeles (United States), ²Institute for Molecular Medicine - Huntington Beach (United States), ³Banner Alzheimer's Institute - Phoenix (United States), ⁴University of California San Francisco - San Francisco (United States)

3.50 p.m

ORAL COMMUNICATIONS

3.50 p.m

OC38 - A multimodal clinical and lifestyle intervention induces multiomic systemic effects and improves cognitive outcomes in Alzheimer's disease

Jared C. Roach¹, Lance E. Edens¹, Sophiya Rajbhandari¹, Junko Hara², Jennifer Bramen^{3,4}, Molly K. Rapozo⁵, Cory Funk¹, William R. Shankle^{6,7,2,8}, Leroy Hood¹

¹Institute For Systems Biology - Seattle, Washington (United States), ²Pickup Family Neurosciences Institute, Hoag Memorial Hospital Presbyterian - Newport Beach, California (United States), ³Pacific Brain Health Center, Pacific Neuroscience Institute - Santa Monica, California (United States), ⁴Department of Translational Neurosciences and Neurotherapeutics, Saint John's Cancer Institute - Santa Monica, California (United States), ⁵Providence St. Joseph Health - Renton, Washington (United States), ⁶Shankle Clinic - Newport Beach, California (United States), ⁷Department of Cognitive Sciences, University of California - Irvine, California (United States), ⁸EMBIC Corporation - Newport Beach, California (United States)

4.05 p.m

OC39 - Advantages of next generation SupraAntigen® platform liposomal vaccines to immunize against pathological targets of Alzheimer's disease

Marija Vukicevic¹, Emma Fiorini¹, David Hickman¹, Raket Carpintero², Marcela Rincon², Maria Pilar Lopez-Deber², Maxime Ayer², Stefanie Siegert², Chiara Babolin², Eva Gollwitzer², Saskia Delpretti-Anex², Piergiorgio Donati², Johannes Streffer^{2,3}, Andrea Pfeifer², Marie Kosco-Vilbois²

¹Ac Immune SA - Lausanne (Switzerland), ²Ac Immune SA - Lausanne (Switzerland), ³University of Antwerp - Antwerpen (Belgium)

4.20 p.m

OC40 - U-p53AZ in prognostication of early onset Alzheimer's disease up to 6 years in advance of the clinical diagnosis

Simona Piccirella¹, Leander Van Neste², Christofer Fowler³, Colin Masters³, Jurgen Fripp⁴, James D. Doecke⁴, Chengjie Xiong⁵, Daniela Uberti⁶, Paul Kinnon¹, Sam Agus⁷

¹Diadem SpA - Brescia (Italy), ²Halix BV - Hoegaarden (Belgium), ³The Florey Institute of Neuroscience and Mental Health - Parkville (Australia), ⁴The Australian e-Health Research Centre, CSIRO - Herston (Australia), ⁵Washington University School of Medicine, Division of Biostatistics - St. Louis (United States), ⁶Department of Molecular and Translational Medicine, University of Brescia - Brescia (Italy), ⁷Diadem US - Boston (United States)

4.35 p.m

OC41 - iWHELD: An RCT of a Novel Digital Non-Pharmacological Intervention to Improve Quality of Life and Reduce Antipsychotics in 741 People Living in Nursing Homes During the COVID-19 Pandemic

Clive Ballard¹, Joanne Mcdermid¹, Adrienne Sweetnam¹

¹University of Exeter - Exeter (United Kingdom)

4.50 p.m

OC42 - Making digital measures fit-for-purpose in Alzheimer's trials

Francesca Cormack¹, Jennifer Sorinas², Claire Meunier³

¹Cambridge Cognition - Cambridge (United Kingdom), ²Novartis - Basel (Switzerland), ³DiMe - San Francisco (United States)

5.05 p.m

End of the Conference Day



POSTER PRESENTATIONS
presented in San Francisco
and available on the CTAD22
digital platform

POSTERS PRESENTATIONS

All posters are available in Pdf format
at all times on the CTAD22 digital platform.

Poster presentations presented **onsite**
in **San Francisco** are indicated with this icon : 

Yosemite/Imperial Ballroom & Registration area - Tower 2

Tuesday, November 29 at 4 p.m to Wednesday, November 30 at 6 p.m

THEME: Clinical Trials: Methodology	P001 to LP14
THEME: New Therapies and Clinical Trials	P024 to LP25
THEME: Clinical Trials: Results	P034 to LP44
THEME: Beyond Amyloid and Tau: Emerging Solutions	P050 to LP49

Thursday, December 1st from 8 a.m to 6 p.m

THEME: Clinical Trials Imaging	P069 to LP62
THEME: Clinical Trials: Biomarkers including plasma	P090 to LP84A
THEME: Cognitive and Functional Endpoints	P126 to LP89A

Friday, December 2nd from 8 a.m to 5 p.m

THEME: Cognitive assessment and clinical trials	P141 to LP92
THEME: Behavioral disorders and clinical trials	P169 to LP93
THEME: Health economics and clinical trials	P172 to LP95
THEME: Epidemiology and clinical trials	P176 to LP96
THEME: Animal Models and Clinical Trials	P187 to LP98
THEME: Proof of Concept/Translational research for Alzheimer Drug Development interventions	P191 to LP105A
THEME: Digital health/E-trials	P205 to LP109
THEME: AD clinical trials and COVID-19	LP110

THEME: Clinical Trials: Methodology

-  **P001** **Feasibility of virtual amyloid PET disclosure with cognitively unimpaired research participants**
Claire Erickson¹, Nathaniel Chin¹, Hannah Rosario¹, Amanda Peterson¹, Sterling Johnson¹, Lindsay Clark¹
¹University Of Wisconsin-Madison - Madison (United States)
-  **P002** **Using common-close trial designs for efficiently detecting slowing of progression in Alzheimer's disease**
Lars Lau Raket¹, Jeffrey Cummings²
¹Novo Nordisk - Søborg (Denmark), ²Chambers-Grundy Center For Transformative Neuroscience, Pam Quirk Brain Health And Biomarker Laboratory, Department Of Brain Health, School Of Integrated Health Sciences, University Of Nevada Las Vegas (unlv) - Las Vegas (United States)
-  **P003** **Evaluating KarXT (xanomeline-tropium) as a treatment for psychosis associated with Alzheimer's disease dementia: design of the phase 3, ADEPT-1, relapse prevention study**
Carolyn Watson¹, Jeffrey Cummings², George Grossberg³, Minsu Kang¹, Ronald Marcus¹
¹Karuna Therapeutics - Boston (United States), ²University Of Nevada Las Vegas School Of Integrated Health Sciences - Las Vegas (United States), ³Saint Louis University School Of Medicine - Saint Louis (United States)
-  **P004** **Number of Days Between Initial Contact and In-Person Visit Predict Attendance Rates for Potential Alzheimer's Disease Trial Participants**
Sarah Starling¹, Gabriela Munoz¹, Miriam Evans¹, Jenicka Engler¹, Stephanie Rutrick¹
¹Adams Clinical - Watertown (United States)
- P005** **Power analysis of a prognostic enrichment procedure based on AD Course Map, a simulation study**
Etienne Maheux¹, Igor Koval¹, Juliette Ortholand¹, Colin Birkenbihl², Vincent Bouteloup³, Stanley Durrleman¹
¹Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, CNRS, Inria, Inserm, AP-HP, Hôpital de la Pitié Salpêtrière, Paris (France), ²Fraunhofer Institute for Algorithms and Scientific Computing SCAI - Sankt Augustin (Germany), ³Université de Bordeaux, Inserm 1219, CIC1401-EC - Bordeaux (France)
-  **P006** **Implementing Novel Clinical Trial Designs in Dementia with Lewy Bodies: A Roadmap to Personalized Medicine**
Carla Abdelnour¹, Jon B. Toledo², Daniel Ferreira³, Federico Rodríguez-Porcel⁴, Parichita Choudhury⁵, Maureen Okafor⁶, Sonja Scholz⁷, Bradley Boeve⁵, Irene Litvan⁸, James Leverenz⁹, Laura Bonanni¹⁰, John-Paul Taylor¹¹, Simon J. G. Lewis¹², Dag Aarsland¹³, Kathleen Poston¹
¹Neurology And Neurological Sciences Department, Stanford University - Palo Alto (United States), ²Department Of Neurology University Of Florida College Of Medicine - Gainesville (United States), ³Division Of Clinical Geriatrics, Department Of Neurobiology, Care Sciences And Society, Karolinska Institutet - Stockholm (Sweden), ⁴Department Of Neurology, Medical University Of South Carolina - Charleston (United States), ⁵Department Of Neurology, Mayo Clinic - Rochester (United States), ⁶Department Of Neurology, Emory University School Of Medicine - Atlanta (United States), ⁷Neurodegenerative Diseases Research Unit, National Institute Of Neurological Disorders And Stroke. Laboratory Of Neurogenetics, National Institute On Aging - Bethesda (United States), ⁸Parkinson and Other Movement Disorders Center, Department of Neurosciences, University of California San Diego - La Jolla (United States), ⁹Lou Ruvo Center for Brain Health, Neurological Institute, and Department of Neurology, Cleveland Clinic - Cleveland (United States), ¹⁰Department of Neuroscience Imaging and Clinical Sciences and CESI, University G d'Annunzio of Chieti-Pescara - Chieti (Italy), ¹¹Translational and Clinical Research Institute, Newcastle University - Newcastle (United Kingdom), ¹²Forefront Parkinson's Disease Research Clinic, Brain And Mind Centre, University Of Sydney - Camperdown Nsw 2050 (Australia), ¹³Institute of Psychiatry, Psychology, & Neuroscience, King's College London - London (United Kingdom)
-  **P007** **Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is commonly misdiagnosed as Alzheimer's disease (AD) and Frontotemporal Dementia (FTD)**
Spyros Papapetropoulos¹, Angela Pontius², Samantha Zappia¹, Matthew Brennan², Leslie Leahy²
¹Vigil Neuroscience - Cambridge (United States), ²Consultant To Vigil Neuroscience - Cambridge (United States)
-  **P008** **Update on the TOGETHER study: a patient- and investigator-blind, randomized, placebo-controlled study evaluating the efficacy, safety and tolerability of bepranemab, UCBO107, in prodromal-to-mild Alzheimer's disease**
Matthew E. Barton¹, Bart Van Den Steen², Hans L. G. Van Tricht², William Byrnes¹, Fiona E. Purcell³, Sarah Ann Southcott³, Daniel Raby³, Yaroslav I. Starshinov³, Colin Ewen²
¹UCB Pharma - Raleigh, North Carolina (United States), ²UCB Pharma - Brussels (Belgium), ³ICON plc - Dublin (Ireland)
-  **P009** **The impact of erratic changes on 1 year change in CDR-SB. An exploratory analysis.**
Alan Kott¹, Xingmei Wang², David Miller²
¹Signant Health - Prague (Czech Republic), ²Signant Health - Blue Bell (United States)
-  **P010** **Early Engagement with the Alzheimer's Disease Community to Gain Insights into Designing the SKYLINE Trial for Pre-symptomatic Alzheimer's Disease**
Fiona Rose¹, Nancy Lynn², Jessica B. Langbaum³, Carolyn Langlois³, Emma Louise Dodd¹, Jannice Roeser⁴, Gesine Respondek⁴, Susanne Ostrowitzki⁴
¹Roche Products Ltd - Welwyn Garden City (United Kingdom), ²BrightFocus Foundation - Clarksburg (United States), ³Banner Alzheimer's Institute - Phoenix (United States), ⁴F. Hoffmann-La Roche Ltd - Basel (Switzerland)
-  **P011** **Contrasting the NIH Toolbox Emotional Battery Outcomes Between Caucasians and African American Older Adult Participants in a Randomized Clinical Trial: I-CONNECT Study**
Kexin Yu¹, Lisa Silbert^{1,2}, Laura Struble³, Hiroko H. Dodge¹
¹NIA-Layton Aging and Alzheimer's Disease Center, Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA - Portland (United States), ²Portland Veterans Affairs Health Care System, Portland, OR, USA - Portland (United States), ³Department of Health Behavior and Biological Sciences, School of Nursing, University of Michigan Ann Arbor, Michigan, USA - Ann Arbor (United States)

THEME: Clinical Trials: Methodology

-  **P012** **Development and Feasibility of a Data-Driven Approach to Preclinical Alzheimer's Disease Clinical Trial Recruitment through Centralized Pre-screening Data Collection**
Dylan Kirn¹, Joshua Grill², Paul Aisen³, Karin Ernstrom³, Seth Gale⁴, Judith Heidebrink⁵, Gregory Jicha⁶, Gustavo Jimenez-Maggiora³, Leigh Johnson⁷, Elaine Peskind⁸, Raymond Scott Turner⁹, David Sultzer², Shunran Wang³, Reisa Sperling⁴, Rema Raman³
¹Department of Neurology, Massachusetts General Hospital - Boston (United States), ²Institute for Memory Impairments and Neurological Disorders, Department of Psychiatry and Human Behavior, University of California Irvine - Irvine (United States), ³Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States), ⁴Department of Neurology, Brigham and Women's Hospital, Harvard Medical School - Boston (United States), ⁵Department of Neurology, University of Michigan - Ann Arbor (United States), ⁶Sanders-Brown Center on Aging, University of Kentucky - Lexington (United States), ⁷Institute for Translational Research, University of North Texas Health Science Center - Fort Worth (United States), ⁸VA Northwest Mental Illness Research, Education, and Clinical Center (MIRECC), VA Puget Sound Health Care System - Seattle (United States), ⁹Department of Neurology, Georgetown University Medical Center - Washington D.c. (United States)
-  **P013** **Design of Pragmatic Trials for Interventions Targeting Cognitive Decline: Benchmarks from the COcoa Supplement and Multivitamin Outcomes Study of the Mind (COSMOS-Mind)**
Mark Espeland¹, Joann Manson², Steve Rapp¹, Howard Sesso², Sarah Gaussoin¹, Sally Shumaker¹, Laura Baker¹
¹Wake Forest School of Medicine - Winston-Salem (United States), ²Brigham and Women's Hospital - Boston (United States)
-  **P014** **Use of the Digit Symbol Substitution Test (DSST) as an entry criterion for a cognitive study of a β 2-AR agonist.**
 Gabriel Vargas¹, Renee Martin¹, Peter Butera¹, Judy Reynolds¹, Tim Anderson², Aliya Asher³, Erik Buntinx⁴, Anthony Ford¹, John Harrison⁵
¹CuraSen - San Carlos (United States), ²New Zealand Brain Research Institute - Christchurch (New Zealand), ³MAC Clinical Research - Manchester (United Kingdom), ⁴Anima Research Center - Alken (Belgium), ⁵Metis Cognition - Kilmington Common (United Kingdom)
-  **P016** **Enhancing Recruitment of Underrepresented Communities with the Deployment of a Mobile Research Unit**
Jill Smith¹, John Dwyer¹, Dawn Batchuluun¹, Tamiko Magee Rodgers¹, Leigh Zisko¹
¹Global Alzheimer's Platform Foundation - Washington Dc (United States)
-  **P017** **Genotypic effects of the TOMM40*523 variant and APOE on longitudinal cognitive change over 4 years: The TOMMORROW Study**
 Haotian Zou¹, Sheng Luo², Michael W. Lutz², David A. Bennett³, Brenda L. Plassman², Kathleen A. Welsh-Bohmer²
¹University of North Carolina - Chapel Hill - Chapel Hill (United States), ²Duke University - Durham (United States), ³Rush University - Chicago (United States)
-  **P018** **Racial/ethnic Group Differences in Response Rate to a Mail Invitation to Participate in a Lifestyle Intervention Trial to Prevent Cognitive Decline (U.S. POINTER Trial)**
Valory Pavlik¹, Melissa Yu¹, Ashley Alexander², John Valenta², Richard Elbein³, Annmarie McDonald³
¹Baylor College Of Medicine - Houston (United States), ²Kelsey Research Foundation - Houston (United States), ³Alzheimer's Association - Houston (United States)
-  **P019** **Development of an abbreviated pre-screening cognitive battery to enhance referral to clinical trials**
Abigail O Connell¹, Eric Fischer¹, Lauren Latham¹, Laura Baker¹, Suzanne Craft¹
¹Wake Forest Alzheimer's Disease Research Center - Winston-Salem (United States)
-  **P020** **Long-Term Nicotine Treatment of Mild Cognitive Impairment (The MIND Study): Baseline Characteristics and Study Progress**
Paul Newhouse¹, Rema Raman², Andrew Saykin³, Julie Dumas⁴, Edward Levin⁵, Kenneth Kellar⁶, Paul Aisen²
¹Vanderbilt University - Nashville (United States), ²USC/ATRI - San Diego (United States), ³Indiana University - Indianapolis (United States), ⁴University of Vermont - Burlington (United States), ⁵Duke University - Durham (United States), ⁶Georgetown University - Washington, Dc (United States)
-  **P021** **Using an end-to-end deep learning model in older adults with MCI to identify AD risk factors on chromosome 19 that exacerbate cognitive decline**
Jinhyeong Bae¹, Liana Apostolova¹, Valentin Pentchev¹, Dustin Hammers¹, Angelina Polsinelli¹, Kelly Nudelman¹, Andrew Saykin¹, Kwangsik Nho¹
¹IUPUI - Indianapolis (United States)
-  **P022** **Pandemic Effects on Duplicate Subjects in Clinical Trials of Alzheimer's Disease**
Thomas Shiovitz¹, Chelsea Steinmetz², Brittany Steinmiller²
¹California Neuroscience Research, CTSdatabase LLC - Sherman Oaks, Ca (United States minor outlying islands), ²CTSdatabase LLC - Sherman Oaks, Ca (United States minor outlying islands)
-  **P023** **The Time Component Test is Inherently Meaningful Because it Combines Evidence Across Outcomes to Measure the Impact of Treatment on Progression Rate in Degenerative Diseases**
Samuel Dickson¹, Suzanne Hendrix¹
¹Pentara Corporation - Salt Lake City (United States)
-  **LP01** **Effect of treatment with the cholinergic precursor Choline Alphoscerate in mild cognitive dysfunction (CARL): Research Protocol**
Enea Traini¹, Anna Carotenuto¹, Vincenzo Andreone², Francesco Amenta¹
¹University of Camerino - Camerino (Italy), ²Neurology Complex Unit, Cardarelli Hospital - Naples (Italy)




-  **LP02** **A Trichotomy Method for Defining Homogeneous Subgroups in a Dementia Population**
Gary Rosenberg¹
¹University of New Mexico - Albuquerque (United States)
- LP03** **Compliance and satisfaction in the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Colombia Trial**
Natalia Acosta-Baena¹, Claudia Muñoz¹, Paula Ospina¹, Sorany Del Rio¹, Liliana Lopez¹, Margarita Giraldo¹, Sindy Duque¹, Alexander Navarro¹, Eric M. Reiman², Nan Hu³, Kemal Asik³, Pierre N. Tariot², Jessica B. Langbaum², Francisco Lopera¹, Silvia Rios-Romenets¹
¹Grupo de Neurociencias de Antioquia (GNA), Universidad de Antioquia, Medellín, Colombia. - Medellín (Colombia), ²Banner Alzheimer's Institute - Phoenix (United States), ³Genentech Inc. - San Francisco (United States)
-  **LP04** **The Global Alzheimer's Platform Foundation's® (GAP's) Inclusive Research Initiative: Enhancing Recruitment of Underrepresented Communities Through Community Connectors**
Dawn Batchuluun¹, Tamiko Rodgers¹, Leigh Zisko¹, Mickeal Key¹, Lisa Thurman¹, John Dwyer¹
¹Global Alzheimer's Platform Foundation - Washington (United States)
-  **LP05** **Mitigating loss of statistical power due to outcome imbalance in clinical trials**
Angela Tam¹, César Laurent¹, Christian Dansereau¹
¹Perceiv AI - Montreal (Canada)
-  **LP07** **A Seamless Phase 2A-Phase 2B Multi-Center Trial to test the Benefits of Benfotiamine on the Progression of Alzheimer's disease (BENFO-TEAM)**
Howard Feldman^{1,2}, Jose Luchsinger³, Karen Messer^{2,4}, Diane Jacobs^{1,2}, David Salmon¹, Carolyn Revta^{1,2}, Jody-Lynn Lupo^{1,2}, Gary Gibson^{5,6}
¹Department of Neurosciences, University of California San Diego - La Jolla (United States), ²Alzheimer's Disease Cooperative Study, University of California San Diego - La Jolla (United States), ³Departments of Medicine and Epidemiology, Columbia University Irving Medical Center - New York (United States), ⁴Division of Biostatistics, University of California San Diego - La Jolla (United States), ⁵Brain and Mind Research Institute, Weil Cornell Medicine - New York (United States), ⁶Burke Neurological Institute - White Plains (United States)
-  **LP08** **Simulation-based power analysis could improve the design of clinical trials in Alzheimer's disease**
Daniel Andrews^{1,2,3}, Douglas L. Arnold^{3,4,5}, Danilo Bzdok^{1,3,6}, Simon Ducharme^{7,8,3}, Howard Chertkow^{9,10,11,12}, D. Louis Collins^{1,4,3}
¹Department of Biomedical Engineering, McGill University - Montreal (Canada), ²Department of Bioengineering, McGill University - Montreal (Canada), ³McConnell Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University - Montreal (Canada), ⁴Department of Neurology and Neurosurgery, McGill University - Montreal (Canada), ⁵NeuroRx Research - Montreal (Canada), ⁶Mila - Quebec Artificial Intelligence Institute - Montreal (Canada), ⁷Department of Psychiatry, McGill University - Montreal (Canada), ⁸Douglas Mental Health University Institute, McGill University - Montreal (Canada), ⁹Baycrest Centre for Geriatric Care - Toronto (Canada), ¹⁰Kimel Centre for Brain Health and Wellness and Anne & Allan Bank Centre for Clinical Research Trials, Baycrest - Toronto (Canada), ¹¹Canadian Consortium on Neurodegeneration in Aging (Canada), ¹²Division of Neurology, Department of Medicine, University of Toronto - Toronto (Canada)
-  **LP09** **The AlzMatch Study: Remote Plasma Acquisition to Pre-screen for Preclinical Alzheimer's Disease Trials**
Sarah Walter¹, Rema Raman¹, Gustavo Jimenez-Maggiora¹, Robert Rissman¹, Joshua Grill², Jason Karlawish², Oliver Langford¹, Stefania Bruschi¹, Michael Donohue¹, Kevin Yarasheski³, Michael Racke⁴, Reisa Sperling⁵, Jeffrey Cummings⁶, Paul Aisen¹
¹Alzheimer's Therapeutic Research Institute, USC - San Diego (United States), ²University of California, Irvine - Irvine (United States), ³C2N Diagnostics - St. Louis (United States), ⁴Quest Diagnostics - Secaucus (United States), ⁵Brigham And Women's Hospital, Massachusetts General Hospital, Harvard Medical - Boston (United States), ⁶Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada - Las Vegas (United States)
-  **LP10** **Disease Progression Modelling Identified MRI-based Subtypes with Cognitive Heterogeneity in A4 Study Preclinical Trial Cohort**
Cameron Shand¹, Neil Oxtoby¹, Michael Donohue², Daniel Alexander¹, Frederik Barkhof^{1,3}
¹University College London (United Kingdom), ²Alzheimer's Therapeutic Research Institute, University Of Southern California (United States), ³Amsterdam UMC (Netherlands)
-  **LP11** **LatAm-FINGERS study design: a multicultural harmonization work across Latin America**
Lucía Crivelli¹, Claudia Suemoto², Ismael Calandri¹, Paulo Caramelli³, Francisco Lopera⁴, Ricardo Nitrini⁵, Ana Luisa Sosa⁶, Rosa Maria Salinas⁶, Lina Marcela Velilla⁴, Monica Yassuda⁵, Ricardo Francisco Allegrí¹, Heather Snyder⁷, Miia Kivipelto⁸, Maria Carrillo⁷
¹Fleni - Buenos Aires (Argentina), ²Division of Geriatrics, University of Sao Paulo Medical School - Sao Paulo (Brazil), ³Behavioral and Cognitive Neurology Unit, Faculdade de Medicina, Universidade Federal de Minas Gerais - Belo Horizonte (Brazil), ⁴Neuroscience Group of Antioquia Medical School, Antioquia University - Antioquia (Colombia), ⁵Department of Neurology, University of São Paulo School of Medicine - Sao Paulo (Brazil), ⁶Laboratorio de demencias del Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez - Mexico City (Mexico), ⁷Alzheimer's Association - Chicago (United States), ⁸Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Stockholm (Sweden)
-  **LP12** **Recruitment Accelerator for Diversity in Aging Research - Cognitive Loss and Dementia (RADAR-CLD): Perspectives on Registry Recruitment**
Mary Sano¹, Jennifer Vasconcellos², Margaret Sewell³, Judith Neugroschl³, Mari Umpierre³, Shehan Chin³, Sharon Brangman⁴, Sarah Mcnamara⁴, Nancy Smith⁴, Kathy Royal⁴, Mike Splaine²
¹Icahn School of Medicine at Mount Sinai - New York City (United States), ²Recruitment Partners LLC - Columbia (United States), ³Icahn School of Medicine at Mount Sinai - New York (United States), ⁴Upstate Medical University - Syracuse (United States)

- 
LP13 **Physician-Driven Patient Recruitment Addresses Barriers in AD Clinical Trial Enrollment**
Erin Beck¹, Micah Eimerbrink¹, Katie Tyler¹, Daniel Gautieri¹
¹SiteRx - New York (United States)
- 
LP14 **A Phase 3 Clinical Trial Protocol to Evaluate the Efficacy and Safety of NA-831 In Subjects with Early Onset of Alzheimer's Disease**
Lloyd Tran¹, Markku Kurkinen¹, Fern Vu¹
¹Biomed Industries, Inc. - San Jose (United States)
- 
LP14A **Development of an abbreviated pre-screening cognitive battery to enhance referral to clinical trials**
Abigail O'connell¹, Eric Fischer¹, Lauren Latham¹, Laura Baker¹, Suzanne Craft¹
¹Wake Forest Alzheimer's Disease Research Center - Winston-Salem (United States)

THEME: New Therapies and Clinical Trials

- 
P024 **Potential Reversal of Alzheimer's Disease pathology by Antibody T8006 Targeting Galectin-3, a Major Cause of Oligomerization of Amyloid Proteins**
Suhail Rasool¹, Jenny Johansson¹, Ludmila Voloboueva¹, Sangmi Lee¹, Nancy Lan¹, Taufeeq Ahmed¹, Dongxu Sun¹
¹Truebinding Inc. - Foster City (United States)
- 
P025 **Whole-Brain Low-Intensity Pulsed Ultrasound Therapy For Early Stage Of Alzheimer's Disease (LIPUS-AD): A Randomized, Double-Blind, Placebo-Controlled Trial**
Hiroaki Shimokawa^{1,2}, Tomohiko Shindo¹, Aiko Ishiki³, Naoki Tomita³, Kumiko Eguchi¹, Takashi Shiroto¹, Jun Takahashi¹, Kentaro Shiratsuchi⁴, Satoshi Yasuda¹, Hiroyuki Arai³
¹Tohoku University Graduate School Of Medicine - Sendai (Japan), ²International University of Health and Welfare - Narita (Japan), ³Institute Of Development, Aging And Cancer, Tohoku University - Sendai (Japan), ⁴Sound Wave Innovation, Co. - Tokyo (Japan)
- 
P026 **CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with mild cognitive impairment due to Alzheimer's disease**
 Alan Lerner^{1,2}, Steven Arnold³, Erin Maxfield⁴, Aaron Koenig³, Maria Toth¹, Brooke Fortin³, Bianca Trombetta³, Andrew Pieper^{5,6,7,8}, Curtis Tatsuoka⁹, Irina Pikuleva⁴
¹Brain Health And Memory Center, Neurological Institute, University Hospitals Cleveland Medical Center - Cleveland (United States), ²Department of Neurology, Case Western Reserve University - Cleveland (United States), ³Alzheimer's Clinical And Translational Research Unit, Massachusetts General Hospital - Boston (United States), ⁴Department Of Ophthalmology And Visual Sciences, Case Western Reserve University - Cleveland (United States), ⁵Harrington Discovery Institute, University Hospitals Cleveland Medical Center - Cleveland (United States), ⁶Department Of Psychiatry, Case Western Reserve University - Cleveland (United States), ⁷Geriatric Psychiatry, GRECC, Louis Stokes Cleveland VA Medical Center - Cleveland (United States), ⁸Institute For Transformative Molecular Medicine, Case Western Reserve University - Cleveland (United States), ⁹Department Of Population And Quantitative Health Sciences, Case Western Reserve University - Cleveland (United States)
- 
P027 **A Phase 2 Study of the Sigma-2 Ligand CT1812 in Participants with Dementia with Lewy Bodies**
James Galvin¹, Magdalena Tolea¹, Michael Grundman², Mary Hamby³, Anthony Caggiano⁴
¹Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine - Boca Raton, FL (United States), ²Grnd Partners - San Diego, Ca (United States), ³Cognition Therapeutics - Pittsburgh, Pa (United States), ⁴Cognition Therapeutics - Purchase, Ny (United States)
- 
P028 **ALZLIGHT Pilot: Preliminary Report on Safety and Feasibility From a Randomized Controlled Trial of Light-Based Brain Stimulation With 40 Hz Invisible Spectral Flickering Light in Patients With Mild-to-Moderate Alzheimer's Disease**
Mikkel Pejstrup Agger^{1,2}, Marcus Schultz Carstensen³, Maibritt Horning^{1,2}, Else Rubæk Danielsen⁴, Anders Ohlhues Baandrup⁴, Mai Nguyen⁵, Mark Alexander Henney⁵, Christopher Ravn Boe Jensen⁵, Kristoffer Hougaard Madsen^{6,7}, Troels Wesenberg Kjær^{1,2}, Kamilla Miskowiak^{8,9}, Paul Michael Petersen³, Peter Høgh^{1,2}
¹Department of Neurology, Zealand University Hospital - Roskilde (Denmark), ²Department of Clinical Medicine, University of Copenhagen - Copenhagen (Denmark), ³Dept. of Electrical and Photonics Engineering, Technical University of Denmark - Kgs. Lyngby (Denmark), ⁴Department of Radiology, Zealand University Hospital - Roskilde (Denmark), ⁵OptoCeutics ApS - Copenhagen (Denmark), ⁶Dept. of Applied Mathematics and Computer Science, Technical University of Denmark - Copenhagen (Denmark), ⁷Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital - Amager and Hvidovre - Copenhagen (Denmark), ⁸Neurocognition and Emotion in Affective Disorders (NEAD) Group, Copenhagen Affective Disorder research Centre (CADIC), Psychiatric Centre Copenhagen - Copenhagen (Denmark), ⁹Department of Psychology, University of Copenhagen - Copenhagen (Denmark)
- 
P029 **Characterization of amyloid-beta protofibrils in Alzheimer's disease brain and the unique binding properties of lecanemab**
Lars Lannfelt¹, Linda Söderberg¹, Malin Johannesson¹, Nicolas Fritz¹, Eleni Gkanatsiou¹, Adeline Rachalski¹, Helen Kylefjord¹, Gunilla Osswald¹, Christer Möller¹
¹BioArctic AB - Stockholm (Sweden)
- 
P030 **AD101 - the clinical profile of a new, first-in-class treatment for Alzheimer's Disease**
Jan Burmeister¹, Serge Gauthier², Sharon Rogers¹
¹AmyriAD Pharma, Inc. - Los Angeles (United States), ²McGill University - Montréal (Canada)

-  **P031** **Impact of pimavanserin on cognitive measures in patients with neuropsychiatric manifestations of Alzheimer's disease: results from 3 placebo-controlled clinical studies**
Clive Ballard¹, Victor Ablner², Sanjeev Pathak², Pierre Tariot¹, Bruce Coate², Ana Berrio², James M Youakim², Srdjan Stankovic²
¹Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania - Philadelphia (United States), ²ACADIA Pharmaceuticals Inc. - Princeton (United States)
-  **P032** **Impact of pimavanserin treatment on motor function in patients with neuropsychiatric manifestations of Alzheimer's disease: results from 3 clinical studies**
 Daniel Weintraub¹, Victor Ablner², Clive Ballard¹, Bruce Coate², Ana Berrio², Sanjeev Pathak², James M Youakim², Srdjan Stankovic²
¹Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania - Philadelphia (United States), ²ACADIA Pharmaceuticals Inc. - Princeton (United States)
-  **P033** **Intravenous treatment with BRICHOS molecular chaperone designed against amyloid-β toxicity improves features of Alzheimer disease pathology in mice**
Jan Johansson¹
¹Karolinska Institutet - Huddinge (Sweden)
- LP15** **Computerized Cognitive Training Restores Neural Activity within the Cognition and Apathy-related Network in Mild Cognitive Impairment**
Jae Myeong Kang¹, Nambeom Kim², Seon Kyung Yun³, Ha-Eun Seo⁴, Sangsoo Kim⁵, Seong-Jin Cho⁶
¹Department of Psychiatry, Gil Medical Center, Gachon University College of Medicine - Incheon (Korea, Republic of) - Incheon (Korea, Republic of), ²Department of Biomedical Engineering Research Center, Gachon University, Incheon, Republic of Korea - Incheon (Korea, Republic of), ³Department of Nursing, Saekyung University College of Nursing, Yeongwol, Republic of Korea - Yeongwol (Korea, Republic of), ⁴Neuroscience Research Institute, Gachon University - Incheon (Korea, Republic of), ⁵Department of Psychiatry, Gachon University Gil Medical Center - Incheon (Korea, Republic of), ⁶Department of Psychiatry, Gil Medical Center, Gachon University College of Medicine - Incheon (Korea, Republic of)
-  **LP16** **Alzheimer's Cognitive Decline Stopped For at Least 2½ Years by In-Home Transcranial Electromagnetic Treatment**
Gary Arendash¹, Haitham Abulaban^{2,3}, Susan Steen², Ross Andel⁴, Yanhong Wang^{5,6}, Yun Bai⁵, Rob Baranowski⁷, Xiaoyang Lin^{5,8}, Ning Shen⁹, Ali Aljassabi^{5,6}, Yitong Li⁵, Chuanhai Cao^{5,6}
¹NeuroEM Therapeutics, Inc. - Phoenix (United States), ²Axiom Clinical Research of Florida - Tampa (United States), ³University of South Florida/Byrd Alzheimer's Institute - Tampa (United States), ⁴Edson College of Nursing and Health Innovation, Arizona State University - Phoenix (United States), ⁵MegaNano Biotech - Tampa (United States), ⁶Taneja College of Pharmacy, University of South Florida - Tampa (United States), ⁷Left Coast Engineering - Escondido (United States), ⁸Taneja College of Pharmacy, University of South Florida - Tampa (United States), ⁹School of Arts and Sciences, University of South Florida - Tampa (United States)
-  **LP17** **First-in-Human Clinical Trial of IBC-Ab002, a Proprietary Human anti-PD-L1 Antibody, in Persons with Early Alzheimer's Disease: Trial Design and Objectives**
Jesse Cedarbaum¹, Philip Scheltens², Catherine Mummery³, Carol David⁴, Dalia Bracha⁴, Eti Yoles⁴, Kuti Baruch⁴, Michal Schwartz⁵
¹Immunobrain Checkpoint - Woodbridge, Ct (United States), ²Amsterdam UMC, Alzheimer Center - Amsterdam (Netherlands), ³Dementia Research Centre, Institute of Neurology, University College London - London (United Kingdom), ⁴Immunobrain Checkpoint - Nes Ziona (Israel), ⁵Weizmann Institute - Rehovot (Israel)
-  **LP19** **Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease: clinical proof of concept in Phase 2 HD study supports clinical development in an ongoing Phase 1/2 AD study**
Terrence Fisher¹, Elizabeth Evans¹, Megan Boise¹, Vikas Mishra¹, Crystal Mallow¹, Ernest Smith¹, John Leonard¹, Andrew Feigin², Eric Siemers³, Elizabeth Sheldon⁴, Raymond Turner⁵, Martin Farlow⁶, Anton Porteinsson⁷, Wendy Bond⁸, Maurice Zauderer¹
¹Vaccinex, Inc. - Rochester (United States), ²NY Langone Health, and for HSG and SIGNAL-HD PIs and coordinators - New York (United States), ³Siemens Integration LLC - Zionsville (United States), ⁴JEM Research Institute - Atlantis (United States), ⁵Re-cognition Health - Fairfax (United States), ⁶Indiana University - Indianapolis (United States), ⁷University of Rochester - Rochester (United States), ⁸Neuropsychiatric Research Center of Southwest Florida - Fort Myers (United States)
-  **LP20** **Does brain-gut photobiomodulation have therapeutic potential in Alzheimer's Disease? Design of a pivotal sham-controlled, randomized, double-blind, multicentric clinical investigation**
 Julien Delrieu¹, Aroa Relano-Gines², Patrice Cristofini², Julie Bisiaux³, Sara Guillemain³, Guillaume Blivet², Jacques Touchon⁴
¹Toulouse University Hospital Gerontopole - Toulouse (France), ²REGEnLIFE - Paris (France), ³RCTS - Lyon (France), ⁴University of Montpellier - Montpellier (France)
-  **LP21** **AC-0027875, a novel gamma-secretase modulator for the treatment of Alzheimer's disease**
Johan Sandin¹, Märta Dahlström¹, Veronica Lidell¹, Azita Rasti¹, Pontus Forsell¹, Sanja Juric¹, Magnus Halldin¹, Maria Backlund¹, Gunnar Nordvall¹
¹AlzeCure Pharma AB - Huddinge (Sweden)
- LP22** **Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults: Brain Amyloid and Vascular Effects of Eioscapentaeoic Acid (BRAVE-EPA) Study Design and Baseline Characteristics**
Carol Van Hulle^{1,2}, Hannah Zylstra³, Cole Aleshia⁴, Eierman Allison⁵, Elena Beckman⁶, Karen Lazar⁷, Blazel Madeleine⁸, Cronin Kate¹, Carey Gleason², Sterling Johnson^{9,1,2}, Sanjay Asthana^{2,1,10}, Carlsson Cynthia^{2,11,10,1}
¹Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison - Madison (United States), ²Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison - Madison (United States), ³School of Medicine and Public Health, University of Wisconsin-Madison - Madison (United States), ⁴Wisconsin Alzheimer's Institute Center, University of Wisconsin-Madison - Madison (United States), ⁵Medical College of Wisconsin-Green Bay - Madison (United States), ⁶Bold Insight - Downer's Grove (United States), ⁷Exact Sciences - Madison (United States), ⁸Cleveland Clinic Lerner College of Medicine - Cleveland (United States), ⁹Wisconsin Alzheimer's Institute, University of Wisconsin-Madison - Madison (United States), ¹⁰Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital - Madison (United States), ¹¹Wisconsin Alzheimer's Institute, University of Wisconsin-Madison - Madison (United States)

-  **LP23** **A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen® in subjects with Mild Alzheimer's Disease/ MCI**
Douglas Galasko¹, Martin Farlow², Brendan Lucey³, Lawrence Honig⁴, Abhay Moghekar⁵, Donald Elbert⁶, Randall Bateman³, Jeremiah Momper¹, Ronald Thomas¹, Robert Rissman¹, Archana Balasubramaniam¹, Maria Maccacchini⁷, Howard Feldman¹
¹UC San Diego - San Diego (United States), ²Indiana University - Indianapolis (United States), ³Washington University - St. Louis (United States), ⁴Columbia University - New York (United States), ⁵Johns Hopkins University - Baltimore (United States), ⁶University of Washington - Seattle (United States), ⁷Annovis Pharmaceuticals - Berwyn (United States)
-  **LP24** **Preclinical characterization of ACD856, a cognitive enhancer in clinical development for the treatment of cognitive dysfunction in Alzheimer's disease, demonstrates increased plasticity, neuroprotection and a possible disease modifying effect**
 Cristina Parrado-Fernández¹, Gunnar Nordvall¹, Sanja Juric¹, Nather Madjid¹, Maria Backlund¹, Märta Dahlström¹, Johan Sandin¹, Pontus Forsell¹
¹Alzecure Pharma AB - Huddinge (Sweden)
-  **LP25** **Overview of the preclinical program for OLX-07010 - a novel inhibitor of tau self-association**
James Moe¹, Barry Levine², Edward Cheesman¹, Patricia Lopez¹, William Erhardt¹, Eliot Davidowitz¹
¹Oligomerix, Inc. - White Plains (United States), ²Levine Tox Consulting, LLC - Chicago (United States)

THEME: Clinical Trials: Results

-  **P034** **Clinical Outcomes From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias**
Elisabeth Rindner¹, Kennedy Mahdavi^{1,2}, Jonathan Haroon¹, Kaya Jordan¹, Margaret Zielinski¹, Victoria Venkatraman^{1,3}, Dayan Goodenowe⁴, Clarence Ahlem⁵, Christopher Reading⁵, Joseph Palumbo⁵, Bijan Pourat⁶, Sheldon Jordan^{1,3}
¹The Regenesys Project - Santa Monica (United States), ²Synaptec Network, - Santa Monica (United States), ³Synaptec Network - Santa Monica (United States), ⁴Prodrome Sciences USA LLC - Temecula (United States), ⁵Biovie Inc. - Carson City (United States), ⁶Pourat MD - Beverly Hills (United States)
-  **P035** **Meta-analysis of high-clearance anti-amyloid immunotherapies trials in early Alzheimer's disease: a significant clinical effect but a low benefit/risk ratio**
Nicolas Villain¹, Vincent Planche²
¹Ap-Hp Sorbonne Université, Hôpital Pitié-Salpêtrière, Department Of Neurology, Institute Of Memory And Alzheimer's Disease - Paris (France), ²Univ. Bordeaux, Cnrs, Imn, Umr 5293 - Bordeaux (France)
-  **P036** **LilqPADD Trial: Targeting Hippocampal Hyperconnectivity in Cognitively Normal Older Adults at Risk for Alzheimer's Disease with AGB101**
 Shi-Jiang Li¹, Arnold Bakker², Yang Wang¹, B. Doug Ward¹, Shelby Schold¹, Piero Antuono¹, Elias Granadillo¹, Malgorzata Franczak¹, Joseph Goveas¹
¹Medical College Of Wisconsin, ²Johns Hopkins University
-  **P037** **Planning the next generation of Alzheimer's Disease clinical trials using diverse patient-level database from the Critical Path for Alzheimer's Disease (CPAD) Consortium**
Sudhir Sivakumaran¹, Nicholas Cullen¹, Zihan Cui¹, Eileen Priest¹, Corissa Lau¹, Hazel White¹, Michael Irizarry², Klaus Romero¹, Yashmin Karten¹
¹Critical Path Institute - Tucson (United States), ²Eisai Inc. - Nutley (United States)
-  **P038** **Critical Path for Alzheimer's Disease (CPAD) Consortium: Accelerating and de-risking therapeutic development in AD by building regulatory decision-making tools**
Sudhir Sivakumaran¹, Nicholas Cullen¹, Corissa Lau¹, Eileen Priest¹, Hazel White¹, Michael Irizarry², Klaus Romero¹, Yashmin Karten¹
¹Critical Path Institute - Tucson (United States), ²Eisai - Nutley (United States)
-  **P039** **Effectiveness of a digitally supported care management program for family and other informal dementia caregivers: baseline data and first results from the GAIN randomized**
Ingo Kilimann¹, Olga Klein², Jochen René Thyrian³, Melanie Boekholt³, Stefan Teipel¹, Wolfgang Hoffmann⁴
¹Deutsches Zentrum Für Neurodegenerative Erkrankungen Dzne Rostock/Greifswald And University Medical Center Rostock, Department Psychosomatics And Psychotherapy - Rostock (Germany), ²Deutsches Zentrum Für Neurodegenerative Erkrankungen Dzne Rostock/Greifswald - Rostock (Germany), ³Deutsches Zentrum Für Neurodegenerative Erkrankungen Dzne Rostock/Greifswald - Greifswald (Germany), ⁴Deutsches Zentrum Für Neurodegenerative Erkrankungen Dzne Rostock/Greifswald And University Hospital Greifswald, Institute For Community Medicine - Greifswald (Germany)
-  **P040** **Repeat IV and SC dosing of the Anti-Sortilin Antibody AL101**
 Michael Ward¹, Felix Yeh¹, Lovingly Park¹, Daniel Maslyar¹, Yijie Liao¹, Hua Long¹, Hernan Picard¹, Michael Kurnellas¹, Mayura Vadhavkar¹, Amber Silva¹
¹Alector, Inc. - South San Francisco (United States)
-  **P041** **SAL-AD: A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's Disease**
Peter Ljubenkov¹, Lawren Vandevrede¹, Rojas Rojas¹, Madison Honey², Argentina Lario Lago¹, Richard Tsai³, Mary Koestler¹, Renaud La Joie¹, Keith Alan Johnson⁴, Li Gan⁵, Stephanie Lessig⁶, James Brewer⁶, Howard Feldman⁶, Charlotte Teunissen⁷, Adam Boxer¹
¹UCSF Memory and Aging Center - San Francisco (United States), ²Amsterdam UMC - Amsterdam (Netherlands), ³Denali Therapeutics - San Francisco (United States), ⁴Harvard Medical School - Boston (United States), ⁵Weill Cornell Medical College - New York (United States), ⁶UC San Diego - San Diego (United States), ⁷Amsterdam UMC - Amsterdam (United States)

-  **P042** Early experience with home administration of subcutaneous gantenerumab by study partner (non-professional care partner) in the GRADUATION study
Richard Perry¹, Frank Boess², Marzia Scelsi³, Timo Grimmer⁴, Rafael Arroyo⁵, Christopher Lane³, Claire Lansdall², Janice Smith³
¹Imperial College London - London (United Kingdom), ²F. Hoffmann-La Roche Ltd - Basel (Switzerland), ³Roche Products Ltd - Welwyn Garden City (United Kingdom), ⁴Klinikum rechts der Isar, Technical University of Munich - Munich (Germany), ⁵Quirónsalud Madrid University Hospital - Madrid (Spain)
-  **P043** A Phase 1b study to evaluate the safety, tolerability and pharmacodynamics of PRI-002 in MCI and mild AD
Oliver Peters¹, Nicoleta-Carmen Cosma¹, Janine Kutzsche¹, Dieter Willbold¹
¹Charité - Berlin (Germany)
-  **P044** Enabling subcutaneous dosing of gantenerumab in Alzheimer's Disease
Beate Bittner¹, Dietmar Schwab¹, Agnes Portron¹, Dominik Lott¹, Frank Boess¹, Rémy Kohler¹, Jakub Wojtowicz¹, Carsten Hofmann¹
¹F. Hoffmann-La Roche Ltd - Basel (Switzerland)
-  **P045** The Internet-Based Conversational Engagement Clinical Trial (I-CONNECT) in Socially Isolated Adults 75+ Years Old: Primary Analyses Results
Hiroko Dodge¹, Patrick Pruitt¹, Xexin Yu¹, Chao-Yi Wu¹, Jeffrey Kaye¹, Lisa Silbert¹, I-Connect Connect-Team¹
¹Oregon Health & Science University - Portland (United States)
-  **P046** Computerized Games versus Crosswords Training in Mild Cognitive Impairment
Davangere Devanand¹, Terry Goldberg¹, Min Qian¹, Murali Doraiswamy²
¹Columbia University Medical Center - New York (United States), ²Duke University - Durham (United States)
-  **P047** Pimavanserin and cardiovascular/electrocardiogram safety in patients with Alzheimer's disease
Pierre Tariot¹, Victor Abler², Sanjeev Pathak², Bruce Coate², Mary Ellen Turner²
¹Banner Alzheimer's Institute and University of Arizona College of Medicine - Phoenix, Az (United States), ²Acadia Pharmaceuticals Inc. - San Diego, Ca (United States)
-  **P048** The effects of the novel phosphodiesterase 9 (PDE9) inhibitor E2027 (irsenontrine) on CSF cGMP, additional CSF and plasma biomarkers, and clinical outcomes in amyloid positive and amyloid negative patients with Dementia with Lewy Bodies (DLB) and Parkinson's Disease Dementia (PDD)
Pallavi Sachdev¹, Kate Pinner², Theresa Devins¹, Larisa Reyderman¹, David Li¹, Shobha Dhadha¹, Lynn Kramer¹, Akihiko Koyama¹, Michael Izarrary¹, Steven Hersch¹
¹Eisai Inc. - Nutley (United States), ²Eisai Ltd. - Hattfield (United Kingdom)
-  **P049** Clinical Activity of the p38 α kinase inhibitor neflamapimod on verbal list learning may be tau pathology dependent in dementia with Lewy bodies (DLB)
John Alam¹, Jennifer Conway¹, Hui-May Chu², Kelly Blackburn¹
¹EIP Pharma, Inc - Boston (United States), ²Anoixis Corporation - Natick (United States)
-  **LP26** Final 4 years results of the clinical trial ASCOMALVA
Anna Carotenuto¹, Angiola Fasanaro¹, Enea Traini¹, Francesco Amenta¹
¹University of Camerino - Camerino (Italy)
-  **LP27** Age-dependent effects of the p75 modulator LM11A-31 on Alzheimer's disease biomarkers in a 26-week safety and exploratory endpoint trial
Hayley Shanks¹, Stephen Massa^{2,3}, Manfred Windisch⁴, Anne Borjesson-Hanson⁵, Frank Longo⁶, Taylor Schmitz¹
¹Western University - London (Canada), ²University of California San Francisco - San Francisco (United States), ³SFVAHCS - San Francisco (United States), ⁴Neuroscios - Graz (Austria), ⁵Karolinska University Hospital - Stockholm (Sweden), ⁶Pharmatrophix - Menlo Park (United States)
-  **LP28** Clinical phase 1b data of the orally available anti-prionic compound RD2 that disassembles A β oligomers into A β monomers
Dieter Willbold^{1,2,3}, Nicoleta Carmen Cosma⁴, Janine Kutzsche¹, Oliver Peters⁴
¹Institute of Biological Information Processing (IBI-7), Forschungszentrum Jülich - Jülich (Germany), ²Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf - Düsseldorf (Germany), ³Priavoid GmbH - Düsseldorf (Germany), ⁴Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin, Charité Berlin - Berlin (Germany)
-  **LP29** Late-life depression, subjective cognitive decline, and their additive risk in incidence of dementia: A nationwide longitudinal study
Sung Yong Park¹, Won Myong Bahk², Sheng-Min Wang², Hyun Kook Lim², Young-Joon Kwon³, Bo-Hyun Yoon⁴, Kwang Hun Lee⁵, Sang-Yeol Lee⁶, Moon-Doo Kim⁷, Beom Woo Nam⁸, Eun Sung Lim⁹
¹Keyo hospital - Uiwang-Si (Korea, Republic of), ²Yeouido St. Mary's Hospital - Seoul (Korea, Republic of), ³Soonchunhyang University Cheonan Hospital - Cheonan (Korea, Republic of), ⁴Naju National Hospital - Naju (Korea, Republic of), ⁵College of Medicine, Dongguk University - Gyeongju (Korea, Republic of), ⁶Wonkwang University Hospital - Iksan (Korea, Republic of), ⁷Jeju National University School of Medicine - Jeju (Korea, Republic of), ⁸Dr. Nam's Psychiatric Clinic - Chungju (Korea, Republic of), ⁹Shinsegae Hyo Hospital - Kimje (Korea, Republic of)
- LP31** Efficacy and safety of benfotiamine plus donepezil for the treatment of patients with mild-to-moderate Alzheimer's disease in a phase 2 clinical trial
Xiaoli Pan¹, Qianhua Zhao², Shaoming Sang¹, Chunjiu Zhong¹
¹Zhongshan Hospital, Fudan University - Shanghai (China), ²Huashan Hospital, Fudan University - Shanghai (China)

-  **LP32** **VIVIAD, A Phase 2b Study Investigating Varoglutamstat in Patients with MCI and Mild AD: Update on Dose Selection and Interim Blinded Safety Results**
Frank Weber¹, Michael Schaeffer²
¹CMO Vivoryon Therapeutics N.V. - München (Germany), ²CBO Vivoryon Therapeutics N.V. - München (Germany)
-  **LP33** **Quantitative EEG results from a multiple ascending dose study in healthy volunteers with NeuroRestore ACD856, a positive modulator of Neurotrophin Trk-receptors**
Martin Jönsson¹, Kristin Önnestam¹, Boel Nilsson¹, Matthias Rother¹, Erik Rein-Hedin², Peter Anderer³, Manuel Kemethofer³, Magnus Halldin¹, Pontus Forsell¹, Gunnar Nordvall¹, Johan Sandin¹, Märta Segerdahl¹
¹AlzeCure Pharma AB - Huddinge (Sweden), ²CTC Clinical Trial Consultants AB - Uppsala (Sweden), ³The Siesta Group Schlafanalyse GmbH - Vienna (Austria)
-  **LP34** **A Randomized Double-Blind Study to Assess the Skin Irritation and Sensitization Potential of Once-Weekly Donepezil Transdermal Delivery System**
 Marwan Sabbagh¹, Philip Mathew², Alan Blau³
¹Barrow Neurological Institute - Phoenix (United States), ²Novum Pharmaceutical Research Services - Toronto (Canada), ³Corium Inc - Grand Rapids (United States)
- LP36** **ABvac40 elicits a predominantly Th2 immune response that supports its excellent safety profile**
María Montañés¹, Carlos Martín-Fortún¹, Sergio Castillo¹, Elisabeth Molina¹, Jose Terencio¹, Manuel Sarasa¹
¹Araclon Biotech-Grifols - Zaragoza (Spain)
-  **LP37** **CY6463 administration in healthy participants was associated with improvements in Alzheimer's disease-relevant biomarkers based on a systematic analysis of multiple Phase 1 clinical trials using KEM® eXplainable AI**
 Martin Kindermans¹, Hichem Chakroun¹, Jennifer Chickering², Chad Glasser², Pablo Iriso¹, Frederic Parmentier¹, Todd Milne², Phebe Wilson², Mohammad Afshar¹
¹Ariana Pharma - Paris (France), ²Cyclerion - Cambridge (United States)
-  **LP38** **A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess tolerability, safety, pharmacokinetics and effect of AZP2006 on cerebrospinal fluid biomarkers in 36 patients with progressive supranuclear palsy**
Philippe Verwaerde¹, Noelle Callizot¹, Susanna Del Signore¹, Aurelien Blondel¹, Cecilia Estrella¹
¹Alzprotect - Loos (France)
-  **LP39** **Three-year omega-3 PUFA trial targeting cerebral white matter lesions and integrity breakdown in older adults: ApoE stratified and exploratory results**
Gene Bowman¹, Charles Murchison², Lisa Silbert³, Hiroko Dodge⁴, Kristen Hagen⁴, David Lahna⁴, Harris William⁵, Jeffrey Kaye³, Joseph Quinn³, Lynne Shinto⁴
¹McCance Center for Brain Health, Department of Neurology, Massachusetts General Brigham and Harvard Medical School - Boston (United States), ²Department of Biostatistics, University of Alabama at Birmingham - Birmingham (United States), ³Department of Neurology, Oregon Health & Science University and Veterans Affairs Portland Health Care System - Portland (United States), ⁴Department of Neurology, Oregon Health & Science University - Portland (United States), ⁵Department of Internal Medicine, University of South Dakota School of Medicine and Fatty Acid Research Institute - Sioux Falls (United States)
-  **LP40** **Accounting for Disease Modification in Models of Cost Effectiveness of MABs Such As Lecanemab and Donanemab**
Suzanne Hendrix¹, Craig Mallincrodt¹, Samuel Dickson¹
¹Pentara Corporation - Millcreek (United States)
-  **LP41** **Effectiveness of Digital-Based Multidomain Intervention for Mild Cognitive Impairment**
Michael D. Patterson¹, Jacklyn Leonardo¹, Syaheed B. Jabar¹, Yuri G. Rykov¹, Bikram A Gangwar¹, Jeremy Yee¹, Nagaendran Kandiah², Kok Pin Ng³
¹Neuroglee Therapeutics - Singapore (Singapore), ²Lee Kong Chian School of Medicine - Singapore (Singapore), ³National Neuroscience Institute - Singapore (Singapore)
-  **LP42** **The SENSE-Cog trial: A Europe-wide randomised controlled trial of hearing and vision augmentation in dementia**
Iracema Leroi¹, Elizabeth Camacho², Nathalie Chaghil-Boissier³, Anna Pavlina Charalambous⁴, John-Paul Connelly¹, Fofi Constantinidou⁵, Renaud David⁶, Rachel A Elliott², Eric Frison³, Mark Hann², Alison Holden², Sean P Kennelly¹, Brian A Lawlor¹, Julie Longobardi³, Antonios M Politis⁷
¹Trinity College Dublin - Dublin (Ireland), ²University of Manchester - Manchester (United Kingdom), ³University of Bordeaux - Bordeaux (France), ⁴European University of Cyprus - Nicosia (Cyprus), ⁵University of Cyprus - Nicosia (Cyprus), ⁶University of Nice Sophia Antipolis - Nice (France), ⁷National and Kapodistrian University - Athens (Greece)
-  **LP43** **MRI changes following treatment of GLP-1 analogue, liraglutide, in patients with Alzheimer's disease (ELAD Study)**
Paul Edison¹, Gracia Daniela Femminella¹, Ritche Craig², Nowell Joseph², Livingston Nicholas¹, Zuzana Walker³, Ridha Basil⁴, Archer Hilary⁵, Karim Salman⁶, Tados George⁷, Koranteng Paul⁷, Holscher Christian⁸, Hinz Rainer⁹, Passmore Peter¹⁰, Ballard Clive¹¹
¹Imperial College London - London (United Kingdom), ²The university of Edinburgh - Edinburgh (United Kingdom), ³University College London - London (United Kingdom), ⁴Brighton and Sussex University Hospitals NHS Trust - Brighton (United Kingdom), ⁵University of Bristol - University Of Bristol (United Kingdom), ⁶Lancashire NHS Trust - Lancashire (United Kingdom), ⁷Birmingham University Hospital - Birmingham (United Kingdom), ⁸Henan University of Chinese Medicine - Henan (China), ⁹University of Manchester - Manchester (United Kingdom), ¹⁰Queens University - Belfast (United Kingdom), ¹¹University of Exeter - Exeter (United Kingdom)
- LP44** **The effects of Pomegranate Seed Oil on Mild Cognitive Impairment**
Thanos Chatzikostopoulos¹, Magda Tsolaki¹
¹Greek Association of Alzheimer's Disease and Related Disorders - Thessaloniki (Greece)

THEME: Beyond Amyloid and Tau: Emerging Solutions

-  **P050** **Mitochondrial methylcytosines as novel blood-based biomarkers for predicting progression to Alzheimer's disease dementia at the mild cognitive impairment stage: a machine learning approach**
 Jose Luis Mosquera¹, [Marta Blanch](#)¹, Nuria Rojo², Inma Rico², Jaume Campdelacreu², Beatriz Fontal¹, Paula Ferrer¹, Christopher Fowler³, Simon Laws⁴, Adrià Tort-Merino⁵, Raquel Sanchez-Valle⁵, Ramon Rene-Ramirez², Jordi Gascon², Marta Barrachina¹
¹ADmit Therapeutics SL - Barcelona (Spain), ²Functional Unit of Dementia, Service of Neurology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute, IDIBELL - Barcelona (Spain), ³The Florey Institute, The University of Melbourne - Melbourne (Australia), ⁴Collaborative Genomics and Translation Group, Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University - Joondalup (Australia), ⁵Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona - Barcelona (Spain)
- P051** **Improvement of cognitive dysfunction following repeated infusion of adipose tissue-derived stem cells**
[Kazuo Shigematsu](#)¹, Mitsuko Ideno², Noyuki Komori³, Hisakazu Yamagishi⁴
¹Minami Kyoto Hospital - Joyo (Japan), ²Takara Bio Inc. - Kyoto (Japan), ³Nagitsuji Hospital - Kyoto (Japan), ⁴Kyoto Prefectural University Of Medicine - Kyoto (Japan)
-  **P052** **Novel application of deep canonical correlation analysis identifies regional brain atrophy linked to proinflammatory gut microbial genera before cognitive decline**
[Margo Heston](#)^{1,2}, Zihang Meng³, Akshay Kohli^{1,2}, Antonio González⁴, Sterling Johnson^{1,2,5}, Rob Knight^{4,6,7,8}, Rima Kaddurah-Daouk^{9,10,11,12}, Federico Rey¹³, Vikas Singh^{3,14,15}, Barbara Bendlin^{1,2,5}
¹Wisconsin Alzheimer's Disease Research Center - Madison (United States), ²Division of Geriatrics, Department of Medicine, University of Wisconsin School of Medicine and Public Health - Madison (United States), ³Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison - Madison (United States), ⁴Department of Pediatrics, University of California, San Diego - La Jolla (United States), ⁵Wisconsin Alzheimer's Institute - Madison (United States), ⁶Department of Bioengineering, University of California, San Diego - La Jolla (United States), ⁷Department of Computer Science & Engineering, University of California, San Diego - La Jolla (United States), ⁸Center for Microbiome Innovation, University of California, San Diego - La Jolla (United States), ⁹Department of Psychiatry and Behavioral Sciences, Duke University - Durham (United States), ¹⁰Department of Medicine, Duke University - Durham (United States), ¹¹Duke Institute of Brain Sciences, Duke University - Durham (United States), ¹²Duke University Medical Center - Durham (United States), ¹³Department of Bacteriology, University of Wisconsin - Madison (United States), ¹⁴Department of Computer Sciences, University of Wisconsin-Madison - Madison (United States), ¹⁵Department of Statistics, University of Wisconsin-Madison - Madison (United States)
-  **P053** **Beyond targeting Ab and tau: Novel formulations of alpha-cyclodextrins for the safe (not ototoxic) and convenient (oral) Prevention and Treatment of Alzheimer's Disease**
[Knut Wittkowski](#)¹
¹Asdera LLC - New York (United States)
-  **P055** **Establishing fluid biomarkers associated with cellular senescence in Alzheimer's disease**
[Bryan Ng](#)¹, Amanda Heslegrave^{1,2}, Nick Fox^{1,3}, Henrik Zetterberg^{1,2,4}
¹Dementia Research Institute, University College London - London (United Kingdom), ²Department of Neurodegenerative Disease, University College London - London (United Kingdom), ³Dementia Research Centre, Queen Square Institute of Neurology, University College London - London (United Kingdom), ⁴Department of Psychiatry and Neurochemistry, University of Gothenburg - Mölndal (Sweden)
- P056** **The Gut-PRO Study: A Pilot Probiotic Intervention Study in Alzheimer's Disease**
[Jea Woo Kang](#)¹, Sandra J. Harding¹, Margo Heston¹, Alfred Eiji s Braceros¹, Nancy Davenport-Sis¹, Nathaniel Chin¹, Henrik Zetterberg², Federico Rey¹, Barbara b Bendlin¹
¹University of Wisconsin-Madison - Madison (United States), ²University of Gothenburg, Sahlgrenska University Hospital - Mölndal (Sweden)
-  **P057** **The potential of flavonoids to enhance mitochondrial function and protect neurons from degeneration in Alzheimer's disease**
[Maria Ankarcrona](#)¹, Luana Naia¹, Giacomo Dentoni¹, Makoto Shimozawa¹, Erika Bereczki¹, Xidan Li², Jianping Liu³, Nuno Santos Leal³, Benjamin Portal⁴, Maria Lindskog⁴, Per Nilsson¹, Massimiliano Gaetani¹
¹Karolinska Institutet (KI) - Solna (Sweden), ²Tsinghua University - Tsinghua (China), ³Karolinska Institutet (KI) - Huddinge (Sweden), ⁴Uppsala University - Uppsala (Sweden)
- P058** **An online dementia prevention using the Cogstim model: A pilot study**
[Raymond Ownby](#)^{1,2}
¹Nova Southeastern University - Fort Lauderdale FL (United States), ²Enalan Communications, Inc. - Fort Lauderdale FL (United States)
-  **P059** **Effects of non-invasive brain stimulation on individual alpha power**
[Oezguer A. Onur](#)¹, Ronja Fassbender¹
¹Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany - Cologne (Germany)
-  **P060** **A pragmatic assessment of ultra-fast MRI in real-life clinical and research cognitive practice**
[Miguel Rosa-Grilo](#)¹, Eoin Mulroy¹, Millie Beament¹, Haroon Chughtai², Dave Thomas¹, Geoff Parker², Nick Fox¹, Catherine Mummery¹
¹UK Dementia Research Centre at University College London (UCL) - London (United Kingdom), ²Centre for Medical Image Computing, Department of Medical Physics & Biomedical Engineering and Department of Neuroinflammation at University College London (UCL) - London (United Kingdom)
- P061** **Optimal conditions for entraining gamma waves using sensory stimulation in older adults**
[Yeseung Park](#)¹, Euisuk Yoon¹, Ki Woong Kim¹
¹Seoul National University - Seoul (Korea, Republic of)

- P062** Serum levels of glucan epitope correlate with tau and predict progression to dementia in combination with APOE4 allele status
Robin Ziyue Zhou¹, Davide Liborio Vetrano², Giulia Grande², Bengt Winblad¹, Lars Tjernberg¹, Sophia Schedin-Weiss¹
¹Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet - Solna (Sweden), ²Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University - Stockholm (Sweden)
- P063** Serum proBDNF predicts memory gains after lifestyle changes in elderly persons - A subgroup analysis among adherent participants in the FINGER study
Anna Matton¹, Krister Håkansson¹, Julen Goicolea¹, Makrina Daniilidou¹, Tiia Ngandu², Gorka Gerenu¹, Alina Solomon³, Hilikka Soininen³, Tiina Laatikainen², Miia Kivipelto¹
¹Karolinska Institutet - Solna (Sweden), ²Finnish Institute on Health and Welfare - Helsinki (Finland), ³University of Eastern Finland - Kuopio (Finland)
- P064** Evaluation of long-term safety and compliance to a multinutrient intervention for up to 8 years in mild cognitive impairment / prodromal Alzheimer's disease: data from the randomised controlled LipiDiDiet trial
Tobias Hartmann^{1,2}, Alina Solomon^{3,4,5}, Pieter Visser^{6,7}, Kai Blennow^{8,9}, Miia Kivipelto^{10,11,5}, Hilikka Soininen^{12,10}
¹Deutsches Institut für Demenzprävention, Saarland University - Homburg (Germany), ²Experimental Neurology - Homburg (Germany), ³Neurology, Institute of Clinical Medicine, University of Eastern Finland - Kuopio (Finland), ⁴Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute - Stockholm (Sweden), ⁵Clinical Trials Unit, Theme Aging, Karolinska University Hospital - Huddinge (Sweden), ⁶Department of Neurology, Alzheimer Center, VU University Medical Center - Amsterdam (Netherlands), ⁷Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht - Maastricht (Netherlands), ⁸Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg - Mölndal (Sweden), ⁹Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), ¹⁰Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland - Kuopio (Finland), ¹¹Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute - Stockholm (Sweden), ¹²Neurocenter, Department of Neurology, Kuopio University Hospital - Kuopio (Finland)
- P066** Clinical utility of non-invasive whole transcriptomic profiling of Alzheimer's disease
 Shusuke Toden¹, Jiali Zhuang¹, Stephen Quake², Robert Rissman³, James Brewer³, John Sninsky¹
¹Molecular Stethoscope - South San Francisco (United States), ²Stanford University - Stanford (United States), ³University of California, San Diego - San Diego (United States)
- P067** Development of a selective estrogen β -receptor phytoestrogen formulation - PhytoSERM - for improving cognitive health to reduce Alzheimer's risk and menopausal symptoms: A Phase 2 randomized clinical trial
 Claudia Lopez¹, Mark Drew¹, Gerson Hernandez¹, Roberta Brinton¹
¹University of Arizona - Tucson (United States)
- LP45** Phylum Firmicutes abundance is associated with brain volumes in a cognitively unimpaired cohort enriched for Alzheimer's disease risk
Muhaïson Ibrahim¹, Heston Margo¹, Jea Woo Kang¹, Gilda Ennis¹, Sandra Harding¹, Sterling Johnson¹, Sanjay Asthana¹, Barbara Bendlin¹, Antonio González², Federico Rey¹, Rob Knight², Rima Kaddurah-Daouk³
¹University of Wisconsin school of Medicine and Public Health - Madison (United States), ²department of pediatrics, university of california, san diego - la jolla - La Jolla (United States), ³Department of Psychiatry and Behavioral Sciences, Duke - Durham (United States)
- LP46** Optimizing detection of prodromal Alzheimer disease in mild cognitive impairment - a 4-year cerebrospinal fluid study of mild behavioral impairment in ADNI and MEMENTO
Zahinoor Ismail¹, Rebeca Leon², Byron Creese³, Clive Ballard³, Philippe Robert⁴, Eric E. Smith¹
¹University of Calgary - Calgary (Canada), ²Hotchkiss Brain Institute - Calgary (Canada), ³University of Exeter - Exeter (United Kingdom), ⁴Université Côte d'Azur - Nice (France)
- LP47** Comparison of cytokine profile in older adults with positive and negative protein biomarkers A β 42, p-Tau, t-Tau and p-Tau /A β 42 ratio
Ivonne Carolina Bolaños Burgos^{1,2,3,4}, Gabriela Tomé Oliveira Engemann^{5,6,4}, Erika Oliveira Hansen⁷, Natalia Silva Dias^{2,8}, Andréa Teixeira Carvalho⁹, Daniela Valadão^{10,4}, Débora Miranda^{2,10,11}, Marco Aurélio Romano-Silva^{2,10,4}, Bernardo Mattos Viana^{2,8,12}, Maria Aparecida Camargos Bicalho^{2,5,1,4}
¹Adult Health Sciences Applied Program - Belo Horizonte (Brazil), ²Hospital das Clínicas - Belo Horizonte (Brazil), ³National Institute of Science and Technology of Molecular Medicine (INCT-MM), Faculdade de Medicina, Universidade Federal de Minas Gerais - Belo Horizonte (Brazil), ⁴Universidade Federal de Minas Gerais - Belo Horizonte (Brazil), ⁵Molecular Medicine Program - Belo Horizonte (Brazil), ⁶Jenny de Andrade Faria Institute- Reference Center for the Elderly Hospital das Clínicas - Belo Horizonte (Brazil), ⁷Jenny de Andrade Faria Institute- Reference Center for the Elderly, Hospital das Clínicas - Belo Horizonte (Brazil), ⁸Older Adult Psychiatry and Psychology Extension Program (PROEPSI) - Belo Horizonte (Brazil), ⁹René Rachou Institute, Oswaldo Cruz Foundation (Fiocruz) - Belo Horizonte (Brazil), ¹⁰National Institute of Science and Technology of Molecular Medicine (INCT-MM) Faculdade de Medicina, Universidade Federal de Minas Gerais - Belo Horizonte (Brazil), ¹¹Universidade Federal de Minas Gerais - Belo Horizonte (Bouvet Island), ¹²Department of Mental Health Faculdade de Medicina, Universidade Federal de Minas Gerais - Belo Horizonte (Brazil)
- LP48** Early Detection of Alzheimer's Disease using microRNAs
Bruno Steinkraus¹, Marco Heuvelman¹, Jeffrey L Cummings², Jean Manson³, Craig Ritchie³
¹Hummingbird Diagnostics - Heidelberg (Germany), ²Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas - Las Vegas (United States), ³Centre for Clinical Brain Sciences, The University of Edinburgh - Edinburgh (United Kingdom)

THEME: Clinical Trials Imaging

-  **P069** **Do the radiomics or structural and functional magnetic resonance imaging give additional information to predict brain amyloid positivity?**
Yoojin Lee¹, Sungyang Jo¹, Jae-Hong Lee¹
¹Asan Medical Center - Seoul (Korea, Republic of)
-  **P070** **Differential effects of cardiometabolic syndrome on brain age in relation to sex and ethnicity**
Sung Hoon Kang¹, Mengting Liu², Sang Won Seo³, Hosung Kim²
¹Department Of Neurology, Korea University Guro Hospital, Korea University College Of Medicine - Seoul (Korea, Republic of), ²Usc Steven Neuroimaging And Informatics Institute, Keck School Of Medicine Of University Of Southern California - Los Angeles (United States), ³Departments Of Neurology, Samsung Medical Center, Sungkyunkwan University School Of Medicine - Seoul (Korea, Republic of)
- P071** **Genome-Wide Association Study of the functional brain network for Alzheimer's Disease**
Minji Kim¹, Jong-Min Lee²
¹Department Of Electronic Engineering, Hanyang University - Seoul (Korea, Republic of), ²Department Of Biomedical Engineering, Hanyang University - Seoul (Korea, Republic of)
-  **P072** **Clinical and radiomic features for predicting the treatment response of repetitive transcranial magnetic stimulation in major neurocognitive disorder**
Hanna Lu¹, Sandra Sau Man Chan¹, Suk Ling Ma¹, Vincent Chung Tong Mok¹, Lin Shi¹, Arthur Dun-Ping Mak¹, Linda Chiu Wa Lam¹
¹The Chinese University of Hong Kong - Hong Kong (Hong Kong)
-  **P073** **Association of regional amyloid burden and brain volume with cognitive performances among individuals with subjective cognitive decline**
Chonghee Lee¹, Dong Won Yang¹, Yun Jeong Hong², Seonghee Ho³, Jee Hyang Jeong⁴, Kee Hyung Park⁵, Sangyun Kim⁶, Min Jeong Wang⁷, Seong Hye Choi⁸, Sanggyu Lee⁹
¹Neurology, Catholic University Of Korea, Seoul St. Mary's Hospital - Seoul (Korea, Republic of), ²Neurology, Catholic University Of Korea, Seoul St. Mary's Hospital - Uijeongbu (Korea, Republic of), ³Neurology, Changwon Hanmaeum Hospital - Changwon (Korea, Republic of), ⁴Neurology, Womans University School Of Medicine, Ewha Womans University Seoul Hospital - Seoul (Korea, Republic of), ⁵Neurology, Gachon University Gil Hospital - Incheon (Korea, Republic of), ⁶Neurology, Seoul National University College Of Medicine, Seoul National University Bundang Hospital - Seongnam (Korea, Republic of), ⁷Neurology, Roa Clinic - Seongnam (Korea, Republic of), ⁸Neurology, Inha University School Of Medicine, Inha University Hospital - Incheon (Korea, Republic of), ⁹Neolab Convergence Inc. - Seoul (Korea, Republic of)
-  **P074** **The role of subthreshold levels of amyloid deposition on dementia conversion-validated with ADNI**
Hyung-Ji Kim¹, Jae-Hong Lee²
¹Uijeongbu Eulji Medical Center - Uijeongbu-Si (Korea, Republic of), ²Asan Medical Center - Seoul (Korea, Republic of)
- P075** **Evaluation of a clinically validated digital platform to provide Diffusion MRI biomarkers in Alzheimer's disease**
Etienne Bories¹, Arthur Bezie¹, Didier Cassereau¹, Julie Rachline¹, Iyed Trimeche¹, Jean-Baptiste Martini¹, Vincent Perlbarg¹
¹BRAINTALE SAS - Strasbourg (France)
-  **P076** **Increase in white matter volume and myelination after 6 months of 40Hz gamma sensory stimulation therapy in patients on Alzheimer's Disease spectrum**
Xiao Da¹, Evan Hempel¹, Holly Mrozak¹, Zach Malchano¹, Brent Vaughan¹, J. Thomas Megerian¹, Mihaly Hajos^{1,2}, Aylin Cimenser¹
¹Cognito Therapeutics - Cambridge, Ma (United States), ²Yale University School of Medicine - New Haven, Ct (United States)
-  **P077** **Summary of ACR Phantom MRI site qualification findings over 7 years and recommendations moving forward**
Luc Bracoud¹, Joonmi Oh², Qui Cao², Chris Conklin³, Madhura Ingalthalakar³, Ha Pham², David Scott², Joyce Suh²
¹Clario (formerly Bioclinica) - Lyon (France), ²Clario (formerly Bioclinica) - San Mateo (United States), ³Clario (formerly Bioclinica) - Princeton (United States)
- P079** **Effects of Alzheimer and Lewy Body Disease Pathologies on Brain Metabolism**
Byong Seok Ye¹, Sungwoo Kang²
¹MD, PhD - Seoul (Korea, Republic of), ²MD - Seoul (Korea, Republic of)
-  **P080** **REducing Sleep Apnoea for the PrEvention of Dementia (RESHAPED): The protocol of a multi-site feasibility randomised controlled trial**
Sharon Naismith¹, Camilla Hoyos¹, Craig Phillips¹, Yaffe Kristine², Ralph Martins³, Nathaniel Marshall¹, Jim Lagopoulos⁴, Melinda Jackson⁵, Loren Mowszowski¹, Ronald Grunstein¹
¹University of Sydney - Sydney (Australia), ²University of California - San Francisco (United States), ³University of Macquarie - Sydney (Australia), ⁴University of Sunshine Coast - Sunshine Coast (Australia), ⁵Monash University - Melbourne (Australia)
- P081** **Arterial stiffness is associated with cortical tau burden**
Young Noh¹
¹Gachon University Gil Medical Center - Incheon (Korea, Republic of)

-  **P082** **Application of fully automatic Hippocampal sub-field segmentation volumes to standard resolution T1 MR Imaging in Alzheimer's disease**
Richard Joules ¹, [Robin Wolz](#) ¹
¹*IXICO - London (United Kingdom)*
-  **P083** **Amϒloid PET centiloid: impact of calibration and processing steps**
Luca Presotto ¹, Mahnaz Shekari ², Lyduine E. Collij ³, Richard Manber ¹, David Vallez Garcıa ³, Juan Domingo Gispert Lopez ², [Robin Wolz](#) ¹
¹*IXICO - London (United Kingdom)*, ²*BarcelonaBeta Brain Research Centre, Pasqual Maragall Foundation - Barcelona (Spain)*, ³*Amsterdam UMC - Amsterdam (Netherlands)*
-  **P084** **Independent effects of hippocampal subfield volumes and p-tau on memory performance in clinically unimpaired older adults**
[Tammy Tran](#) ¹, Alexandra Trelle ¹, Wilson Edward ¹, Gayle Deutsch ¹, Sharon Sha ¹, Katrin Andreasson ¹, Valerie Carr ¹, Geoffrey Kerchner ¹, Elizabeth Mormino ¹, Anthony Wagner ¹
¹*Stanford University - Stanford (United States)*
- P085** **Supporting the Communication of Modern Alzheimer's Data through Augmented Reality and Web Technologies**
[Tyler Ard](#) ¹, Bienkowski Michael ¹, Arthur Toga ¹
¹*USC Stevens Neuroimaging and Informatics Institute - Los Angeles (United States)*
-  **P086** **Longitudinal assessment of novel imaging markers of neuroinflammation, axonal density and demyelination as biomarkers in Alzheimer's Disease**
Maggie Roy ¹, [Jean-Rene Belanger](#) ¹, Matthieu Dumont ¹, Jean-Christophe Houde ¹, Maxime Descoteaux ¹
¹*Imeka - Sherbrooke (Canada)*
-  **P087** **Predicting PET-determined ATN biomarker status in Alzheimer's disease with MRI using deep convolutional neural networks**
[Christopher Lew](#) ¹, Longfei Zhou ¹, Maciej Mazurowski ¹, P Murali Doraiswamy ¹, Susan Landau ², Jeffrey Petrella ³
¹*Duke University Medical Center - Durham (United States)*, ²*University of California, Berkeley - Berkeley (United States)*, ³*Duke University Medical Center - Durham (United States)*
-  **P088** **Early [18F]-PI-2620 tau PET signal in the stages preceding AD dementia**
[Christina Young](#) ¹, Hillary Vossler ¹, Edward Wilson ¹, Alexandra Trelle ², Kathleen Poston ¹, Michael Zeineh ¹, Michael Greicius ¹, Greg Zaharchuk ¹, Victor Henderson ¹, Anthony Wagner ², Katrin Andreasson ¹, Guido Davidzon ¹, Elizabeth Mormino ¹
¹*Stanford ADRC - Stanford (United States)*, ²*Stanford Department of Psychology - Stanford (United States)*
-  **P089** **Amϒloid and tau burden in an at-risk, cognitively unimpaired clinical trial cohort: Neuroimaging data from the U.S. POINTER trial**
[Alice Murphy](#) ¹, Theresa Harrison ¹, Tyler Ward ¹, Prashanthi Vemuri ², Robert Koeppe ³, Samuel Lockhart ⁴, Mark Espeland ⁴, Danielle Harvey ⁵, Joseph Masdeu ⁶, Hwamee Oh ⁷, Darren Gitelman ⁸, Neelum Aggarwal ⁹, Laura Baker ⁴, Charles Decarli ⁵, Susan Landau ¹
¹*U.C. Berkeley (United States)*, ²*Mayo Clinic (United States)*, ³*University of Michigan (United States)*, ⁴*Wake Forest School of Medicine (United States)*, ⁵*U.C. Davis (United States)*, ⁶*Houston Methodist (United States)*, ⁷*Brown University (United States)*, ⁸*Advocate Lutheran General Hospital (United States)*, ⁹*Rush University Medical Center (United States)*
-  **LP50** **First microtubule-based PET imaging studies in cognitively normal and impaired older adult subjects--a pilot study**
Naresh Damuka ¹, Bhuvanachandra Bhoopal ¹, Mack Miller ¹, Ivan Krizan ¹, Samuel Lockhart ¹, Melissa Rundle ¹, Akiva Mintz ², Suzanne Craft ¹, [Kiran K Solingapuram Sai](#) ¹
¹*Wake Forest School of Medicine - Winston Salem (United States)*, ²*Columbia University Medical Center - New York (United States)*
-  **LP51** **Comparative Study on the Predictive Value of Different Resting-State Functional Magnetic Resonance Imaging Parameters in Preclinical Alzheimer's Disease**
[Won-Myong Bahk](#) ¹, Young-Joon Kwon ², Bo-Hyun Yoon ³, Kwanghun Lee ⁴, Sang-Yeol Lee ⁵, Moon-Doo Kim ⁶, Beomwoo Nam ⁷, Sung-Yong Park ⁸, Eunsung Lim ⁹, Sheng-Min Wang ¹, Hyun Kook Lim ¹
¹*The Catholic University of Korea - Seoul (Korea, Republic of)*, ²*Soonchunhyang University - Cheonan (Korea, Republic of)*, ³*Naju National Hospital - Naju (Korea, Republic of)*, ⁴*Dongguk University - Gyeongju (Korea, Republic of)*, ⁵*Wonkwang University - Iksan (Korea, Republic of)*, ⁶*Jeju National University - Jeju (Korea, Republic of)*, ⁷*Dr. Nam's Psychiatric Clinic - Chungju (Korea, Republic of)*, ⁸*Keyo Hospital - Uiwang (Korea, Republic of)*, ⁹*Shinsegae Hyo Hospital - Kimje (Korea, Republic of)*
-  **LP52** **Development of Random Forest Algorithm Based Prediction Model of Alzheimer's Disease Using Neurodegeneration Pattern**
[Kwanghun Lee](#) ¹, Won-Myong Bahk ², Young-Joon Kwon ³, Bo-Hyun Yoon ⁴, Sang-Yeol Lee ⁵, Moon-Doo Kim ⁶, Beomwoo Nam ⁷, Sung-Yong Park ⁸, Eunsung Lim ⁹, Sheng-Min Wang ², Hyun Kook Lim ²
¹*Department of Psychiatry Dongguk University Hospital - Gyeongju (Korea, Republic of)*, ²*Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of)*, ³*Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University - Cheonan (Korea, Republic of)*, ⁴*Department of Psychiatry, Naju National Hospital - Naju (Korea, Republic of)*, ⁵*Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine - Iksan (Korea, Republic of)*, ⁶*Department of Psychiatry, Jeju National University School of Medicine - Jeju (Korea, Republic of)*, ⁷*Dr. Nam's Psychiatric Clinic - Chungju (Korea, Republic of)*, ⁸*Department of Psychiatry, Keyo Hospital - Uiwang (Korea, Republic of)*, ⁹*Department of Psychiatry, Shinsegae Hyo Hospital - Kimje (Korea, Republic of)*
-  **LP53** **Association between white matter hyperintensities (WMH) volume and cognitive function in Alzheimer's disease**
[Yoon Bo-Hyun](#) ¹, Bahk Won-Myong ², Kwon Young-Joon ³, Lee Kwanghun ⁴, Lee Sang-Yeol ⁵, Kim Moon-Doo ⁶, Nam Beomwoo ⁷, Park Sung-Yong ⁸, Lim Eunsung ⁹
¹*Department of Psychiatry, Naju National Hospital - Naju (Korea, Republic of)*, ²*Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of)*, ³*Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University - Cheonan (Korea, Republic of)*, ⁴*Department of Psychiatry, College of Medicine, Dongguk University - Gyeongju (Korea, Republic of)*, ⁵*Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine - Iksan (Korea, Republic of)*, ⁶*Department of Psychiatry, Jeju National University School of Medicine - Jeju (Korea, Republic of)*, ⁷*Dr. Nam's Psychiatric Clinic - Chungju (Korea, Republic of)*, ⁸*Department of Psychiatry, Keyo Hospital - Uiwang (Korea, Republic of)*, ⁹*Department of Psychiatry, Shinsegae Hyo Hospital - Kimju (Korea, Republic of)*

-  **LP53A** **Cross sectional association between frailty and white matter hyperintensity among Alzheimer`s disease**
Kim Moon-Doo¹, Bahk Won-Myong Bahk², Kwon Young-Joon³, Yoon Bo-Hyun⁴, Lee Kwanghun⁵, Lee Sang-Yeol⁶, Nam Beomwoo⁷, Park Sung-Yong⁸, Lim Eunsung⁹
¹Department of Psychiatry, Jeju National University School of Medicine - Jeju (Korea, Republic of),²Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of),³Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University - Cheonan (Korea, Republic of),⁴Department of Psychiatry, Naju National Hospital - Naju (Korea, Republic of),⁵Department of Psychiatry, College of Medicine, Dongguk University - Gyeongju (Korea, Republic of),⁶Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine - Iksan (Korea, Republic of),⁷Dr. Nam's Psychiatric Clinic - Chugju (Korea, Republic of),⁸Department of Psychiatry, Keyo Hospital - Uiwang (Korea, Republic of),⁹Department of Psychiatry, Shinsegae Hyo Hospital - Kimje(Korea, Republic of)
-  **LP54** **Clinical and biomarker characteristics of subjective cognitive decline who progressed to MCI within 24-months follow-up**
Dong Won Yang¹, Chunghwee Lee¹, Yun-Jeong Hong², Seonghee Ho³, Jee Hyang Jeong⁴, Kee Hyung Park⁵, Sangyun Kim⁶, Min Jeong Wang⁷, Seong Hye Choi⁸, Sanggyu Lee⁹
¹Department Of Neurology, College Of Medicine, The Catholic University Of Korea - Seoul (Korea, Republic of),²Department of Neurology, The Catholic University of Korea Uijeongbu St. Mary's Hospital, Uijeongbu, Republic of Korea - Uijeongbu (Korea, Republic of),³Department of Neurology, Changwon Hanmaeum Hospitaljeongbu, Republic of Korea - Changwon (Korea, Republic of),⁴Department of Neurology, Womans University School of Medicine, Ewha Womans University Seoul HospitalChangwon Hanmaeum Hospitaljeongbu, Republic of Korea - Seoul (Korea, Republic of),⁵Department of Neurology, Gachon University Gil Hospital - Incheon (Korea, Republic of),⁶Department of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital - Bundang (Korea, Republic of),⁷Neurology, ROA Clinic - Bundang (Korea, Republic of),⁸Department of Neurology, Inha University School of Medicine, Inha University Hospital - Incheon (Korea, Republic of),⁹NeoLAB convergence Inc - Seoul (Korea, Republic of)
-  **LP55** **In Vivo Head-To-Head Comparison of [18F]GTP1 and [18F]MK6240 in Alzheimer's Disease**
Matteo Tonietto¹, Cristian Constantinescu², Sandra Sanabria Bohorquez³, Roger Gunn⁴, David Russell⁵, Edmond Teng³, Dan Abramzon³, Karen Pickthorn³, Gregory Klein¹
¹Hoffmann-La Roche, Ltd. - Basel (Switzerland),²Invicro, LLC - Needham (United States),³Genentech, Inc. - South San Francisco (United States),⁴Invicro, LLC - London (United Kingdom),⁵Invicro, LLC - Needham (United Kingdom)
-  **LP56** **Evaluating the Impact of Carotid Endarterectomy on Cognition and Hippocampal Fractional Anisotropy**
Adam Bernstein¹, Juan Arias¹, Craig Weinkauff¹, Theodore Trouard¹
¹University of Arizona - Tucson (United States)
-  **LP57** **New insights into the contribution of tau PET imaging in AD therapeutic trials**
Julien Lagarde^{1,2,3}, Pauline Olivier¹, Matteo Tonietto^{3,4}, Philippe Gervais³, Fabien Caillé³, Martin Moussion⁵, Michel Bottlaender^{3,6}, Marie Sarazin^{1,7,8}
¹Department of Neurology of Memory and Language, GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte Anne - Paris (France),²Université Paris Cité - Paris (France),³Université Paris-Saclay, BioMaps, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm - Orsay (France),⁴Research and Early Development (pRED), Hoffmann-La Roche - Basel (Switzerland),⁵Centre d'Evaluation Troubles Psychiques et Vieillessement, GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte Anne, France - Paris (France),⁶Université Paris-Saclay, UNIACT, Neurospin, Joliot Institute, CEA - Gif Sur Yvette (France),⁷Université Paris Cité - Paris (France) ,⁸Université Paris-Saclay, BioMaps, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, - Orsay (France)
-  **LP58** **Methods to decrease sample size needed for longitudinal Flortaucipir tau PET**
Suzanne Baker¹, Pablo Aguilar Dominguez¹, Susan Landau², Theresa Harrison², Renaud Lajoie³, Tyler Ward², Kailin Zhuang², Gil Rabinovici³, William Jagust²
¹Lawrence Berkeley National Lab - Berkeley (United States),²University of California, Berkeley - Berkeley (United States),³University of California, San Francisco - San Francisco (United States)
-  **LP59** **Prevalence of microhemorrhages, superficial siderosis and other MRI abnormalities in a population of cognitively unimpaired older adults from the CHARIOT-PRO study**
Luc Bracoud¹, Chi Udeh-Momoh², Ziad Saad³, Dimitra Kafetsouli⁴, Emmett Daly⁴, Onah Okoye⁴, Parthenia Giannakopoulou⁴, David Scott⁵, Joyce Suhy⁵, Susan Baker⁶, Gerald Novak⁶, Craig Ritchie⁷, Lefkos Middleton², Lefkos Middleton⁸
¹Clario - Lyon (France),²AGE Research, School of Public Health, Imperial College of London - London (United Kingdom) - London (United Kingdom),³Janssen Research and Development - La Jolla (United States),⁴AGE Research, School of Public Health, Imperial College of London - London (United Kingdom),⁵Clario - San Mateo (United States),⁶Janssen Research and Development - Titusville (United States),⁷University of Edinburgh - Edinburgh (United Kingdom),⁸Imperial College Healthcare NHS Trust - London (United Kingdom)
-  **LP60** **Prediction of longitudinal change in CDR Sum of Boxes using a cortical microstructural AD signature from baseline diffusion MRI**
Ged Ridgway¹, Mario Torso¹, Dimitra Tzaferou¹, Michele Valotti¹, Ian Hardingham¹, Steven Chance¹, Adni Alzheimer's Disease Neuroimaging Initiative²
¹Oxford Brain Diagnostics Ltd - Oxford (United Kingdom),²Alzheimer's Disease Neuroimaging Initiative (United States)
-  **LP61** **Cortical microstructural measures from diffusion MRI correlate with cognitive composite scores and predict their longitudinal changes**
Mario Torso¹, Ged Ridgway¹, Michele Valotti¹, Ian Hardingham¹, Steven Chance¹, Adni Alzheimer's Disease Neuroimaging Initiative²
¹Oxford Brain Diagnostics Ltd - Oxford (United Kingdom),²Alzheimer's Disease Neuroimaging Initiative (United States)
-  **LP62** **APOEε4 carriership and Aβ positivity for the populational enrichment of clinical trials testing drug effects on tau tangles**
João Pedro Ferrari-Souza¹, Pâmela Ferreira¹, Bruna Bellaver¹, Guilherme Povala¹, Firoza Lussier¹, Douglas Leffa¹, Cécile Tissot², Joseph Therriault², Thomas Karikari³, Jean-Paul Soucy², Serge Gauthier², Eduardo Zimmer⁴, Pedro Rosa-Neto², Tharick Pascoal¹
¹University of Pittsburgh - Pittsburgh (United States),²McGill University - Montreal (Canada),³University of Gothenburg - Mölndal (Sweden),⁴Universidade Federal do Rio Grande do Sul - Porto Alegre (Brazil)

THEME: Clinical Trials: Biomarkers including plasma

- P090** **Impacts of amyloid burden on longitudinal cognitive declines in subjective cognitive decline: a prospective cohort study**
Yun Jeong Hong¹, Dong Won Yang², Seonghee Ho², Kwonoh Park³, Jee Hyang Jeong⁴, Kee Hyung Park⁵, Sangyun Kim⁶, Min Jeong Wang⁶, Seong Hye Choi⁷, Sanggyu Lee⁸
¹Uijeongbu St. Mary's Hospital - Uijeongbu (Korea, Republic of), ²Seoul St. Mary's Hospital - Seoul (Korea, Republic of), ³Pusan National University Yangsan Hospital - Yangsan (Korea, Republic of), ⁴Ewha Womans University Seoul Hospital - Seoul (Korea, Republic of), ⁵Gachon University Gil Hospital - Incheon (Korea, Republic of), ⁶Seoul National University College Of Medicine, Seoul National University Bundang Hospital - Seongnam (Korea, Republic of), ⁷Inha University School Of Medicine - Incheon (Korea, Republic of), ⁸Neolab Convergence Inc. - Seoul (Korea, Republic of)
- P091** **Predictive value of plasma p-tau181 versus baseline amyloid-PET for longitudinal amyloid accumulation in asymptomatic Alzheimer's Disease**
Rik Vandenberghe¹, Steffi De Meyer¹, Emma Luckett¹, Jeroen Vanbrabant², Jolien Schaevebeke¹, Mariska Reinartz¹, Isabelle Cleynen³, Erik Stoops², Eugene Vanmechelen², Koen Van Laere⁴
¹Alzheimer Research Centre Ku Leuven, Leuven Brain Institute - Leuven (Belgium), ²Adx Neurosciences - Zwijnaarde (Belgium), ³Laboratory For Complex Genetics - Leuven (Belgium), ⁴Nuclear Medicine Service, University Hospitals Leuven - Leuven (Belgium)
- P092** **Blood biomarkers for Alzheimer's disease to predict dementia risk in a large clinic-based cohort: implications for clinical trials**
Vincent Planche¹, Vincent Bouteloup¹, Geneviève Chêne¹, Carole Dufouil¹
¹Bordeaux University - Bordeaux (France)
- P093** **Independent Effect of Body Mass Index Variation on Amyloid-β Positivity**
Sung Hoon Kang¹, Jong Hyuk Kim², Kyunga Kim², Sang Won Seo³
¹Department Of Neurology, Korea University Guro Hospital, Korea University College Of Medicine - Seoul (Korea, Republic of), ²Department Of Digital Health, Saihst, Sungkyunkwan University - Seoul (Korea, Republic of), ³Department Of Neurology, Samsung Medical Center, Sungkyunkwan University School Of Medicine - Seoul (Korea, Republic of)
- P094** **Phase 2 study reveals an adequate PK/PD relationship of bosutinib in Dementia with Lewy Bodies and clears the path for larger Phase 2/3 investigations**
Charbel Mousa¹, Fernando Pagan², Torres-Yaghi Yasar², Hebron Michaleine¹, Turner Raymond S¹, Ahn Jaeil¹
¹Georgetown University Medical Center - Washington (United States), ²Medstar Georgetown Hospital - Washington (United States)
- P095** **Biomarker Assessments From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias**
Jonathan Haroon¹, Kennedy Mahdavi^{1,2}, Kaya Jordan¹, Elisabeth Rindner¹, Margaret Zielinski¹, Victoria Venkatraman^{1,2}, Dayan Goodenowe³, Kaitlyn Hofmeister³, Clarence Ahlem⁴, Christopher Reading⁴, Joseph Palumbo⁴, Bijan Pourat⁵, Sheldon Jordan^{1,2}
¹The Regenesys Project - Santa Monica (United States), ²Synaptec Network - Santa Monica (United States), ³Prodrome Sciences USA LLC - Temecula (United States), ⁴Biovie Inc. - Carson City (United States), ⁵Pourat MD - Beverly Hills (United States)
- P096** **Robustness of cerebrospinal fluid (CSF) amyloid-β 1-42/amyloid-β 1-40 (Aβ42/Aβ40) and phosphorylated tau/amyloid-β 1-42 (pTau/Aβ42) biomarker ratios in classification of amyloid positron emission tomography (PET) positivity in routine clinical use**
Chad Logan¹, Henrik Schinke¹, Christina Rabe², Maryline Simon³, Oskar Hansson^{4,5}, Kaj Blennow^{6,7}, Erik Stomrud^{4,5}
¹Roche Diagnostics GmbH - Penzberg (Germany), ²Genentech, Inc. - South San Francisco (United States), ³Roche Diagnostics International Ltd - Rotkreuz (Switzerland), ⁴Clinical Memory Research Unit, Department Of Clinical Sciences Malmö, Lund University - Malmö (Sweden), ⁵Memory Clinic, Skåne University Hospital - Malmö (Sweden), ⁶Department Of Psychiatry And Neurochemistry, Institute Of Neuroscience And Physiology, The Sahlgrenska Academy At The University Of Gothenburg - Mölndal (Sweden), ⁷Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden)
- P097** **The biomarker-based etiological diagnosis of neurocognitive disorders: the European Inter-Societal Delphi Consensus**
Stefania Orini^{1,2}, Cristina Festari³, Federico Massa⁴, Matteo Cotta Ramosino^{5,6}, Flavio Nobili^{7,8}, Giovanni Battista Frisoni^{9,10} The European Inter-Societal Consensus On The Biomarker-Based Diagnosis Of Dement¹¹
¹Alzheimer's Unit-Memory Clinic, Irccs Istituto Centro San Giovanni Di Dio Fatebenefratelli - Brescia, (Italy), ²Dipartimento di Scienze Cliniche e Sperimentali, Università degli Studi di Brescia, - Brescia (Italy), ³Laboratory Of Alzheimer's Neuroimaging And Epidemiology, Irccs Istituto Centro San Giovanni Di Dio Fatebenefratelli - Brescia, (Italy), ⁴Department Of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal And Child Health (dino-gmi), University Of Genoa - Genoa (Italy), ⁵Unit Of Behavioral Neurology, Irccs Mondino Foundation, - Pavia (Italy), ⁶Department of Brain and Behavioral Sciences, University of Pavia, - Pavia, (Italy), ⁷Department Of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal And Child Health (dino-gmi), University Of Genoa, - Genoa (Italy), ⁸IRCCS Ospedale Policlinico San Martino, - Genoa (Italy), ⁹Laboratory Of Neuroimaging Of Aging (lanvie), University Of Geneva, - Geneva (Switzerland), ¹⁰Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, G - Geneva (Switzerland), ¹¹The European Inter-Societal Consensus On The Biomarker-Based Diagnosis Of Dementia
- P098** **Predicting amyloid positivity with blood-based biomarkers including p-tau181**
 Kwon Hyuk Sung¹, Lee Eun-Hye¹, Park Hyun-Hee¹, Koh Seong-Ho¹
¹Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine - Guri (Korea, Republic of)

- P099** **Data-driven 18F-Flortaucipir cut-offs for preclinical and early AD**
 Giulia Quattrini ^{1,2}, Clarissa Ferrari ³, Michela Pievani ¹, Federica Ribaldi ⁴, Szymon Tomczyk ⁴, Giovanni Battista Frisoni ⁴, Valentina Garibotto ⁴, **Maira Marizzoni** ¹
¹Laboratory Of Alzheimer's Neuroimaging And Epidemiology (lane), Irccs Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia, Italy - Brescia (Italy), ²Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy - Brescia (Italy), ³Unit Of Statistics, Irccs Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia, Italy - Brescia (Italy), ⁴Memory Clinic And Lanvie-Laboratory Of Neuroimaging Of Aging, University Hospitals And University Of Geneva, Geneva, Switzerland - Geneva (Switzerland)
-  **P100** **Biological Brain Age Prediction Using Machine Learning on Structural Neuroimaging Data: Multi-Cohort Validation Against Biomarkers of Alzheimer's Disease and Neurodegeneration stratified by sex**
 Irene Cumpido Mayoral ^{1,2}, Marta Milà-Alomà ^{1,2,3,4}, Luigi Lorenzini ⁵, Alle Meije Wink ⁵, Henk J.m.m. Mutsaerts ⁵, Sven Haller ⁶, Gael Chetelat ⁷, Frederik Barkhof ^{5,8}, Margherita Carboni ⁹, Gwendlyn Kollmorgen ¹⁰, Henrik Zetterberg ^{11,12,13,14}, Kaj Blennow ^{11,12}, Marc Suárez-Calvet ^{1,3,4,15}, Verónica Vilaplana ¹⁶, Juan Domingo Gispert ^{1,3,17}
¹Barcelona@eta Brain Research Center (bbrc), Pasqual Maragall Foundation - Barcelona (Spain), ²Universitat Pompeu Fabra - Barcelona (Spain), ³IMIM (Hospital del Mar Medical Research Institute) - Barcelona (Spain), ⁴CIBER Fragilidad y Envejecimiento Saludable (CIBERFES) - Madrid (Spain), ⁵Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), ⁶CIRD Centre d'Imagerie Rive Droite - Geneva (Switzerland), ⁷Imaging of Neurological Disorders, Institut Blood and Brain @ Caen-Normandie, Cyceron - Caen (France), ⁸Institutes of Neurology and Healthcare Engineering, University College London - London (United Kingdom), ⁹Roche Diagnostics International Ltd - Rotkreuz Zg (Switzerland), ¹⁰Roche Diagnostics GmbH - Penzberg (Germany), ¹¹Institute of Neuroscience and Physiology, University of Gothenburg - Mölndal (Sweden), ¹²Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), ¹³Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology - London (United Kingdom), ¹⁴UK Dementia Research Institute at UCL - London (United Kingdom), ¹⁵Servei de Neurologia, Hospital del Mar - Barcelona (Spain), ¹⁶Department of Signal Theory and Communications, Universitat Politècnica de Catalunya - Barcelona (Spain), ¹⁷Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) - Madrid (Spain)
-  **P101** **Cerebrospinal fluid placental growth factor in relation to cerebrovascular disease and diabetes in non-demented elderly**
 Eske Christiane Gertje ^{1,2}, Shorena Janelidze ¹, Danielle Van Westen ^{3,4}, Erik Stomrud ^{1,5}, Sebastian Palmqvist ^{1,5}, Oskar Hansson ^{1,5}, Niklas Mattsson-Carlgen ^{1,6,7}
¹Clinical Memory Research Unit, Department Of Clinical Sciences Malmö, Lund University - Malmö (Sweden), ²Department of Internal Medicine, Skåne University Hospital - Lund (Sweden), ³Diagnostic Radiology, Department Of Clinical Sciences Lund, Lund University - Lund (Sweden), ⁴Imaging and Function, Skåne University Hospital - Lund (Sweden), ⁵Memory Clinic, Skåne University Hospital - Malmö (Sweden), ⁶Department of Clinical Sciences Lund, Neurology, Lund University, Skåne University Hospital - Lund (Sweden), ⁷Wallenberg Center for Molecular Medicine, Lund University - Lund (Sweden)
-  **P102** **Plasma AD biomarkers can Predict Hippocampal Atrophy**
 Hyung-Ji Kim ¹, Jae-Hong Lee ²
¹Uijeongbu Eulji Medical Center - Uijeongbu-Si (Korea, Republic of), ²Asan Medical Center - Seoul (Korea, Republic of)
-  **P103** **Assessment of Plasma p-tau181 in TANGO, a Phase 2 study of Gosuramemab in Patients with early Alzheimer's Disease**
 Julie Czerkowicz ¹, Jessica Kong ¹, Annie Racine ¹, Carrie Rubel ¹, Jessica Collins ¹, Melanie Shulman ¹, Danielle Graham ¹, John Beaver ¹, Samantha Budd Haeberlein ¹
¹Biogen - Cambridge (United States)
-  **P104** **Corneal confocal microscopy and MRI brain volumetry: Prognostic biomarkers for progression from mild cognitive impairment to dementia**
 Georgios Ponirakis ¹, Rayaz Malik ¹
¹Weill Cornell Medicine in Qatar - Doha (Qatar)
-  **P105** **Oligomer biomarkers for preclinical and clinical drug development in neurodegenerative disorders**
 Oliver Bannach ^{1,2}, Lara Blömeke ^{1,2}, Bettina Kass ¹, Alice Chen-Plotkin ³, Oliver Peters ⁴, **Dieter Willbold** ^{1,5}
¹Forschungszentrum Jülich - Jülich (Germany), ²atlyoid GmbH - Düsseldorf (Germany), ³University of Pennsylvania - Philadelphia (United States), ⁴Charité Universitätsmedizin Berlin - Berlin (Germany), ⁵Heinrich-Heine-Universität Düsseldorf - Düsseldorf (Germany)
-  **P106** **Exploratory study on the proteomic and transcriptomic content of plasma extracellular vesicles in AD patients**
 Maria Solaguren-Beascoa ¹, Ana Gámez-Valero ^{1,2}, Ana M. Ortiz ³, Carla Minguet ³, Ricardo Gonzalo ³, Georgina Escaramis ^{1,2}, Montserrat Costa ³, Eulàlia Martí ^{1,2}
¹Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Institut de Neurociències, Universitat de Barcelona - Barcelona (Spain), ²Centro de Investigación Biomédica en Red sobre Epidemiología y Salud Pública (CIBERESP) - Barcelona (Spain), ³Grifols Bioscience Research Group - Barcelona (Spain)
-  **P107** **Towards the development and validation of a general-purpose regulatory-grade neuroimage analysis tool**
 Nick Henscheid ¹, Ioannis Pappas ², Ryan Cabeen ², Jagdeep Podichetty ¹, Samuel Hobel ², Christopher Weber ³, Yashmin Karten ¹, Klaus Romero ¹, Sudhir Sivakumaran ¹, Arthur Toga ²
¹Critical Path Institute - Tucson (United States), ²University of Southern California - Los Angeles (United States), ³Alzheimer's Association - Chicago (United States)
- P108** **Comparative performance of plasma Aβ42/Aβ40 and p-tau181 for the detection of early brain amyloid deposition in individuals with subjective cognitive decline**
 María Pascual-Lucas ¹, José Antonio Allué ¹, Leticia Sarasa ¹, Noelia Fandos ¹, Sergio Castillo ¹, Jose Terencio ¹, Manuel Sarasa ¹, Juan Pablo Tartari ², Ángela Sanabria ^{2,3}, Lluís Tárraga ^{2,3}, Agustín Ruiz ^{2,3}, Marta Marquí ^{2,3}, Mercè Boada ^{2,3}
¹Araclon Biotech-Grifols - Zaragoza (Spain), ²Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya - Barcelona (Spain), ³CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III - Madrid (Spain)

-  **P109** **Evaluation of blood-based plasma biomarkers as potential markers of amyloid burden in preclinical Alzheimer's Disease**
Charisse N. Winston¹, Oliver Lanford², Natalie Levin¹, Rema Raman², Kevin Yarasheski³, Tim West³, Sarah Abdel-Latif², Michael Donohue², Akinori Nakamura⁴, Kenji Toba⁵, Colin L. Masters⁶, James Doecke⁷, Reisa A. Sperling⁸, Paul S. Aisen⁹, Robert A. Rissman¹⁰
¹Department of Neurosciences, University of California San Diego - La Jolla (United States), ²Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California - San Diego (United States), ³C2N Diagnostics - St. Louis (United States), ⁴Department of Biomarker Research, National Center for Geriatrics and Gerontology - Obu (Japan), ⁵National Center for Geriatrics and Gerontology, Obu, Aichi, Japan, and Tokyo Metropolitan Institute of Gerontology - Obu (Japan), ⁶The Florey Institute, The University of Melbourne - Parkville (Australia), ⁷The Commonwealth Scientific and Industrial Research Organization - Herston Qld (Australia), ⁸Harvard Medical School - Boston (United States), ⁹Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California - Los Angeles (United States), ¹⁰Department of Neurosciences, University of California San Diego and VA San Diego Healthcare System - La Jolla (United States)
-  **P110** **Myocardial sympathetic denervation biomarkers for early detection of prodromal DLB**
Mee Young Park¹, Dong Sung Shin¹
¹Neurology Yeungnam University Medical Center - Daegu (Korea, Republic of)
-  **P111** **pTau181 plasma biomarker performance as an inclusion criterion in the RETHINK-ALZ and REFOCUS-ALZ trials in mild-to-moderate Alzheimer's disease**
Anna Mammel¹, Pankaj Kumar², Lindsay Burns³, Donald Biehl¹, Mary Encarnacion², Anna Cruz², Ging-Yuek Robin Hsiung⁴, Ian Mackenzie⁴, Veronica Hirsch-Reinshagen⁴, Ali Mousavi², Ryan Fortna^{1,5}, James Kupiec³, Hans Frykman^{2,4}
¹Neurocode - Bellingham, Washington (United States), ²BC Neuroimmunology - Vancouver (Canada), ³Cassava Sciences - Austin, Texas (United States), ⁴University of British Columbia - Vancouver (Canada), ⁵Northwest Pathology - Bellingham, Washington (United States)
-  **P112** **Critical evaluation and comparison of biomarker values in commercial CSF with Lumipulse® to support assay development for clinical trials**
Hugo Vanderstichele¹, Mahsan Rafizadeh², Erika Cline², Johnson Derrick³, Erica Simmons³, Robert Dean², Jasna Jerecic²
¹Biomarkable - Gent (Belgium), ²Acumen Pharmaceuticals - Charlottesville (United States), ³B2S Life sciences - Indianapolis (United States)
-  **P113** **Detection of CSF alpha-synuclein in patients with prodromal Lewy body disease**
Melanie Plastini¹, Carla Abdelnour¹, Marian Shahid¹, Manuel Medina², Nelson Kha², Hanna Hovren², Jennifer Lamoureux², Victor Henderson¹, Kathleen Poston¹
¹Stanford University - Palo Alto (United States), ²Amprion Clinical Laboratory - San Diego (United States)
- P114** **Effect of butyrylcholinesterase genotype on patients with Alzheimer's disease treated with rivastigmine**
Hairin Kim^{1,2}, So Yeon Cho³, Gieun Nam², Kichul Kim^{4,2}, Eosu Kim³, Jun-Young Lee²
¹Emocog Inc. - Seoul (Korea, Republic of), ²Department of Psychiatry, Seoul Metropolitan Government-Seoul National University Boramae Medical Center - Seoul (Korea, Republic of), ³Department of Psychiatry, Institute of Behavioral Science in Medicine, Brain Korea 21 Plus Project for Medical Science, Yonsei University College of Medicine - Seoul (Korea, Republic of), ⁴Epi Biotech Co., Ltd. - Incheon (Korea, Republic of)
-  **P115** **Impact of Alzheimer's Disease Biomarker Disclosure to Cognitively Unimpaired Individuals: Experiences from a Truncated Randomized Phase 2b/3 Clinical Trial**
Joshua Grill¹, Rema Raman², Garrett Miller², Karin Ernstrom², Michael Donohue², Paul Aisen², Reisa Sperling³, David Henley⁴, H. Robert Brashear⁴, Gary Romano⁴, Gerald Novak⁴
¹University of California Irvine - Irvine (United States), ²Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA - San Diego (United States), ³Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA - Boston (United States), ⁴Janssen Research & Development LLC - Titusville (United States)
-  **P116** **Pharmacodynamic Effects of Semorinemab on Plasma and CSF Tau Biomarkers in a Phase 2 Trial in Mild-to-Moderate Alzheimer's Disease (Lauriet)**
Stephen Schauer¹, Julie Lee¹, Veronica Anania¹, Balazs Toth¹, Lee Honigberg¹, Kristin Wildsmith¹, Vidya Ramakrishnan¹, Michael Dolton¹, Sandra Sanabria Bohorquez¹, Edmond Teng¹, Cecilia Monteiro¹
¹Genentech, Inc. - South San Francisco (United States)
-  **P117** **Novel technology platform for the direct and sensitive detection of circulating AD-related molecules in blood**
Carine Lim¹
¹Sunbird Bio - Singapore (Singapore)
-  **P118** **Recruitment of amyloid positive individuals and early Alzheimer's patients in a primary care setting – results from the BioFINDER Primary Care study**
Sebastian Palmqvist¹, Pontus Tideman¹, Erik Stomrud¹, Ruben Smith¹, Antoine Leuzy¹, Sadek Jafar Jasem¹, Niklas Mattsson-Carlgrén¹, Anna Orduña Dolado¹, Shorena Janelidze¹, Oskar Hansson¹
¹Lund University - Malmö (Sweden)
-  **P119** **Deep plasma and CSF proteomics profiling of the AMBAR study**
Chunmiao (mia) Feng¹, Ricardo Gonzalo², Carla Minguet², Pilar Lafuente², Ana Maria Ortiz², Scott Lohr¹, Mercè Boada³, Oscar López⁴, Antonio Paez², Steven Braithwaite¹, Montserrat Costa², Benoit Lehallier¹
¹Alkermest, a Grifols company - San Carlos (United States), ²Grifols - Barcelona (Spain), ³Universitat Internacional de Catalunya - Barcelona (Spain), ⁴University of Pittsburgh - Pittsburgh (United States)
-  **P120** **Association of neighborhood-level socioeconomic disadvantage with CSF biomarkers of Alzheimer's disease and neurodegeneration**
Gilda Ennis¹, Megan Zuelsdorff¹, Ryan Powell¹, Tobey Bethausser¹, William Buckingham¹, Yue Ma¹, Carol Van Hulle¹, Margherita Carboni², Gwendlyn Kollmorgen³, Carey Gleason¹, Sterling Johnson¹, Kaj Blennow⁴, Henrik Zetterberg⁴, Amy Kind¹, Barbara Bendlin¹
¹University of Wisconsin - Madison - Madison (United States), ²Roche Diagnostics International Ltd - Rotkreuz (Switzerland), ³Roche Diagnostics GmbH - Penzberg (Germany), ⁴University of Gothenburg - Gothenburg (Sweden)

-  **P121** **Use of the PrecivityAD blood test in regular clinical practice: Preliminary observations from a dementia clinic**
Jonathan Drake^{1,2}, Lori Daiello^{1,2}, Chuang-Kuo Wu^{1,2}
¹Rhode Island Hospital - Providence (United States), ²Warren Alpert Medical School of Brown University - Providence (United States)
- P122** **Genome-wide association studies of ARIA from the aducanumab phase 3 ENGAGE and EMERGE studies**
Stephanie Loomis¹, Ryan Miller¹, Carmen Castrillo-Viguera¹, Kimberly Umans¹, Wenting Cheng¹, John O'gorman¹, Richard Hughes¹, Samantha Budd Haerberlein¹, Christopher Whelan¹
¹Biogen - Cambridge (United States)
- P123** **Low plasma Aβ42/Aβ40 ratio in older adults with enlarged perivascular spaces**
Arunima Kapoor¹, Aimee Gaubert¹, Amy Nguyen¹, Belinda Yew², Jung Yun Jang¹, Shubir Dutt², Yanrong Li¹, John P. Alitin³, Jean K Ho¹, Anna E. Blanken², Isabel J Sible², Anisa Marshall², Alessandra Martini¹, Elizabeth Head¹, Daniel A Nation¹
¹University of California, Irvine - Irvine (United States), ²University of Southern California - Los Angeles (United States), ³University of California, Irvine - Irvine (United States) - Irvine (United States)
-  **P124** **NADALS: An open-label basket trial evaluating the JAK inhibitor baricitinib in Alzheimer's Disease and Amyotrophic Lateral Sclerosis**
Shayda Daneshvari¹, Pia Webb¹, Anne-Marie Wills¹, James Berry¹, Steven Arnold¹, Mark Albers¹
¹MGH - Boston (United States)
-  **P125** **Examining the trajectory of neurodegeneration biomarkers and its association with cognitive profiles and amyloid in late middle-aged adults: Results from the Wisconsin Registry for Alzheimer's Prevention (WRAP)**
Lianlian Du^{1,2}, Tobey Betthausen^{1,3,4}, Karly Cody^{1,3,4}, Erin Jonaitis^{1,3,4}, Cory Burghy¹, Bruce Hermann^{1,5}, Bret Larget⁶, Rick Chappell^{3,2}, Sterling Johnson^{1,3,4,7}, Rebecca Kosciak^{1,3,4}
¹Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health - Madison, WI (United States), ²Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin-Madison - Madison, WI (United States), ³Wisconsin Alzheimer's Disease Research Center - Madison, WI (United States), ⁴Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health - Madison, WI (United States), ⁵Department of Neurology, University of Wisconsin-Madison School of Medicine and Public Health - Madison, WI (United States), ⁶Department of Statistics, University of Wisconsin-Madison - Madison, WI (United States), ⁷Madison VA GRECC, William S. Middleton Memorial Hospital - Madison, WI (United States)
-  **LP63** **Racial Differences in Predicting Concurrent and Longitudinal Cognitive Outcomes by CSF Biomarkers of Alzheimer Disease among Cognitively Normal Individuals**
Chengjie Xiong¹, James Lah², Cecelia Manzanara², Allan Levey², David Wolk³, Leslie Shaw³, Suzanne Schindler¹, Rachel Henson¹, Anne Fagan¹, Jason Hassenstab¹, Tammie Benzinger¹, Quoc Bui¹, Folasade Agboola¹, Julia Gray¹, John Morris¹
¹Washington University - St. Louis (United States), ²Emory University - Atlanta (United States), ³University of Pennsylvania - Philadelphia (United States)
-  **LP64** **Blood-based dementia pathology stratification utilizing neuron-derived exosomes**
Erez Eitan¹, Olga Volpert¹, Katya Elgart¹
¹NeuroDex - Natick (United States)
-  **LP65** **Sex-specific diagnostic properties of AD plasma biomarkers in cognitively unimpaired at-risk individuals**
Marta Mila Aloma¹, Nicholas Ashton², Thomas Karikari², Anna Brugulat Serrat¹, Eugeen Vanmechelen³, Jeroen Vanbrabant³, Erik Stoops³, Theresa Ann Day⁴, Maria Teresa Ferretti⁵, Jose Luis Molinuevo¹, Jeffrey L Dage⁶, Henrik Zetterberg², Juan Domingo Gispert¹, Kaj Blennow², Marc Suárez-Calvet¹
¹BarcelonaBeta Brain Research Center - Barcelona (Spain), ²University of Gothenburg - Mölndal (Sweden), ³ADx Neurosciences - Ghent (Belgium), ⁴Lilly Research Laboratories, Eli Lilly and Company - Indianapolis (United States), ⁵Women's Brain Project - Guntershausen (Switzerland), ⁶Stark Neurosciences Research Institute, Indiana University School of Medicine - Indianapolis (United States)
-  **LP66** **Baseline plasma pTau181 improves prediction of cognitive decline in amyloid positive subjects with mild cognitive impairment**
Viswanath Devanarayan¹, Pallavi Sachdev¹, Arnaud Charil¹, Akihiko Koyama¹, Larisa Reyderman¹, Chad Swanson¹, Harald Hampel¹, Michael Irizarry¹, Shobha Dhadha¹, Lynn Kramer¹
¹Eisai, Inc. - Nutley (United States)
-  **LP67** **Association of circulating brain-enriched microRNAs with demographic and clinical factors in A4 screening plasma samples from cognitively normal individuals**
Michael Keifer¹, Kira Sheinerman², Vladimir Tsvinsky³, Brittany Martinez², Robert Rissman⁴, Samuil Umansky²
¹DiamiR Biosciences - San Francisco (United States), ²DiamiR Biosciences - Monmouth Junction (United States), ³DiamiR Biosciences - Boston (United States), ⁴University of California San Diego School of Medicine - San Diego (United States)
-  **LP68** **Age dependency of plasma β-amyloid measured by fully automated and highly specific immunoassays in a Japanese cohort study (SESSA)**
Kengo Ishiki¹, Moniruzzaman², Yuichiro Yano², Keiko Kondo², Aya Kadota², Masahiro Miura¹, Shigeki Iwanaga¹, Masaki Nishimura³, Hirotsugu Ueshima², Katsuyuki Miura²
¹Central Research Laboratories, Sysmex Corporation - Kobe (Japan), ²NCD Epidemiology Research Center (NERC), Shiga University of Medical Science - Otsu (Japan), ³Molecular Neuroscience Research Center, Shiga University of Medical Science - Otsu (Japan)
-  **LP69** **A Fully-Automated and Scalable Plasma Phospho-Tau181 Assay for Alzheimer's Disease**
Edward N. Wilson¹, Christina B. Young¹, Manu Vandijck², Joseph P. Quinn³, Christopher H. Van Dyck⁴, Angus Nairn⁴, Sharon Sha¹, Victor W. Henderson¹, Frank M. Longo¹, Michael D. Greicius¹, Anthony D. Wagner¹, Tony Wyss-Coray¹, Kathleen L. Poston¹, Elizabeth C. Mormino¹, Katrin I. Andreasson¹
¹Stanford University - Stanford (United States), ²Fujirebio NV - Ghent (Belgium), ³Oregon Health & Science University - Portland (United States), ⁴Yale University - New Haven (United States)

- LP70** **Plasma p-tau181 in the Multidomain Alzheimer Prevention Trial (MAPT)**
Nicola Coley^{1,2}, Henrik Zetterberg³, Sophie Guyonnet^{2,1}, Philippe De Souto Barreto^{1,2}, Kaj Blennow³, Nicolas Ashton³, Sandrine Andrieu^{1,2}, Bruno Vellas^{2,1}
¹INSERM, University of Toulouse - Toulouse (France), ²Toulouse University Hospital - Toulouse (France), ³University of Gothenburg - Gothenburg (Sweden)
- LP71** **The effect of neprilysin inhibition on Alzheimer's disease plasma biomarkers: results from a randomized controlled trial evaluating sacubitril/valsartan in cognitively unimpaired individuals at risk for heart failure**
Wagner S. Brum¹, Kieran F. Docherty², Nicholas J. Ashton¹, Shorena Janelidze³, Pardeep S. Jhund², Oskar Hansson³, Henrik Zetterberg¹, John J. V. McMurray⁴, Kaj Blennow¹
¹Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg - Mölndal (Sweden), ²BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow - Glasgow (United Kingdom), ³Clinical Memory Research Unit, Faculty of Medicine, Lund University - Lund (Sweden), ⁴New British Heart Foundation Cardiovascular Research Centre, University of Glasgow - Glasgow (United Kingdom)
- LP72** **Simultaneous mass spectrometric quantification of multiple tau species in blood shows differential association with amyloid and tau pathology**
Laia Montoliu-Gaya¹, Andrea L. Benedet¹, Agathe Vrillon², Cécile Tissot³, Wagner S. Brum¹, Nicholas J. Ashton¹, Juan Lantero-Rodriguez¹, Gunnar Brinkmalm¹, Johanna Nilsson¹, Henrik Zetterberg¹, Johan Gobom¹, Claire Paquet², Pedro Rosa-Neto³, Kaj Blennow¹
¹Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. - Gothenburg (Sweden), ²Cognitive Neurology Center, GHU Nord APHP Hospital Lariboisière Fernand Widal, Université de Paris, Paris, France. - Paris (France), ³Translational Neuroimaging Laboratory, McGill Centre for Studies in Aging, McGill University, Montreal, Quebec, Canada. - Montréal (Canada)
- LP73** **Cerebrospinal fluid proteomics reveal 5 molecular subtypes in Alzheimer's disease: implications for personalised treatment**
 Betty Tijms¹, Wiesje Van Der Flier¹, Charlotte Teunissen¹, Jort Vijverberg¹, Yolande Pijnenburg¹, Even Birkeland², Frode Berven², Pieter Jelle Visser¹
¹Amsterdam UMC, location VUmc - Amsterdam (Netherlands), ²University of Bergen - Bergen (Norway)
- LP74** **Effects of pre-analytical parameters on plasma β -amyloid level**
Kengo Ishiki¹, Kazuto Yamashita¹, Shunsuke Watanabe¹, Masahiro Miura¹, Shigeaki Iwanaga¹, Toshiyuki Sato¹
¹Central Research Laboratories, Sysmex Corporation - Kobe (Japan)
- LP75** **Effect of a 1-year nutritional blend supplementation on plasma p-tau181 levels among community-dwelling older adults: a secondary analysis of the Nolan Study**
Kelly Giudici¹, Sophie Guyonnet^{1,2}, Christelle Cantet^{1,2}, Philippe De Souto Barreto^{1,2}, Kaj Blennow^{3,4}, Henrik Zetterberg^{3,4}, Corina Boschat⁵, Julie Hudry⁵, Sandrine Andrieu^{6,2}, Bruno Vellas^{1,2}, Jeroen Schmitt^{5,7,8}
¹Institute of Aging, Gerontopole of Toulouse, Toulouse University Hospital - Toulouse (France), ²CERPOP UMR1295, University of Toulouse III, Inserm, UPS - Toulouse (France), ³Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg - Mölndal (Sweden), ⁴Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), ⁵Société des Produits Nestlé SA, Nestlé Research - Lausanne (Switzerland), ⁶Department of Epidemiology and Public Health, Toulouse University Hospital - Toulouse (France), ⁷Singapore Institute of Food and Biotechnology Innovation, Agency for Science, Technology and Research - Singapore (Singapore), ⁸Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research - Singapore (Singapore)
- LP76** **A novel accessible and scalable assay for pTau217 in blood**
Stuart Portbury¹, Inge Verberk², Sherif Bayoumy², Wiesje Van Der Flier², Jeroen Vandrabrant³, Charlotte Teunissen², Eric Stoops³, Andreas Jeromin¹
¹ALZpath - Carlsbad, Ca (United States), ²Amsterdam UMC - Amsterdam (Netherlands), ³ADX Neurosciences - Gent (Belgium)
- LP77** **Longitudinal associations of changes in blood-based markers for neurodegenerative diseases in clinical trials on Alzheimer's disease**
Danni Li¹, Matthew Glittenberg¹, Dereck Salisbury¹, Vankee Feng Lin², Fang Yu³
¹University of Minnesota - Minneapolis (United States), ²Stanford University - San Francisco (United States), ³Arizona State University (United States)
- LP78** **Plasma p-tau and NFL potential utility as surrogate biomarkers in preventive clinical trials**
Pamela L. Ferreira¹, João Pedro Ferrari-Souza¹, Cécile Tissot², Bruna Bellaver¹, Douglas T. Leffa¹, Guilherme Povala¹, Firoza Z. Lussier¹, Joseph Theriault², Jean-Paul Soucy², Serge Gauthier², Victor L. Villemagne¹, Pedro Rosa-Neto², Thomas K. Karikari¹, Tharick A. Pascoal¹
¹Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA. - Pittsburgh (United States), ²Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada. - Montreal (Canada)
- LP79** **Fosgonimeton provides congruent benefit on diverse biomarkers of neurodegeneration, significantly correlating with a composite clinical score of cognition and function in Alzheimer's disease**
Hans Moebius¹, Kai-Bin Ooi¹, Michael Hale¹, Sharay Setti¹, Kayla Kleist¹, Charles Bernick²
¹Athira Pharma - Bothell (United States), ²Cleveland Clinic Lou Ruvo Center for Brain Health - Las Vegas (United States)
- LP80** **In an optimized CSF collection protocol the ptau181/A β 1-42 ratio increases preanalytical variability over measuring A β 1-42 alone**
Rianne Esquivel¹, Sara Ho², Jacqueline Darrow², Amanda Calabro¹, Parmi Thakker², Sara Gannon¹, Francesca De Simone¹, Abhay Moghekar²
¹Fujirebio Diagnostics Inc - Malvern (United States), ²Johns Hopkins School of Medicine - Baltimore (United States)
- LP81** **Analytical Feasibility of Composite Plasma Phosphorylated Tau and A β Biomarker for Predicting Amyloid PET Positivity**
Anthony W. Bannon¹, William Z. Potter², Stephen Zicha³, Leslie M. Shaw⁴, Henrik Zetterberg⁵, Ziad S. Saad⁶, Jeffrey Dage⁷, Iwona Dobler⁸, David L. Raunig⁹, Kyle Ferber¹⁰, Carrie E. Rubel¹⁰, Suzanne E. Schindler¹¹, Mike Baratta³, Emily A. Meyers¹², Erin G. Rosenbaugh¹³
¹AbbVie - North Chicago (United States), ²Subject Matter Expert (United States), ³Takeda, Pharmaceutical Company Ltd. - Cambridge (United States), ⁴Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania - Philadelphia (United States), ⁵Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg - Mölndal (Sweden), ⁶Neuroscience Biomarkers, Janssen Research and Development LLC - La Jolla (United States), ⁷Stark Neurosciences Research Institute at Indiana University School of Medicine - Indianapolis (United States), ⁸Takeda, Pharmaceutical Company Ltd - Cambridge (United States), ⁹Takeda, Pharmaceutical Company Ltd. - Cambridge (United States), ¹⁰Biogen - Cambridge (United States), ¹¹Department of Neurology, Washington University School of Medicine - St. Louis (United States), ¹²Alzheimer's Association - Chicago (United States), ¹³Foundation for the National Institutes of Health - North Bethesda (United States)

-  **LP82** The development of an automated EEG-based machine learning pipeline for the detection of Alzheimer's Disease, a proof-of-concept study for clinical trial biomarkers
Nicholas Chedid¹
¹SynapseBio Inc - New York (United States)
-  **LP83** Towards implementation of plasma phospho-tau 181 as a screening tool for patient recruitment
Andreja Emersic¹, Bjørn-Eivind Kirsebom^{2,3}, Wagner S Brum^{4,5}, Marianne Wettergreen^{6,7}, Bengt Winblad^{8,9}, Kaj Blennow^{10,11}, Milica Gregoric Kramberger^{1,12}, Tormod Fladby^{6,13}
¹Department of Neurology, University Medical Centre - Ljubljana (Slovenia), ²Department of Neurology, University Hospital of North Norway - Tromsø (Norway), ³Department of Neurology, Medical faculty, University of Ljubljana - Ljubljana (Slovenia), ⁴Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Clinical Neurochemistry Laboratory, The Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Gothenburg (Sweden), ⁵Department of Psychology, Faculty of Health Sciences, UiT, The Arctic University of Norway - Tromsø (Norway), ⁶Department of Neurology, Akershus University Hospital - Lørenskog (Norway), ⁷Institute of Clinical Medicine, University of Oslo - Lørenskog (Norway), ⁸Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics Karolinska Institutet - Stockholm (Sweden), ⁹Clinical Molecular Biology (EpiGen), University of Oslo - Oslo (Norway), ¹⁰Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Clinical Neurochemistry Laboratory, The Sahlgrenska Academy at the University of Gothenburg - Gothenburg (Sweden), ¹¹Karolinska University Hospital - Stockholm (Sweden), ¹²Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Gothenburg (Sweden), ¹³Universidade Federal do Rio Grande do Sul (UFRGS) - Porto Alegre (Brazil)
-  **LP84** Leukocyte-Derived Ratios Are Associated With Dementia
Yu Na Kim^{1,2}, Saleena Arif²
¹Boston University - Boston (United States), ²DotHouse Health - Boston (United States)
-  **LP84A** Three group classification of participants based on fully automated plasma β -amyloid measurements to achieve high positive and negative predictive values
Kazuto Yamashita¹, Masahiro Miura¹, Kota Nagai², David Verbel³, Shigeki Iwanaga¹, Toshiyuki Sato¹, Tomokazu Yoshida⁴, Atsushi Iwata⁵
¹Central Research Laboratories, Sysmex Corporation - Kobe (Japan), ²Japan and Asia Clinical Development Department, Eisai Co., Ltd - Tokyo (Japan), ³Biostatistics, Eisai Inc. - Nutley (United States), ⁴Sysmex Corporation - Kobe (Japan), ⁵Department of Neurology, Tokyo Metropolitan Geriatric Hospital and Institute of gerontology - Tokyo (Japan)

THEME: Cognitive and Functional Endpoints

-  **P126** Visit-to-visit blood pressure variability and cognition in the SPRINT MIND trial
Isabel Sible¹, Daniel Nation²
¹Usc - Los Angeles (United States), ²Uc Irvine - Irvine (United States)
-  **P127** Classification and Prediction of Different Cognitive Trajectories in Cognitively Normal Elderly
Young Ju Kim¹, Si Eun Kim², Alice Hahn³, Soo Hyun Cho⁴, Duk L. Na¹, Jun Pyo Kim¹, Hyemin Jang¹, Hee Jin Kim¹, Juhee Chin¹, Sang Won Seo¹
¹Samsung Medical Center - Seoul (Korea, Republic of), ²Haeundae Paik Hospital - Busan (Korea, Republic of), ³Johns Hopkins Bloomberg School Of Public Health - Baltimore (Korea, Republic of), ⁴Chonnam National University Hospital - Chonnam (Korea, Republic of)
- P128** What's in a score: Comparing and aligning scores based on item response theory and classical test theory for the Amsterdam Instrumental Activities of Daily Living Questionnaire
Mark Dubbelman¹, Merel Postema¹, Roos Jutten², John Harrison¹, Craig Ritchie³, Benjamin Schalet⁴, Caroline Terwee⁵, Wiesje Van Der Flier¹, Philip Scheltens¹, Sietske Sikkes¹
¹Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Umc Location Vumc - Amsterdam (Netherlands), ²Department Of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States), ³University Of Edinburgh - Edinburgh (United Kingdom), ⁴Department Of Medical Social Sciences, Feinberg School Of Medicine, Northwestern University - Chicago (United States), ⁵Amsterdam Umc Location Vumc, Epidemiology And Data Science, Amsterdam Umc - Amsterdam (Netherlands)
-  **P129** Slowing of Alzheimer's Disease Progression with NeuroAid
Christopher Li-Hsian Chen¹, Yogesh Pokharkar², Narayanaswamy Venketasubramanian³
¹National University of Singapore - Singapore (Singapore), ²Singapore Clinical Research Institute - Singapore (Singapore), ³Raffles Hospital - Singapore (Singapore)
-  **P130** A Multicenter, Phase 3, Randomized, Double-Blind, Placebo-Controlled Investigation of Safety and Efficacy of Nilotinib BE in Early Alzheimer's Disease (NILEAD)
Yasar Torres-Yaghi¹, Marwan Sabbagh², Chris Hoyt³, Kimberly Guedes³, Fernando Pagan¹, Raymond Turner¹, Jaeil Ahn¹, Charbel Moussa¹
¹Georgetown - Washington, DC (United States), ²Barrow - Phoenix, AZ (United States), ³Keiferx - Washington, DC (United States)

- P131** **Subjective illness representations in an early-stage Alzheimer's disease population: psychometric properties of the RADIX questionnaire**
 Alberto Villarejo-Galende ¹, Elena García-Arcelay ², Gerard Piñol-Ripoll ³, Antonio Del Olmo-Rodríguez ⁴, Felix Viñuela ⁵, Mercè Boada ⁶, Emilio Franco-Macias ⁷, Almudena Ibañez De La Peña ⁸, Mario Riverol ⁹, Jorge Maurino ²
¹Department Of Neurology, Hospital Universitario 12 De Octubre - Madrid (Spain), ²Medical Department, Roche Farma - Madrid (Spain), ³Unitat Trastorns Cognitius, Hospital Universitari De Santa Maria - Lleida (Spain), ⁴Department Of Neurology, Hospital Universitario Dr. Peset - Valencia (Spain), ⁵Department Of Neurology, Hospital Universitario Virgen Macarena - Sevilla (Spain), ⁶Ace Alzheimer Center Barcelona - Barcelona (Spain), ⁷Department Of Neurology, Hospital Universitario Virgen Del Rocío - Sevilla (Spain), ⁸Centro De Investigación De Parkinson, Policlínica Guipúzcoa - San Sebastián (Spain), ⁹Department Of Neurology, Clínica Universidad De Navarra - Pamplona (Spain)
- P132** **Impact of Disease Progression on Dependency in Patients with Mild and Moderate Alzheimer Disease**
Wenyu Ye ¹, Julie Chandler ¹, Xiaojuan Mi ², Antje Tockhorn-Heidenreich ¹, Joseph Johnston ¹, Erin Doty ¹
¹Eli Lilly And Company - Indianapolis (United States), ²Techdata Services Company - King Of Prussia (United States)
- P133** **The responsiveness of cognitive and functional outcome measures in preclinical Alzheimer's disease: Implications for trial design**
Mark Dubbelman ¹, Heleen Hendriksen ¹, Lois Ottenhoff ¹, Everard Vijverberg ¹, Niels Prins ², Lior Kroeze ¹, Argonde Van Harten ¹, Bart Van Berckel ¹, John Harrison ¹, Wiesje Van Der Flier ¹, Sietske Sikkes ¹
¹Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Umc Location Vumc - Amsterdam (Netherlands), ²Brain Research Center - Amsterdam (Netherlands)
- P134** **The effect of dietary habit on the progression of Alzheimer's disease: A CREDOS (Clinical Research Center for Dementia of South Korea) study**
Yangki Minn ¹, Seonghye Choi ²
¹Kangnam Sacred Heart Hospital, Hallym University - Seoul (Korea, Republic of), ²Inha University Medicval Center - Incheon (Korea, Republic of)
- P135** **Length of administration of ADAS-Cog and CDR assessment impacts data quality**
Barbara Echevarria ¹
¹WCG Clinical Endpoint Solutions - Hamilton (United States)
- P136** **A randomized study to evaluate the efficacy of Donepezil in improving visuospatial abilities in patients with mild cognitive impairment using eye-tracker**
Kim Ko Woon ¹, Wang Qi ², Koo Se Hee ³, Shin Byoung-Soo ¹
¹Department of Neurology, Jeonbuk National University Medical School and Hospital - Jeonju (Korea, Republic of), ²Jeonbuk National University Medical School - Jeonju (Korea, Republic of), ³Biomedical Research Institute of Jeonbuk National University Hospital - Jeonju (Korea, Republic of)
- P137** **A Phase 2b, Randomized, Placebo-Controlled Trial to Evaluate the Effects of SAGE-718 in Patients with Alzheimer's Disease: Study Design**
 Aaron Koenig ¹, Tiffany Lago ¹, Jason Johannesen ¹, Sigui Li ¹, Emily Freitag ¹, Jeffrey Wald ¹, Katrina Paumier ¹, Michael Quirk ¹, James Doherty ¹
¹Sage Therapeutics, Inc. - Cambridge, Massachusetts (United States)
- P138** **Bringing meaning to personalised Brain Health: a tool that empowers individuals to define and monitor personally meaningful change**
Stina Saunders ¹, David Bates ², Ankur Bharija ^{2,3}, Joyce Gomes-Osman ^{2,4}, Saturnino Luz ¹, Graciela Muniz-Terrera ¹, Álvaro Pascual-Leone ^{2,5}, Craig Ritchie ¹
¹Centre for Clinical Brain Sciences, University of Edinburgh, UK - Edinburgh (United Kingdom), ²Linus Health Inc., Boston, MA, USA - Boston (United States), ³Department of Medicine, Division of Primary Care and Population Health, Stanford Medicine, Stanford, USA - Stanford (United States), ⁴Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA - Miami (United States), ⁵Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA - Boston (United States)
- P139** **Dementia conversion rate differences between patients with high- and low-risk amnesic mild cognitive impairment in the real-world: A prospective, multicenter, observational study**
Hyemin Jang ¹, Duk L. Na ², Jay Cheol Kwon ³, Mee Young Park ⁴, Yeonsil Moon ⁵, Jung Seok Lee ⁶, Kyung-Won Park ⁷, Ae Young Lee ⁸, Hanna Cho ⁹, Jae-Hong Lee ¹⁰, Byeong Chae Kim ¹¹, Kee Hyung Park ¹², Byung-Chul Lee ¹³, Hojin Choi ¹⁴, Kim Jieun ¹⁵, Na-Yeon Jung ¹⁶
¹Samsung Alzheimer's Convergence Research Center, Samsung Medical Center - Seoul (Korea, Republic of), ²Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), ³Department of Neurology, Changwon Fatima Hospital - Changwon (Korea, Republic of), ⁴Department of Neurology, Yeungnam University College of Medicine - Daegu (Korea, Republic of), ⁵Department of Neurology, Konkuk University Medical Center, Konkuk University School of Medicine - Seoul (Korea, Republic of), ⁶Department of Neurology, Jeju National University College of Medicine - Jeju (Korea, Republic of), ⁷Department of Neuroscience, Cognitive Disorders and Dementia Center, Dong-A University College of Medicine and Institute of Convergence Bio-Health - Busan (Korea, Republic of), ⁸Department of Neurology, Chungnam National University School of Medicine - Daejeon (Korea, Republic of), ⁹Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of), ¹⁰Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine - Seoul (Korea, Republic of), ¹¹Department of Neurology, Chonnam National University Medical School & Hospital - Gwangju (Korea, Republic of), ¹²Department of Neurology, College of Medicine, Gachon University Gil Hospital - Incheon (Korea, Republic of), ¹³Department of Neurology, Hallym University College of Medicine - Seoul (Korea, Republic of), ¹⁴Department of Neurology, Hanyang University Guri Hospital - Guri (Korea, Republic of), ¹⁵Department of Medical, Eisai Korea Inc. - Seoul (Korea, Republic of), ¹⁶Department of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine - Yangsan (Korea, Republic of)
- P140** **Predicting tau PET signal in prodromal-to mild Alzheimer's disease from speech biomarkers and machine learning**
 Mario Mina ¹, Johannes Troeger ¹, Louisa Schwed ¹, Nicklas Linz ¹, Sandra Sanabria Bohórquez ², Somaye Hashemifar ², Tina Boggiano ³, Edmond Teng ²
¹ki:elements - Saarbruecken (Germany), ²Genentech Inc - San Francisco (United States), ³F. Hoffmann-La Roche Ltd - Basel (Switzerland)

-  **LP85** **A multicenter, Randomised, Open-label, prospective study to estimate the add-on effects of Memantine as Ebixa® Oral pump (solution) on language in moderate to severe Alzheimer's Disease patients already receiving donepezil (ROMEQ-AD)**
Hee-Jin Kim¹, Hyun Jeong Han², Yongsoo Shim³, Byeong C. Kim⁴, Kee Hyung Park⁴, So Young Moon⁵, Seong Hye Choi⁶, Dong Won Yang⁷, Bora Yoon⁸, Eun-Joo Kim⁹, Jee Hyang Jeong¹⁰, Seol-Heui Han¹¹
¹Professor of Neurology Department of College of Medicine, Hanyang University - Seoul (Korea, Republic of), ²Department of Neurology, Myongji Hospital, Hanyang University College of Medicine - Seoul (Korea, Republic of), ³Department of Neurology, The Catholic university of Korea Eunpyeong St. Mary's Hospital - Seoul (Korea, Republic of), ⁴Department of Neurology, Chonnam National University Medical School - Seoul (Korea, Republic of), ⁵Department of Neurology, Ajou University School of Medicine - Seoul (Korea, Republic of), ⁶Department of Neurology, Inha University School of Medicine - Seoul (Korea, Republic of), ⁷Department of Neurology, The Catholic University of Korea, Seoul St. Mary's hospital - Seoul (Korea, Republic of), ⁸Department of Neurology, Konyang University College of Medicine - Seoul (Korea, Republic of), ⁹Department of Neurology, Pusan National University Hospital - Seoul (Korea, Republic of), ¹⁰Department of Neurology, Ewha Womans University Seoul Hospital - Seoul (Korea, Republic of), ¹¹Department of Neurology, Konkuk University College of Medicine - Seoul (Korea, Republic of)
-  **LP86** **Effectiveness of Vortioxetine in Patients With Major Depressive Disorder and Early Dementia: The MEMORY Study**
Michael Cronquist Christensen¹, Simon Nitschky Schmidt¹, Iria Grande²
¹H. Lundbeck A/S - Valby (Denmark), ²Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM - Barcelona (Spain)
-  **LP87** **Assessing Clinically Meaningful Functional Outcomes in Preclinical Alzheimer's Disease**
Carla Romano¹, Gerald Novak², Jiyoung Choi³, Shanshan Qin¹, David Henley², Mike Donohue³, Gary Romano⁴, Rema Raman³, Rebecca Amariglio⁵, Paul Aisen³, Reisa Sperling⁵
¹RTI-HS - Research Triangle Park (United States), ²Janssen - Titusville (United States), ³USC - San Diego (United States), ⁴Alector - San Francisco (United States), ⁵Harvard - Boston (United States)
-  **LP88** **Characterizing Cognitive Changes in Early-Stage Alzheimer's Disease using Latent Cognitive Measures from the ADNI Dataset**
Jason Bock^{1,2}, Junko Hara^{1,3}, Dennis Fortier¹, Bruce Albala^{4,5}
¹Embic Corporation - Newport Beach (United States), ²Dept. of Cognitive Sciences, University of California at Irvine - Irvine (United States), ³Pickup Family Neuroscience Institute, Hoag Memorial Hospital - Newport Beach (United States), ⁴UCI Center for Clinical Research - Irvine (United States), ⁵UCI School of Medicine - Irvine (United States)
-  **LP89** **Neurogenesis Hypothesis with a case study- Phase 2A Clinical Trials Results of NA-831 for the treatment of Alzheimer's disease**
 Markku Kurkinen¹, Lloyd Tran¹
¹Biomed Industries, Inc. - San Jose (United States)
-  **LP89A** **Cognitive Composite Outcome Measures for Clinical Trials: Can You Have Too Much of a Good Thing?**
 Xinran Wang¹, Diane Jacobs¹, David Salmon¹, Howard Feldman¹, Sarah Banks¹, Steven Edland¹
¹University of California San Diego - La Jolla (United States)

THEME: Cognitive assessment and clinical trials

- P141 **SKT Short Cognitive Performance Test for the detection of early cognitive decline – data from international validation studies**
Mark Stemmler¹
¹University Of Erlangen-Nuremberg - Erlangen (Germany)
- P142 **ImPACT Cognitive Assessment: What are we measuring**
James Gyurke¹, Phiiil Schatz²
¹Riverside Insights - Lutz (United States), ²Saint Joseph's University - Philadelphia (United States)
-  P143 **Validation of an objective, speech-based object content score for measuring disease progression in AD**
Jessica Robin¹, Mengdan Xu², Michael Detke³, William Simpson²
¹Winterlight Labs - Vancouver (Canada), ²Winterlight Labs - Toronto (Canada), ³Detke Biopharma Consulting - Indianapolis (United States)
-  P144 **Relationship between telomere shortening and early subjective depressive symptoms and cognitive complaints in older adults**
Seong-Ho Koh¹, Myung-Hoon Han¹, Eun-Hye Lee¹, Hyun-Hee Park¹, Seong Hye Choi²
¹Hanyang University - Seoul (Korea, Republic of), ²Inha University - Incheon (Korea, Republic of)
-  P145 **Accuracy of automated scoring of word recall assessments**
Rachel Kindellan¹, Celia Fidalgo¹, William Simpson¹, Jessica Robin¹
¹Winterlight Labs - Toronto (Canada)
-  P147 **Pre-Screening Prodromal AD Trial Populations over the Telephone Using a Speech Biomarker for Cognition — Preliminary Results from AUTONOMY Phase 2 AD Trial Recruitment**
Stephen Ruhmel¹, Johannes Tröger², Nicklas Linz², Janna Herrmann², Mary Quiceno¹, Kai Langel¹
¹Janssen Research & Development, LLC (United States), ²ki:elements - Saarbrücken (Germany), ³Janssen-Cilag (Spain)
-  P148 **The difference in trajectories according to early amyloid accumulation in normal cognitive elderly**
Young Ju Kim¹, Min Young Chun¹, Hyemin Jang¹, Hee Jin Kim¹, Jeong-Yeon Seo¹, Sang Won Seo¹
¹Samsung Medical Center - Seoul (Korea, Republic of)
-  P149 **Rater Error Pattern on the CDR Outcome Assessment in Alzheimer's Disease Clinical Trials**
Jordan Barbone¹, Erin Barney¹, Jason Cromer¹, Robyn Leventhal¹, Lisle Kingery¹, Svenja Wacker¹
¹Cogstate - New Haven (United States)
-  P150 **Preliminary psychometric and clinical validation of information processing speed in early Alzheimer's Disease using a smartphone-based remote assessment**
Arnaud M. Wolfer¹, Irma T. Kurniawan¹, Kirsten I. Taylor¹, Florian Lipsmeier¹, Thanneer M. Perumal¹
¹Roche Pharma Research And Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 - Basel (Switzerland)
-  P151 **Rater Error Pattern on the MMSE and ADAS-Cog Outcome Assessments in Alzheimer's Disease Clinical Trials**
Svenja Wacker¹, Jordan Barbone¹, Erin Barney¹, Jason Cromer¹, Lisle Kingery¹, Robyn Leventhal¹
¹Cogstate - New Haven (United States)
-  P152 **Preliminary psychometric and clinical validation of executive function in early Alzheimer's diseases using a smartphone-based assessment**
Irma T. Kurniawan¹, Arnaud M. Wolfer¹, Christopher Chatham¹, Eduardo Aponte¹, Stefan Holiga¹, Thanneer M. Perumal¹, Kirsten I. Taylor¹
¹Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124 - Basel (Switzerland)
-  P153 **Preliminary psychometric and clinical validation of visuospatial working memory deficits in early Alzheimer's Disease measured with a smartphone based digital assessment**
Eduardo A. Aponte¹, Kirsten I. Taylor¹, Arnaud M. Wolfer¹, Christopher Chatham¹, Thanneer M. Perumal¹
¹Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124 - Basel (Switzerland)
-  P154 **The Phase 2 LUMINAR Trial Assessing SAGE-718 in Patients with Mild Cognitive Impairment or Mild Dementia due to Alzheimer's Disease**
Aaron Koenig¹, Shishuka Malhotra², Jeffrey Wald¹, Jennifer Petrillo¹, Katrina Paumier¹, Jason Johannesen¹, Sigui Li¹, Michael Quirk¹, Emily Freitag¹, James Doherty¹
¹Sage Therapeutics, Inc. - Cambridge, Massachusetts (United States), ²Neuro-Behavioral Clinical Research, Inc. - North Canton, Ohio (United States)

POSTER PRESENTATIONS

Friday, December 2nd from 8 a.m to 5 p.m

Poster presentations presented onsite in San Francisco are indicated with this icon: 


-  P155 **Longitudinal Evolution of Financial Capacity and Cerebral Tau and Amyloid Burden in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Dementia**
Kayden Mimmack¹, Emily Sprague^{2,3}, Rebecca Amariglio^{1,2,3}, Patrizia Vannini^{1,2,3}, Gad Marshall^{1,2,3}
¹Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States), ²Department of Neurology, Brigham and Women's Hospital, Harvard Medical School - Boston (United States), ³Center for Alzheimer Research and Treatment - Boston (United States)
-  P156 **Potential Influence of Cognitive Heterogeneity in a Clinical Trial for Mild-to-Moderate Probable Alzheimer's Dementia**
Diane Jacobs¹, Yuqi Qiu², David Salmon¹, Karen Messer¹, Lia Donahue³, Steven Kaplita³, Irfan Qureshi³, Howard Feldman¹
¹University of California San Diego - La Jolla (United States), ²School of Statistics, East China Normal University - Shanghai (China), ³Biohaven Pharmaceuticals, Inc - New Haven (United States)
-  P157 **Impact of Different Rates of Disease Progression in Individuals with Amyloid Positive Alzheimer's Disease - Findings from the Alzheimer's Disease Neuroimaging Initiative**
Julie M Chandler¹, Mihaela Georgieva², Urvi Desai², Noam Kirson², Wenyu Ye¹, Andres Gomez-Lievano², Annalise Hilts³, Dody Eid², Angela Zhao², Traci Schilling¹
¹Eli Lilly and Company - Indianapolis (United States), ²Analysis Group - Boston (United States), ³Groupe d'Analyse - Montréal (Canada)
-  P158 **Causal in silico patient models can inform Alzheimer's disease patient identification and endpoint selection for early-stage clinical trials**
So-Youn Shin¹, Shokeen Deepanshi¹, Apoorva Bharthur¹, Todd Oakland¹, Jeanne Latourelle¹
¹GNS Healthcare - Somerville, Ma (United States)
-  P159 **Clinical predictors for conversion to Alzheimer's dementia in patients with mild cognitive impairment using Amyloid PET imaging : Interim results**
Kyung Won Park¹, Seon-Jeong Kim¹, Do-Young Kang², Young-Jin Jeong²
¹Department of Neurology, Dong-A University College of Medicine - Busan (Korea, Republic of), ²Department of Nuclear Medicine, Dong-A University College of Medicine - Busan (Korea, Republic of)
- P160 **Clinical Trajectory of Preclinical AD Over 36 Months in the CHARIOT Study**
Gerald Novak¹, Susan Baker¹, Keith Karcher¹, David Henley^{1,2}, Chi Udeh-Momoh³, Oliver Robinson⁴, Geraint Price³, Tam Watermeyer⁵, Craig Ritchie⁵, Lefkos Middleton^{3,4}
¹Janssen R&D - Titusville, Nj (United States), ²Indiana University School of Medicine - Indianapolis, In (United States), ³Imperial College Healthcare NHS Trust - London (United Kingdom), ⁴AGE Research, School of Public Health, Imperial College of London - London (United Kingdom), ⁵Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences, University of Edinburgh - Edinburgh (United Kingdom)
-  P161 **Impact of Different Rates of Disease Progression in Individuals with Amyloid Positive Alzheimer's Disease - Findings from the National Alzheimer's Coordinating Center**
Julie M Chandler¹, Mihaela Georgieva², Urvi Desai², Noam Kirson², Wenyu Ye¹, Angela Zhao², Dody Eid², Andres Gomez-Lievano², Annalise Hilts³, Traci Schilling¹
¹Eli Lilly and Company - Indianapolis (United States), ²Analysis Group - Boston (United States), ³Groupe d'Analyse - Montréal (Canada)
-  P162 **Rescreening on RBANS delayed memory index? Forget about it!**
Marwan N Sabbagh¹, Wojciech Michalak², Charlotte Thim Hansen², Lars Lau Raket², Christian Ahmad Wichmann², Alice Clark²
¹Barrow Neurological Institute - Phoenix, Arizona (United States), ²Novo Nordisk A/S - Søborg (Denmark)
- P163 **Predictors of memory impairment in mild cognitive impairment with low Mini-Mental State Examination recall scores**
Seon Young Ryu¹, Sang Bong Lee¹, Taek Jun Lee¹, Yu Jin Jung¹
¹The Catholic University of Korea, Daejeon St. Mary's Hospital - Daejeon (Korea, Republic of)
-  P164 **Increased numbers of modifiable dementia risk factors amplify adverse effects on cognition across the adult lifespan**
Annalise Laplume¹, Larissa Mcketton¹, Brian Levine^{1,2,3}, Angela Troyer^{4,5}, Nicole Anderson^{1,2,6}
¹Rotman Research Institute, Baycrest Health Sciences - Toronto (Canada), ²Department of Psychology, University of Toronto - Toronto (Canada), ³Department of Medicine (Neurology), University of Toronto - Toronto (Canada), ⁴Department Of Psychology, University Of Toronto - Toronto (Canada), ⁵Neuropsychology and Cognitive Health Program, Baycrest Health Sciences - Toronto (Canada), ⁶Department of Psychiatry, University of Toronto - Toronto (Canada)
-  P165 **Feasibility, Reliability, and Validity of Remote Smartphone Data Collection in Frontotemporal Dementia using the ALLFTD Mobile App**
Adam Staffaroni¹, Jack Taylor¹, Annie Clark¹, Hilary Heuer¹, Amy Wise¹, Masood Manoochehri², Leah Forsberg³, Carly Mester³, Meghana Rao³, Danielle Brushaber³, Julio Rojas¹, Joel Kramer¹, Bradley Boeve³, Howard Rosen¹, Adam Boxer¹
¹UCSF - San Francisco (United States), ²Columbia University - New York (United States), ³Mayo Clinic - Rochester (United States)
-  P166 **Calculating Generalized Recall Probability Using Digital Cognitive Biomarkers Derived from Wordlist Memory Test Assessment**
Junko Hara^{1,2}, Jason Bock^{1,3}, Kaavya Shah⁴, Dennis Fortier¹, Michael Lee³
¹Embic Corporation - Newport Beach (United States), ²Pickup Family Neuroscience Institute and Hoag Center for Research and Education, Hoag Memorial Hospital - Newport Beach (United States), ³Dept. of Cognitive Sciences, University of California at Irvine - Irvine (United States), ⁴University of California at Berkeley - Berkeley (United States)
-  P167 **Digital Cognitive Biomarkers for the ADAS-Cog Word Recall Test: Accuracy and Validity of Classifying Cognitive Impairment**
Jason Bock^{1,2}, Junko Hara^{1,3}, Dennis Fortier¹, Tushar Mangrola¹, William Shankle^{1,2,3}, Michael Lee²
¹Embic Corporation - Newport Beach (United States), ²Dept. of Cognitive Sciences, University of California at Irvine - Irvine (United States), ³Pickup Family Neuroscience Institute, Hoag Memorial Hospital - Newport Beach (United States)

-  **P168** **A novel 2-minute high-frequency assessment of episodic memory, shows diurnality, time varying patterns in fatigue and mood which become more tightly coupled with age**
Alexander Anwyll-Irvine ¹, Alexander Kaula ¹, Nick Taptiklis ¹, Cashdollar Nathan ¹, Francesca Cormack ¹
¹Cambridge Cognition - Cambridge (United Kingdom)
-  **LP90** **Achieving 98% scoring accuracy in a novel voice-based multi-day learning paradigm**
Nick Taptiklis ¹, Alex Kaula ¹, Hayley Tseng ¹, Francesca Cormack ¹
¹Cambridge Cognition - Cambridge (United Kingdom)
-  **LP91** **Sex differences in the association between tau PET and cognition in preclinical AD (A4 study)**
Xin Wang ¹, Erin Sundermann ¹, Sarah Banks ¹
¹University of California, San Diego - San Diego (United States)
-  **LP92** **Stepped-Assessment for Cognitive Screening and Evaluation: MemTrax-CogniFit**
Curtis Ashford ¹, James Clifford ², Michael Bergeron ³, Jon Andoni ⁴, John Ashford ⁵, Carlos Rodriguez ⁶
¹MemTrax, LLC - Redwood City (United States), ²College of San Mateo - San Mateo (United States), ³University of Hartford - Hartford (United States), ⁴Nebriia University - Madrid (Spain), ⁵Stanford - Palo Alto (United States), ⁶CogniFit, Inc. - Madrid (Spain)

THEME: Behavioral disorders and clinical trials

-  **P169** **A proof-of-concept study to evaluate efficacy of NanoLithium on the progression of Neuropsychiatric symptoms in patients with mild-to-severe Alzheimer's disease**
Maria Soto ¹, Solene Guilliot ², Pierre-Jean Ousset ¹, Davide Angioni ¹, Nathalie Sastre Hengan ¹, Jean-Claude Maurel ², Jacques Touchon ³
¹Department Of Geriatrics, Gerontopole, University Hôpital Toulouse, France - Toulouse (France), ²Medesis Pharma - Baillargues (France), ³Montpellier School Of Medecine; University Of Montpellier - Montpellier (France)
- P170** **Phase-3 Study of Masupirdine (SUVN-502), a 5-HT6 Receptor Antagonist, For the Potential Treatment of Agitation in Participants with Dementia of Alzheimer's Type**
Jayarajan Pradeep ¹, Ravula Jyothsna ¹, Jetta Satish ¹, Goyal Vinod Kumar ¹, Benade Vijay ¹, Shinde Anil ¹, Pandey Santosh Kumar ¹, Subramanian Ramkumar ¹, Mohammed Abdul Rasheed ¹, Nirogi Ramakrishna ¹
¹Suven Life Sciences Ltd - Hyderabad (India)
-  **P171** **Safety and Tolerability of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Pooled Results From Three Phase III Trials**
Daniel Lee ¹, Mary Slomkowski ¹, Nanco Hefting ², Dalei Chen ¹, Klaus Larsen ², Eva Kohegyi ¹, Mary Hobart ¹, Alpesh Shah ¹, Alvin Estilo ¹, Moeen Panni ¹, Anja Farovik ², Maia Miguelez ¹, Pedro Such ², George Grossberg ³
¹Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton, New Jersey (United States), ²H. Lundbeck A/S - Valby, Copenhagen (Denmark), ³Department of Psychiatry and Behavioral Neuroscience at Saint Louis University School of Medicine - St Louis, Missouri (United States)
-  **LP93** **Effects of Brexpiprazole on Severity of Agitation in Alzheimer's Dementia: An Analysis of Clinical Global Impression data from Two Phase III Fixed-Dose Trials**
Daniel Lee ¹, Mary Slomkowski ¹, Nanco Hefting ², Dalei Chen ¹, Klaus Larsen ², Eva Kohegyi ¹, Mary Hobart ¹, Alpesh Shah ¹, Alvin Estilo ¹, Moeen Panni ¹, Anja Farovik ², Maia Miguelez ¹, Pedro Such ²
¹Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton, New Jersey (United States), ²H. Lundbeck A/S - Valby, Copenhagen (Denmark)

THEME: Health economics and clinical trials

-  **P172** **Health economic considerations in the development of a preventive Alzheimer's treatment**
Soeren Matthe ¹, Kate Jun ¹, Samantha Chu ², Mark Hanson ¹, Eric Reiman ³, Jeffrey Kordower ⁴
¹University Of Southern California - Los Angeles (United States), ²Cornell University - Ithaca (United States), ³Banner Alzheimer's Institute - Phoenix (United States), ⁴Arizona State University - Tempe (United States)
-  **P173** **Long-Term Care Insurance Service Utilization pattern according to clinical factors of Dementia**
Jun Hong Lee ¹
¹National Health Insurance Service Ilsan Hospital - Goyang-Si (Korea, Republic of)
-  **P174** **The Impact on R&D Investment of the CMS National Coverage Determination for Amyloid-directed Monoclonal Antibodies in Alzheimer's Disease**
Duane Schulthess ¹, Harry Bowen ²
¹vital transformation - Wezembeek Oppem (Belgium), ²Queens University - Charlotte (United States)
-  **P175** **Bridging clinical trials and health economic models in Alzheimer's disease**
Linus Jonsson ¹, Ron Handels ², Colin Green ¹
¹Karolinska Institutet - Stockholm (Sweden), ²Maastricht University - Maastricht (Netherlands)










POSTER PRESENTATIONS

Friday, December 2nd from 8 a.m to 5 p.m

Poster presentations presented
onsite in San Francisco
are indicated with this icon: 

-  **LP94** **A more precise diagnosis by means of amyloid-PET contributes to delayed institutionalization, lower mortality and reduced care costs in a tertiary memory clinic setting**
Wiesje Van Der Flier¹, Ingrid Van Maurik¹, Hana Broulikova¹, Arenda Mank¹, Els Bakker¹, Arno De Wilde², Femke Bouwman¹, Andrew Stephens³, Bart Van Berckel¹, Philip Scheltens¹
¹Amsterdam UMC - Amsterdam (Netherlands), ²EQT Life Sciences - Amsterdam (Netherlands), ³Life-MI - Berlin (Netherlands)
-  **LP95** **Economic burden of daily transitions to later stages of AD dementia in the US**
Moaven Razavi¹, William Herring², Cai Gillis³, Nancy Maserejian³, Peter Pemberton-Ross⁴, Mina Nejati³
¹Schneider Institutes for Health Policy and Research, Brandeis University - Waltham (United States), ²RTI Health Solutions - Research Triangle Park (United States), ³Biogen - Boston (United States), ⁴Biogen - Baar (Switzerland)

THEME: Epidemiology and clinical trials




-  **P176** **Identification of medical conditions as risk factors for mild cognitive impairment – a US claims database study**
Gang Li¹, Toschi Nicola², Batrla Richard³, Galvin James⁴, Henley David⁵, De Santi Susan⁶, Hampel Harald⁶
¹Eisai Inc - Hillsborough (United States), ²Rome University - Rome (Italy), ³Eisai Inc - Basel (Switzerland), ⁴Miami University - Miami (United States), ⁵Janssen - Indianapolis (United States), ⁶Eisai Inc - Nutley (United States)
-  **P177** **Safety of fluorine 18-labeled amyloid tracers: pharmacovigilance validation using a large real-world database**
Kenichiro Sato¹, Yoshiki Niimi², Ryoko Ihara³, Kazushi Suzuki⁴, Atsushi Iwata³, Takeshi Iwatsubo¹
¹University Of Tokyo - Tokyo (Japan), ²University Of Tokyo Hospital - Tokyo (Japan), ³Tokyo Metropolitan Geriatric Medical Center Hospital - Tokyo (Japan), ⁴National Defense Medical College - Saitama (Japan)
-  **P178** **Diagnosis and clinical trial recruitment of patients with early onset Alzheimer's disease in clinical practice: Single center experience in Japan**
Masanori Kurihara¹, Ryoko Ihara¹, Kenji Ishibashi², Kenji Ishii², Kazutomi Kanemaru¹, Atsushi Iwata¹
¹Department Of Neurology, Tokyo Metropolitan Geriatric Hospital And Institute Of Gerontology - Tokyo (Japan), ²Research Team For Neuroimaging, Tokyo Metropolitan Geriatric Hospital And Institute Of Gerontology - Tokyo (Japan)
-  **P179** **Treatment status of Alzheimer's dementia using common data model in South Korea**
Song Jeong Yun¹, Jang Jae-Won^{1,2}
¹Kangwon National University Hospital - Chuncheon (Korea, Republic of), ²Kangwon National University College of Medicine - Chuncheon (Korea, Republic of)
-  **P180** **Globalization of Alzheimer disease clinical trials: recommendations for trial implementation in low- and middle-income countries**
Jorge Llibre-Guerra¹
¹Washington University School Of Medicine In St.louis - St. Louis (United States)
-  **P181** **The Minority Report: An Update on Minority recruitment from a large site in Central Florida**
Sandra Torres¹, Sheila Baez-Torres¹, Stephanie Cassidy¹, Brandon Lenox¹, Sean Stanton¹, Jennifer West¹
¹K2 elements, Orlando, FL (United States)
-  **P182** **Generalizability of cognitive results from clinical trial participants to older adult population: addressing external validity**
Vahan Aslanyan¹, Howard N. Hodis^{1,2,3}, Jan St. John^{1,2}, Naoko Kono^{1,2}, Victor Henderson⁴, Wendy J Mack¹
¹Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California - Los Angeles, Ca (United States), ²Atherosclerosis Research Unit, Keck School of Medicine, University of Southern California - Los Angeles, Ca (United States), ³Department of Medicine, Keck School of Medicine, University of Southern California - Los Angeles, Ca (United States), ⁴Department of Epidemiology and Department of Neurology and Neurological Sciences, School of Medicine, Stanford University - Stanford, Ca (United States)
-  **P184** **Prevalence Estimations for the Alzheimer's Disease Continuum in the US Health and Retirement Study**
Amir Abbas Tahami Monfared^{1,2}, Quanwu Zhang¹, Aastha Chandak³, Artak Khachatryan⁴, Laura De Benedetti⁵, Noemi Hummel⁶
¹Eisai Inc - Nutley (United States), ²Biostatistics and Occupational Health, McGill University - Montreal (Canada), ³Certara Inc - New York (United States), ⁴Certara Ltd. - Sheffield (United Kingdom), ⁵Certara Canada Corporation - Montreal (United States), ⁶Certara GmbH - Lörrach (Germany)
- P185** **Association between A/T/N profiles and mortality in patients with cognitive disorders**
Mélina Régy^{1,2}, Aline Dugravot¹, Bernard Hanseeuw³, Julien Dumurgier¹
¹CRESS U1153 Epidemiology of Ageing and neurodegenerative diseases (Inserm) - Paris (France), ²Brain Ageing Lab (Catholic University of Louvain - Brussels (Belgium), ³Brain Aging Lab (St-Luc Hospital) - Bruxelles (Belgium)
-  **P186** **Ultra high risk and high predictability of Alzheimer's disease onset in people with Down syndrome: implications for clinical trials**
Juan Fortea^{1,2,3}, Alberto Lleo^{1,2}, Alexandre Bejanin^{1,2}, Maria Florencia Iulita^{1,2}
¹Memory Unit and Biomedical Research Institute Sant Pau (IIB Sant Pau), Neurology Department, Hospital de la Santa Creu i Sant Pau - Barcelona (Spain), ²Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED) - Madrid (Spain), ³Barcelona Down Medical Center, Fundació Catalana Síndrome de Down - Barcelona (Spain)

-  **LP96** **Asymptomatic extracranial carotid atherosclerosis and its association with incident Alzheimer's dementia**
 Francesca Vitali ¹, Ikeoluwapo Bolakale-Rufai ¹, Gregory Branigan ¹, Juan Arias ¹, Eric Reinman ¹, Roberta Brinton ¹, Craig Weinkauff ¹
¹University of Arizona - Tucson (United States)

THEME: Animal Models and clinical trials

-  **P187** **The Probucol in Alzheimer's trial: a double-blind RCT investigating cognitive outcomes, cerebral amyloid and brain morphometry based on positive proof-of-concept preclinical findings**
John Mamo ¹, Roger Clarnette ², Virginie Lam ¹, Michael Bynevelt ³, Gerald Watts ⁴, Carolyn Orr ⁴, Poh Loh ⁴, Christopher Reid ¹, Satvinder Dhaliwal ¹, Suzanne Robinson ¹, Ryusuke Takechi ¹, Robert Adam ⁵, Mauro Vaccarezza ¹
¹Curtin University - Perth (Australia), ²Australian Alzheimer's Research Foundation - Perth (Australia), ³Sir Charles Gardiner Hospital - Perth (Australia), ⁴University of Western Australia - Perth (Australia), ⁵University of Queensland - Perth (Australia)
-  **P188** **A novel small molecule inhibitor reduces toxic amyloid oligomers to rescue disease in AD mice**
Vidhu Mathur ¹, Kevin Burk ¹, Xikun Liu ², Sagar Gaikwad ³, Rakez Kaye ³, Michael T Bowers ², Katie Planey ¹, Ambuj Singh ⁴
¹Acelot Inc. - Santa Barbara (United States), ²Department of Chemistry and Biochemistry, University of California - Lubbock (United States), ³Departments of Neurology & Neuroscience & Cell Biology & Anatomy, University of Texas Medical Branch - Galveston (United States), ⁴Acelot Inc - Santa Barbara (United States)
-  **P189** **T-type calcium channel modulator AD101 improves cognitive function in animal models of memory and learning impairment and provides a rationale for the potential clinical use of AD101 in the symptomatic treatment of Alzheimer's disease**
Jan Burmeister ¹, Serge Gauthier ², Sharon Rogers ¹
¹Amyriad Pharma, Inc. - Los Angeles (United States), ²McGill University - Montréal (Canada)
-  **P190** **Effects of T-type calcium channel modulator AD101 on the accumulation of Beta Amyloid, Tau and polyubiquitinated proteins in animal models of Alzheimer's Disease**
Jan Burmeister ¹, Serge Gauthier ², Sharon Rogers ¹
¹Amyriad Pharma, Inc. - Los Angeles (United States), ²McGill University - Montréal (Canada)
-  **LP97** **Modulation of peripheral monocytes by a proteasome-based adjuvant (Protollin) for the treatment of Alzheimer's disease**
Panayota Kolypetri ¹, Lei Liu ¹, Estefania Solana ¹, Christian Gauthier ¹, Tarun Singhal ¹, Seth Gale ¹, Tanuja Chitnis ¹, Dennis Selkoe ¹, Howard Weiner ¹
¹BWH - Boston (United States)
-  **LP98** **An efficacious therapy for Alzheimer Disease already exists, and it is commercially exploitable**
Diego Dolcetta ¹, Stefano Giovagnoli ², Dominici Roberto ³
¹Istituto di Neuroscienze di Rosà - Vicenza (Italy), ²Department of Pharmaceutical Sciences, University of Perugia, Italy - Perugia (Italy), ³Dep of Biochemistry, Desio Hospital - Brianza (Italy)

THEME: Proof of Concept/Translational research for Alzheimer Drug Development interventions

-  **P191** **A combination of PET tracers serves as a potential trial biomarker for equilibrative nucleoside transporter 1 (ENT1) inhibition treatment of Alzheimer's disease**
Ching-Pang Chang ^{1,2}, Ching-Wen Wu ^{1,2}, Chien-Yu Lin ^{1,2}, Kuo-Chen Wu ^{1,3}, Hsin-Hsien Yeh ⁴, Chun-Yi Wu ⁵, Chi-Chang Weng ⁶, Ling-Wei Hsin ³, Chun-Jung Lin ³, Yijuang Chern ^{1,2}
¹Biomedical Translation Research Center, Academia Sinica - Taipei (Taiwan, Republic of China), ²Institute of Biomedical Sciences, Academia Sinica - Taipei (Taiwan, Republic of China), ³School of Pharmacy, National Taiwan University - Taipei (Taiwan, Republic of China), ⁴Brain research center, National Yang Ming Chiao Tung University - Taipei (Taiwan, Republic of China), ⁵Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University - Taipei (Taiwan, Republic of China), ⁶Department of Medical Imaging and Radiological Sciences, Chang Gung University - Taoyuan (Taiwan, Republic of China)
-  **P192** **XanaMIA Phase 1b trial with Xanamem® achieves primary endpoints: results and strategic update**
Michael Woodward ¹, Paul Rolan ², Miriam Roesner ², Jack Taylor ², Tamara Miller ², Paul Maruff ³
¹Aged Care Research And Memory Clinic, Austin Health - Melbourne (Australia), ²Actinogen Medical - Sydney (Australia), ³Cogstate Ltd - Melbourne (Australia)
-  **P193** **Leveraging untapped national synergies to accelerate representation of Hispanic/Latinos in clinical trials on dementia: the progress of the new Consorcio between the National Association of Hispanic Nurses and the Alzheimer's Association**
Elena Portacolone ¹, Adriana Perez ², Carl V. Hill ³, Julio C. Rojas ¹
¹University California San Francisco - San Francisco (United States), ²Penn University - Philadelphia (United States), ³Alzheimer's Association - Chicago (United States)

-  **P195** **Astrocytic Regulatory mechanism on PM2.5-induced neuronal cell death and neuroinflammation**
Seol-Heui Han¹, Ryeong-Eun Kim², Kyoung Ja Kwon^{2,3}
¹Department Of Neurology, Konkuk Hospital Medical Center, 120-1 Neungdong-Ro, Gwangjin-Gu - Seoul (Korea, Republic of), ²Department Of Neuroscience, School Of Medicine, Konkuk University - Seoul (Korea, Republic of), ³Department of Neurology, Konkuk Hospital Medical center, 120-1 Neungdong-ro, Gwangjin-Gu - Seoul (Korea, Republic of)
- P196** **Impact of Semaglutide in Amyloid Positivity (ISAP): Protocol for a Randomised Double-Blind Placebo-Controlled Trial in Amyloid Positive Individuals**
Ivan Koychev¹, Amanda Adler¹, Paul Edison², Brian Tom³, Joanne Milton¹, Joe Butchart⁴, Adam Hampshire², Charles Marshall⁵, Elizabeth Coulthard⁶, Henrik Zetterberg⁷, Francesca Cormack⁸, Catherine Mummery⁹, Rury Holman¹
¹University of Oxford - Oxford (United Kingdom), ²Imperial College London - London (United Kingdom), ³University of Cambridge - Cambridge (United Kingdom), ⁴Royal Devon University Healthcare NHS Foundation Trust - Exeter (United Kingdom), ⁵Queen Mary University of London - London (United Kingdom), ⁶University of Bristol - Bristol (United Kingdom), ⁷University of Gothenburg - Gothenburg (United Kingdom), ⁸Cambridge Cognition - Cambridge (United Kingdom), ⁹University College London - London (United Kingdom)
-  **P197** **The novel FKBP51-Hsp90 interaction inhibitor attenuates high-fat-induced cognitive impairment**
Bengt Winblad¹, Lisha Wang¹, Jakub Wojcieszak¹, Rajnish Kumar¹, Pavel Pavlov¹
¹Karolinska Institutet - Stockholm (Sweden)
-  **P198** **Intracellular A β accumulation in hippocampal neurons leads to endosomal/lysosomal leakage**
Sophia Schedin Weiss¹, Yang Gao¹, Lars Tjernberg¹
¹Karolinska Institutet - Solna (Sweden)
- P199** **ALZ-201, a monoclonal antibody therapy for specific neutralisation of toxic amyloid- β in Alzheimer's disease**
Anders Sandberg¹
¹Alzinova AB - Gothenburg (Sweden)
-  **P200** **Reducing toxic amyloid- β oligomers in AD through precise targeting of the molecular mechanisms of oligomer formation with small molecule inhibitors**
Johnny Habchi¹, Kerry Jenkins¹, Samata Pandey¹, Roxine Staats¹, Sunehera Sarwat¹, Benedetta Mannini¹, Xiaoting Yang¹, Luke Rajah¹, Samuel Cohen¹, Suzanne Brewerton¹, Alleyn Plowright¹
¹Wren Therapeutics Limited - Cambridge (United Kingdom)
-  **P201** **The bromodomain and extraterminal domain protein inhibitor apabetalone inhibits the neurotoxic kynurenine pathway in monocytes and brain endothelial cells**
 Sylwia Wasiak¹, Li Fu¹, Stephanie Stotz¹, Dean Gilham¹, Laura Tsujikawa¹, Chris Sarsons¹, Jeffrey Kroon², Erik Stroes², Norman Wong¹, Michael Sweeney³, Jan Johansson³, Ewelina Kulikowski¹
¹Resverlogix - Calgary (Canada), ²University of Amsterdam - Amsterdam (Netherlands), ³Resverlogix - San Francisco (United States)
-  **P202** **A novel therapeutic approach to treat Alzheimer's disease: The brain-specific signal peptide peptidase-like 2b (SPPL2b)**
Simone Tambaro¹, Riccardo Maccioni², Caterina Trivisan³, Stefania Zerial³, Annika Wagener⁴, Yuniesky Andrade-Talavera¹, Federico Picciau², Caterina Grassi⁵, Gefei Chen⁶, André Fisahn¹, Bernd Schröder⁷, Per Nilsson¹
¹Department of Neurobiology, Care Sciences and Society (NVS) Division of Neurogeriatrics, Karolinska Institutet - Solna (Sweden), ²Department of Biomedical Sciences, Neuroscience and Clinical Pharmacology, University of Cagliari - Cagliari (Italy), ³Department of life science, University of Trieste - Trieste (Italy), ⁴Interdisciplinary center for Neuroscience, Heidelberg University - Heidelberg (Germany), ⁵Department of Pharmacy and Biotechnology, University of Bologna - Bologna (Italy), ⁶Department of Biosciences and Nutrition, Karolinska Institutet - Huddinge (Sweden), ⁷Institute of Physiological Chemistry, Technische Universität Dresden - Dresden (Germany)
-  **P203** **Increased CSF-decorin predicts brain pathological changes driven by Alzheimer's A β amyloidosis**
 Richeng Jiang¹, Una Smailovic¹, Hazal Haytural¹, Betty Tijms², Hao Li¹, Ganna Shevchenko³, Johan Gobom⁴, Sofie Nyström⁵, Per Hammarström⁵, Stina Syvänen³, Henrik Zetterberg⁴, Bengt Winblad¹, Jonas Bergquist³, Pieter Jelle Visser², Per Nilsson¹
¹Karolinska Institutet - Stockholm (Sweden), ²Amsterdam UMC - Amsterdam (Netherlands), ³Uppsala University - Uppsala (Sweden), ⁴Sahlgrenska Academy at the University of Gothenburg - Gothenburg (Sweden), ⁵Linköping University - Linköping (Sweden)
-  **P204** **Antibodies generated against an A β -derived oligomer: Efforts toward a novel Alzheimer's disease immunotherapy**
Chelsea Marie Parrocha¹, Adam Kreutzer², Jesse Pascual³, Cherie Stringer³, Jennifer Nguyen¹, Ashley Ith¹, Elizabeth Head³, James Nowick^{2,1}
¹Department of Pharmaceutical Sciences, University of California Irvine - Irvine (United States), ²Department of Chemistry, University of California Irvine - Irvine (United States), ³Department of Pathology and Laboratory Medicine, University of California Irvine - Irvine (United States)

POSTER PRESENTATIONS

Friday, December 2nd from 8 a.m to 5 p.m

-  **LP99** Reduction of plasma p-Tau181 from a Phase1a Randomized Trial of NNI-362 in a healthy aged population consistent with amelioration of tau hyperphosphorylation in human differentiated neuron cultures
Raymond Turner¹, Michelle Mielke², Judith Kelleher-Andersson³
¹Georgetown Univ. - Washington, Dc (United States), ²Mayo Clinic - Rochester, Mn (United States), ³Neuronascent, Inc. - Clarksville, Md (United States)
-  **LP100** Inhibition of equilibrative nucleoside transporter 1 (ENT1) inhibitor as a novel therapeutic treatment to rescue Alzheimer's disease pathology and cognitive impairment
Ching-Wen Wu^{1,2}, Ching-Pang Chang^{1,2}, Chien-Yu Lin^{1,2}, Kuo-Chen Wu^{2,3}, Hsin-Hsien Yeh⁴, Chun-Jung Lin^{2,3}, Yijuang Chern^{1,5}
¹Institute of Biomedical Sciences, Academia Sinica - Taipei (Taiwan, Republic of China), ²Biomedical Translation Research Center, Academia Sinica - Taipei (Taiwan, Republic of China), ³School of Pharmacy, National Taiwan University - Taipei (Taiwan, Republic of China), ⁴Brain research center, National Yang Ming Chiao Tung University - Taipei (Taiwan, Republic of China), ⁵Biomedical Translation Research Center - Taipei (Taiwan, Republic of China)
-  **LP101** Characterizing the molecular determinants of the Lecanemab paratope binding site by combining in silico prediction and in vitro Fab analysis on AD brain extracts
Jean-Pierre Bellier¹, Lei Liu¹, Dennis J Selkoe¹
¹Brigham and Women's - Boston (United States)
-  **LP102** Effects of the p38 α kinase inhibitor neflamapimod on the basal forebrain, assessed by structural MRI, in Alzheimer's disease (AD)
John Alam¹, Chen-Pei Lin², Samantha Noteboom², Niels Prins³, Frederik Barkhof⁴, Laura Jonkman², Menno Schoonheim²
¹EIP Pharma - Boston (United States), ²Amsterdam UMC, Location VUmc, Vrije Universiteit Amsterdam, Department of Anatomy and Neurosciences, Amsterdam Neuroscience - Amsterdam (Netherlands), ³Brain Research Center - Amsterdam (Netherlands), ⁴Amsterdam UMC, Location VUmc, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience - Amsterdam (Netherlands)
-  **LP103** Connectivity-based amyloid-tau interaction model: stages, stratification, and prediction of clinical benefit
Wha Jin Lee¹, Jesse Brown², Hye Ryun Kim³, Renaud La Joie², Hanna Cho⁴, Chul Hyoung Lyoo⁴, Gil Rabinovici², William Seeley², Joon-Kyung Seong^{1,3}
¹Neuroxt, Inc. - Seoul (Korea, Republic of), ²University of California, San Francisco - San Francisco (United States), ³Seoul Women's University - Seoul (Korea, Republic of), ⁴Gangnam Severance Hospital - Seoul (Korea, Republic of), ⁵Korea University - Seoul (Korea, Republic of)
-  **LP104** MRI-based real-world implementation for predicting regional tau pathology and its application to amyloid-lowering treatment indication
Wha Jin Lee¹, Hanna Cho², Chul Hyoung Lyoo², Joon-Kyung Seong^{1,3}
¹Neuroxt, Inc. - Seoul (Korea, Republic of), ²Gangnam Severance Hospital - Seoul (Korea, Republic of), ³Korea University - Seoul (Korea, Republic of)
-  **LP105** Hydroxylated docosahexaenoic acid as an alternative therapeutic approach for Alzheimer disease in terms of efficacy and safety
Victoria Llado^{1,2}, Sebastià Parets^{3,2}, Joan Cabot^{3,2}, Marc Miralles^{3,2}, Maria Antònia Fiol-Deroque², Laura Trujillo-Estrada⁴, Paula Fernández-García^{3,5}, Xavier Busquets², Antonia Gutiérrez⁴, Pablo Vicente Escribá^{6,3}, Manuel Torres⁶
¹Laminar Pharma Inc - Acton, Ma (United States), ²Laboratory of Molecular Cell Biomedicine, University of the Balearic Islands - Palma (Spain), ³R&D Department, Laminar Pharmaceuticals - Palma (Spain), ⁴Department of Cell Biology, University of Malaga, CIBERNED, IBIMA - Málaga (Spain), ⁵Laboratory of Molecular Cell Biomedicine, University of the Balearic Islands - Palma (Spain) - Palma (Spain) - Palma (Spain), ⁶Laboratory of Molecular Cell Biomedicine, University of the Balearic Islands - Palma (Spain)
-  **LP105A** Rigor and Replication in Alzheimer's Therapeutic Development: A Case Study
Adrian Heilbut¹, Jesse Brodtkin², Patrick Markey³, Enea Milioris⁴
¹Logphase Research - New York (United States), ²Behavioral Instruments - New Jersey (United States), ³Berlin (Germany), ⁴London (United Kingdom)

THEME: Digital Health/E-Trials

- P205** Assessment of deep learning algorithm of diagnosing Alzheimer's disease with Korean elderly
Jong Bin Bae¹, Ji Won Han¹, Ki Woong Kim^{1,2,3,4}, Jun Sung Kim^{2,5}
¹Department Of Neuropsychiatry, Seoul National University Bundang Hospital, Gyeonggido, Korea - Seongnam (Korea, Republic of), ²Institute of Human Behavioral Medicine, Seoul National University Medical Research Center, Seoul, Korea - Seoul (Korea, Republic of), ³Department of Psychiatry, Seoul National University, College of Medicine, Seoul, South Korea - Seoul (Korea, Republic of), ⁴Department of Brain and Cognitive Science, Seoul National University College of Natural Sciences, Seoul, South Korea - Seoul (Korea, Republic of), ⁵Department of Neuropsychiatry, Seoul National University Bundang Hospital, Gyeonggido, Korea - Seongnam (Korea, Republic of)
- P206** A case-control clinical trial on the diagnostic performance for Alzheimer's Disease of a deep learning-based classification system using brain magnetic resonance imaging of Korean elderly
Jun Sung Kim^{1,2}, Jong Bin Bae¹, Subin Lee³, Ji Won Han⁴, Ki Woong Kim^{4,5,2}
¹Department Of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, Korea - Seongnam (Korea, Republic of), ²Institute of Human Behavioral Medicine, Seoul National University Medical Research Center, Seoul, Korea - Seoul (Korea, Republic of), ³Department Of Electrical And Computer Engineering, Seoul National University, Seoul, Korea - Seoul (Korea, Republic of), ⁴Department Of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, Korea - Seoul (Korea, Republic of), ⁵Department of Psychiatry, Seoul National University, College of Medicine, Seoul, South Korea - Seoul (Korea, Republic of)
-  **P207** The Effect of Home-based Cognitive Training Using Workbook and Tablet PC in Presenile Dementia Patients
Jay Kwon¹, Kyeongsoo Lee², Tae-You Kim³, Tae-Kyeong Eom¹
¹Department Of Neurology, Changwon Fatima Hospital - Changwon (Korea, Republic of), ²Department Of Neurology, Samsung Medical Center - Changwon (Korea, Republic of), ³Department Of Neurology, Busan Wilis Hospital - Busan (Korea, Republic of)

POSTER PRESENTATIONS

Friday, December 2nd from 8 a.m to 5 p.m

Poster presentations presented onsite in San Francisco are indicated with this icon: 

- P208** Efficacy of the 'Finger-to-brain' game on cognitive function of older adults with mild cognitive impairment: a randomized controlled crossover trial
Ji Won Han^{1,2}, Dong Gyu Moon¹, Jung Uk Shin¹, Yeseung Park³, Min Jeong Kwon³, Hae In Kim³, Woori Moon¹, Dae Jong Oh^{4,2}, Jong Bin Bae^{1,2}, Ki Woong Kim^{5,2,3}
¹Department Of Neuropsychiatry, Seoul National University Bundang Hospital - Seongnam-Si (Korea, Republic of), ²Department of Psychiatry, Seoul National University College of Medicine - Seoul (Korea, Republic of), ³Department Of Brain And Cognitive Science, Seoul National University College Of Natural Sciences - Seoul (Korea, Republic of), ⁴Department Of Psychiatry, Smg-Snu Boramae Medical Center - Seoul (Korea, Republic of), ⁵Department Of Neuropsychiatry, Seoul National University Bundang Hospital - Seongnam-si (Korea, Republic of)
-  **P209** Feasibility, acceptability, and adherence of a remote smartphone-based self-assessment of cognition, function, and behavior in early Alzheimer's disease
Thanneer Malai Perumal¹, Arnaud Wolfer¹, Miguel Veloso², Irma T. Kurniawan¹, Gollou Keita³, Niels Hagenbuch⁴, Beijue Shi⁵, Foteini Orfanidou⁶, David Watson⁷, Mercè Boada Rovira⁸, Kirsten I. Taylor²
¹Roche Pharma Research And Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd - Basel (Switzerland), ²Roche Pharma Research And Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., - Basel (Switzerland), ³Cytel Inc., - Geneve (Switzerland), ⁴Global Product Development Data And Statistical Sciences, F. Hoffmann-La Roche Ltd. - Basel (Switzerland), ⁵Global Product Development Medical Affairs, F. Hoffmann-La Roche Ltd., - Basel (Switzerland), ⁶Global Product Development, Personalized Healthcare, Digital Health, F. Hoffmann-La Roche Ltd., - Basel (Switzerland), ⁷Alzheimer's Research And Treatment Center - Wellington (United States), ⁸Networking Research Center On Neurodegenerative Diseases (ciberned), Instituto De Salud Carlos Iii - Madrid (Spain)
- P210** Effect of internet-based mindfulness training on cognitive and psychological well-being and EEG brain activity in the elderly: preliminary results
Samantha Galluzzi¹, Mariangela Lanfredi¹, Alberto Chiesa², Cristina Festari¹, Serena Meloni¹, Roberta Rossi¹, Evita Tomasoni¹, Davide Moretti¹, Michela Pievani¹
¹IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli - Brescia (Italy), ²Istituto Mente e Corpo and Associazione di Psicologia Cognitiva - Scuola di Psicoterapia Cognitiva - Bologna, Rome (Italy)
-  **P211** Increasing Study Power via Frequent Speech-Based Assessments of Cognition
Gabriela Stegmann¹, Shira Hahn¹, Julie Liss¹, Visar Berisha¹, Kimberly Mueller²
¹Arizona State University and Aural Analytics - Scottsdale, Az (United States), ²University of Wisconsin - Madison - Madison, Wi (United States)
-  **P212** A Multimodal Deep Learning Approach to Prediction of Cognitive Decline and its Potential Application in Clinical Trials for Alzheimer's Disease
Caihua Wang¹, Yuanzhong Li¹, Hiroyuki Yamaguchi², Hisateru Tachimori³, Atsushi Sekiguchi⁴, Yuichi Yamashita²
¹Imaging Technology Center, FUJIFILM Corporation - Kanagawa (Japan), ²Department of Information Medicine, National Institute of Neuroscience, National Center of Neurology and Psychiatry - Tokyo (Japan), ³Department of Clinical Epidemiology, Translational Medical Center, National Center of Neurology and Psychiatry - Tokyo (Japan), ⁴Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry - Tokyo (Japan)
-  **P213** Preliminary Results of a Digital Pilot to Improve AD Trial Retention by Managing Caregiver Stress
Rosemary Laird^{1,2}, Jessica Branning¹
¹ClinCloud Clinical Trials - Viera (United States), ²Navigating Aging Needs LLC - Orlando (United States)
- P214** Brain Network Difference between Mild Cognitive Impairment and Alzheimer's Disease Dementia Using EEG
Hong Yuseong¹, Baik Kyoungwon², Park Ukeob¹, Ye Byoung Seok², Kang Seung Wan¹
¹iMediSync Inc. - Seoul (Korea, Republic of), ²Yonsei University College of Medicine - Seoul (Korea, Republic of)
-  **P215** Using Ecological Momentary Assessment to Measure Real-World Effects of a Combined Computerized Cognitive and Functional Skills training Program in Mild Cognitive Impairment
Philip Harvey¹, Peter Kallestrup², Sara Czaja³
¹University of Miami Miller School of Medicine - Miami (United States), ²i-Function - Miami (United States), ³Weill Cornell Medical Center - New York (United States)
-  **P216** The effects of home-based cognitive intervention with chat-bot on brain function in patients with amnesic mild cognitive impairment
Geon Ha Kim¹, Bori Kim¹, Jee Hyang Jeong¹
¹EwhaW.University - Seoul (Korea, Republic of)
- P217** Remote computer-based cognitive training: short- and long-term benefits on cognition and daily living in patients with Alzheimer's disease
Samar Dimachki¹, Franck Tarpin-Bernard², Stéphanie De Chalvron², Bernard Croisile³, Hanna Chainay¹
¹Laboratoire d'Étude des Mécanismes Cognitifs, Université Lyon 2 - Lyon (France), ²Scientific Brain Training SA - Lyon (France), ³Service de Neuropsychologie, Centre Mémoire de Ressource et de Recherche de Lyon, Hôpital Neurologique - Lyon (France)
-  **P218** Taking care of family dementia caregivers: A qualitative examination of patient perspectives and perceived health outcomes after receiving usual care and after a digitally supported care management program
Olga Klein¹, Antonia Karras², Wolfgang Hoffmann^{3,4}, Stefan Teipel^{1,2}, Ingo Kilimann^{1,2}
¹Deutsches Zentrum fuer Neurodegenerative Erkrankungen - Rostock (Germany) - Rostock (Germany), ²Clinic for Psychosomatics and Psychotherapy, University Medical Center Rostock - Rostock (Germany), ³Deutsches Zentrum fuer Neurodegenerative Erkrankungen - Greifswald (Germany), ⁴Institute for Community Medicine, Section Epidemiology and Community Health, University Medicine Greifswald - Greifswald (Germany)
-  **P219** Intuition: a brain health study using multimodal digital biomarkers to decipher cognitive profiles of individuals at-risk for Alzheimer's and related dementias
Monroe Butler¹, Anton Porsteinsson², Sean Kenny¹, Hansen Lenyoun³, Matt Hobbs¹, Roland Brown¹, Matt Bianchi³, James Williams¹, Audrey Gabelle¹, Shibeshih Belachew¹, Intuition Study Scientific Committee Intuition Study Scientific Committee¹
¹Biogen - Cambridge (United States), ²University of Rochester Medical Center - Rochester (United States), ³Apple - Cupertino (United States)

POSTER PRESENTATIONS

Friday, December 2nd from 8 a.m to 5 p.m

-  **P220** **Cognitive health in underrepresented populations: early learnings from the Intuition brain health study**
Rhoda Au¹, Monroe Butler², Hanson Lenyoun³, Sean Kenny², Roland Brown², Paramita Saha-Chaudhuri², Matt Bianchi³, James Williams², Audrey Gabelle², Shibeshih Belachew², Intuition Study Scientific Committee Intuition Study Scientific Committee²
¹Boston University School of Medicine - Boston (United States), ²Biogen - Cambridge (United States), ³Apple - Cupertino (United States)
-  **P221** **Analyzing Facial Expressions and Poses Captured During Video Chats for Early Identification of MCI - Proof of Concept Study: I-CONNECT Project**
Muath Alsuhaibani¹, Ali Pourramezan Fard¹, Hiroko Dodge^{2,3}, Mohammad Mahoor¹
¹School of Electrical and Computer Engineering, University of Denver - Denver (United States), ²Layton Aging and Alzheimer's Disease Center, Oregon Health & Science University - Portland (United States), ³Oregon Center for Aging and Technology (ORCATECH), Oregon Health & Science University - Portland (United States)
- P222** **Using AI and Natural Language Processing Algorithms to Screen Older Adults with Mild Cognitive or Early Alzheimer's Disease**
Stephanie Melgar-Donis^{1,2}, Jarid Siewierski³, Rohola Zandie^{1,3}, Daniel Pittman¹, Lombe Chileshe¹, Hojjat Abdollahi³, Maryam Habibi³, Brock Soicher³, Eshrat Emamian³, Mohammad Mahoor^{3,4}
¹University of Denver - Denver (United States), ²DreamFace Technologies, LLC, ³DreamFace Technologies, LLC - Centennial, Co (United States), ⁴University of Denver - Denver (United States)
-  **LP106** **Development of a machine learning model to diagnose dementia using questionnaires assessing subjective memory complaints and depressive symptoms**
Myeongju Kim¹, Jieun Hong¹, Jinbyeong Park¹, Jiwon Han¹, Ki Woong Kim¹
¹Seoul National University Bundang Hospital - Seongnam-Si (Korea, Republic of)
-  **LP107** **The Community Engaged Digital Alzheimer's Research (CEDAR) Study: Digital Engagement Strategies to Increase ADRD Research Participation of Black Americans**
Anna Aaronson^{1,2,3}, Miriam Ashford^{1,2,3}, Danqi Zhu⁴, Heining Cham⁴, Catherine Conti^{1,2,3}, Xinyue Deng⁴, Roxanne Alaniz⁵, R. Scott Mackin^{2,3}, Michael Weiner^{1,2,3}, Desiree Byrd⁶, Robert W Turner⁷, Carl Hill⁸, Rachel Nosheny^{2,3}, Monica Rivera Mindt^{4,9}
¹Northern California Institute for Research and Education (NCIRE), Department of Veterans Affairs Medical Center - San Francisco (United States), ²Veterans Affairs Advanced Research Center - San Francisco (United States), ³University of California, San Francisco - San Francisco (United States), ⁴Department of Psychology, Latin American Latino Studies, African and African American Studies, Fordham University - New York (United States), ⁵Alaniz Marketing - Novato (United States), ⁶CUNY, Queens College - Queens (United States), ⁷George Washington University - Washington (United States), ⁸Alzheimer's Association - Chicago (United States), ⁹Department of Neurology, Icahn School of Medicine at Mount Sinai - New York (United States)
-  **LP108** **Questionnaire-based Computer Assisted Diagnosis (CADx) is useful for identifying Alzheimer's Disease**
Timothy Daly¹, David Weisman²
¹Sorbonne Université - Paris (France), ²Abington Neurological Associates - Abington (United States)
-  **LP109** **Advancing Measurement in Alzheimer's Disease and Related Disorders Through Digitizing Assessment of Meaningful Aspects of Health**
Pip Griffiths¹, Chao-Yi Wu², Danielle Stefko³, Lucy Cesnakova⁴, Jennifer Goldsack⁵
¹The Digital Medicine Society - Saumur (France), ²The Digital Medicine Society - Portland (United States), ³The Digital Medicine Society - Nashville (United States), ⁴The Digital Medicine Society - Prague (Czech Republic), ⁵The Digital Medicine Society - Sarasota (United States)

THEME: AD Clinical trials and COVID-19

-  **LP110** **Sustained accelerated cognitive decline in older adults as a result of the Covid-19 pandemic: Analysis of the PROTECT UK study data**
Anne Corbett¹, Clive Ballard¹, Byron Creese¹, Adam Hampshire², Dag Aarsland³, Helen Brooker¹
¹University of Exeter - Exeter (United Kingdom), ²Imperial College London - London (United Kingdom), ³King's College London - London (United Kingdom)

It is reminded that the papers presented during the Congress, whatever their form (oral, written or poster) are placed under the sole responsibility of their authors and co-authors. In no case, the positions, research, results presented during the CTAD Congress & published in the JPAD are likely to engage the responsibility of the Congress.

Practical Details

Conference Venue

HILTON UNION SQUARE

333 O'Farrell Street

San Francisco, CA 94102



MEETING ROOMS


> Conference Room

All sessions will be held in **Grand Ballroom AB – Tower 2.**

> Posters Sessions and Coffee Breaks

Yosemite/Imperial Ballrooms – Tower 2

Meet our poster presenters during the coffee breaks. A poster assistance desk will be available to locate the posters – Days of poster presentations are on page 24.



NEW at CTAD this year
Enjoy a morning coffee while touring the posters from 8 a.m to 9 a.m on Wednesday, Thursday and Friday.



Free WiFi available at CTAD

Network: CTAD22 – Password: CTAD22

> Mobile App



Download the VFairs mobile app on the Apple Store or Google Play. Login with the email address used to register, then click on CTAD22 and enjoy the conference at your fingertips, you can watch the livestream from the Ballroom, access the virtual poster hall and connect with your colleagues!

> CTAD22 digital platform

To access our digital platform simply go to www.ctad22.com and enter with your email address.



> Speaker ready room opening hours:

- Tuesday, November 29: 1 p.m to 6 p.m
- Wednesday, November 30 to Friday, December 2: 7:30 a.m to 5:30 p.m

> Lunch on your own at CTAD22

A complete list of restaurants and take-out outlets is available in your attendee bag and on the CTAD22 Mobile App. Coffee will be available from 1:00 to 1:30 p.m to enjoy the poster presentations.

> CTAD Welcome Reception

Tuesday, November 29 from 6:30 p.m to 7:30 p.m
Continental Ballroom – Tower 3

CTAD would like to thank its 2022 privileged partners
for their continued support.

Platinum Sponsor



Alzheimer's
Drug Discovery
Foundation

Gold Sponsors





Clinical Trials on Alzheimer's Disease

Graphic Design: Melanie Vaisselle - @Tiemey

Follow us on social media!



[@CTADConference](https://twitter.com/CTADConference)
[#CTAD22](https://twitter.com/CTADConference)



[CTAD Conference](https://www.facebook.com/CTADConference)



[CTAD Alzheimer](https://www.linkedin.com/company/CTADAlzheimer)

Email: ctad@ant-congres.com
www.ctad-alzheimer.com

Notes

A series of horizontal dashed lines for writing notes.

Notes

CTAD Alzheimer 2023

Clinical Trials on Alzheimer's Disease



©Mircea Costina

October 24-27, 2023
Boston, MA - USA

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11
Monte Carlo '12 / San Diego '13 / Philadelphia '14 / Barcelona '15 / San Diego '16
Boston '17 / Barcelona '18 / San Diego '19 / Virtual '20 / Boston '21 / San Francisco '22

www.ctad-alzheimer.com

Email: ctad@ant-congres.com

